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Degenerative joint disease (DJD) is one of the most common causes of chronic pain in cats. Two studies 
were designed to identify risk factors for DJD in 6-year-old cats by examining prospective data from a 
longitudinal cohort study, and compare the activity profiles and quality of life of cats with (cases) and 
without (controls) early owner-reported signs of impaired mobility using orthopaedic examination, 
accelerometry and owner-completed questionnaires (Feline Musculoskeletal Pain Index (FMPI), 
VetMetrica). 
Binomial logistic regression using backwards elimination identified four risk factors for increased owner-
reported mobility impairment score in 6-year-old cats: entire neuter status at six months of age (OR=1.97, 
95%CI 1.26–3.07), sustained trauma before six years of age (OR=1.85, 95%CI 1.3–2.6), outdoor access at 
six years of age (OR=1.67, 95%CI 0.96–2.9), and overweight/obese status at six years of age (OR=1.62, 
95%CI 1.13–2.33). Case cats scored significantly lower than control cats for the FMPI (p=0.003) and the 
VetMetrica domain of comfort (p=0.002), but not vitality (p=0.009) or emotional wellbeing (p=0.018). Total 
pain (p<0.0001), crepitus (p=0.002) and thickening (p=0.003) scores were higher in case cats. 
Accelerometry differentiated cases from controls with a 90.9% accuracy. 
Risk factor analysis demonstrated that obesity, outdoor access, and a history of trauma predispose cats to 
developing DJD, whereas neutering appears to decrease that risk. Changes in joint health as detected by 
orthopaedic examination and accelerometry reflected owner-reported mobility changes, differentiating 
cats with early DJD-related signs from healthy cats, whilst the VetMetrica comfort domain score indicated 
an impaired quality of life of cats with early DJD compared to healthy cats. Being able to recognise signs of 
mobility impairment earlier would allow interventions aimed at slowing DJD progression, thereby 
improving feline health and welfare. These findings have identified that orthopaedic examination, FMPI 













2. DEDICATION AND ACKNOWLEDGEMENTS 
I wish to thank all the people without whom I would not have been able to complete this research project. 
I would like to thank to my research supervisors, Dr Emily Blackwell, Dr Jo Murrell and Professor Sorrel 
Langley-Hobbs for their thoughtful comments and recommendations on my research and this dissertation. 
I wish to express my deepest gratitude for Dr Blackwell’s guidance, support and encouragement which has 
been invaluable throughout this study.  
I am particularly indebted to Zoetis for funding this scholarship and enabling me to move one step closer 
to my dreams. I am thankful to Professor Séverine Tasker for believing in me and supporting me for the 
first months of my scholarship. I am grateful to my current scholarship supervisor, Dr Natalie Finch, who 
has been inspiring me to excel since we first met five years ago and supported me throughout my 
scholarship (I promise I will finish the calcitonin paper!). 
I would like to express my gratitude to the Bristol Cats team and particularly Mel W., whose support with 
recruitment allowed my studies to flourish (sorry for all the extra work Mel!), as well as the Animal 
Behaviour and Welfare group, especially Helena H. and Livia B., who supported me and had to put up with 
my stresses for the past two years! I would also like to thank Eli Smith for drawing some of the figures in 
my thesis. 
I would like to express my gratitude and appreciation for the owners of Bristol Cats Study cats who have 
been completing questionnaires year after year, as well as for the owners of all cats who allowed me into 
their homes to examine their cats; without them I would have no content for my thesis. 
I am particularly grateful for my family and for all the support they have shown me through this research, 
especially my partner Richard Smith; I would not have been where I am today without your unconditional 
support. 
My biggest thanks go to all the cats I have met during my veterinary career and during this study; you are 
truly amazing, and this research is for you. My most heartfelt thanks and love goes to Lucy who has not left 
iii 
 
my side since my undergraduate years and has been an inspirational part of my life; you will always hold a 









3. AUTHOR’S DECLARATION 
 
I declare that the work in this dissertation was carried out in accordance with the requirements of the 
University's Regulations and Code of Practice for Research Degree Programmes and that it has not been 
submitted for any other academic award. Except where indicated by specific reference in the text, the work 
is the candidate's own work. Work done in collaboration with, or with the assistance of, others, is indicated 
as such. Any views expressed in the dissertation are those of the author. 
 















4. TABLE OF CONTENTS 
1. INTRODUCTION ....................................................................................................................................... 1 
1.1 GENERAL BACKGROUND .............................................................................................................................. 1 
1.2 THE FELINE JOINT ....................................................................................................................................... 3 
1.2.1 Physiology ......................................................................................................................................... 3 
1.2.2 Joint Disorders................................................................................................................................... 4 
1.2.3 Physiology of Pain ............................................................................................................................. 4 
1.3 FELINE DEGENERATIVE JOINT DISEASE ............................................................................................................ 7 
1.3.1 Definition .......................................................................................................................................... 7 
1.3.2 Pathophysiology of Degenerative Joint Disease ............................................................................... 7 
1.3.2.1 Pathophysiology of Degenerative Joint Disease-related Pain .................................................................. 8 
1.3.3 Prevalence ......................................................................................................................................... 9 
1.3.4 Causes ............................................................................................................................................. 11 
1.3.5 Risk Factors ..................................................................................................................................... 16 
1.3.6 Clinical Signs ................................................................................................................................... 18 
1.3.7 Diagnostic Methods ........................................................................................................................ 19 
1.3.7.1 History Evaluation and Owner Observations ......................................................................................... 20 
1.3.7.2 Physical Examination.............................................................................................................................. 20 
1.3.7.3 Radiography ........................................................................................................................................... 21 
1.4 CHRONIC PAIN ASSESSMENT IN FELINE DEGENERATIVE JOINT DISEASE................................................................ 24 
1.4.1 Subjective Outcome Measures of Chronic Pain ............................................................................... 24 
1.4.1.1 Clinical Metrology Instruments .............................................................................................................. 24 
1.4.1.2 Quality of Life ......................................................................................................................................... 26 
1.4.2 The Placebo Effect in Feline Degenerative Joint Disease ................................................................ 29 
1.4.3 Objective Outcome Measures of Chronic Pain ................................................................................ 30 
1.4.3.1 Gait Analysis ........................................................................................................................................... 30 
1.4.3.2 Accelerometry ........................................................................................................................................ 31 
1.4.3.3 Goniometry ............................................................................................................................................ 32 
1.4.3.4 Quantitative Sensory Testing ................................................................................................................. 32 
vi 
 
1.4.3.5 Biological Markers .................................................................................................................................. 32 
1.4.3.6 Other Objective Measures ..................................................................................................................... 33 
1.5 MANAGEMENT OF DEGENERATIVE JOINT DISEASE .......................................................................................... 34 
1.5.1 Advantages of Early Detection ........................................................................................................ 34 
1.5.2 Pharmacological Pain Management ............................................................................................... 34 
1.5.2.1 Non-Steroidal Anti-Inflammatory Drugs ................................................................................................ 34 
1.5.2.2 Piprants .................................................................................................................................................. 36 
1.5.2.3 Centrally Acting Drugs ............................................................................................................................ 36 
1.5.2.4 Anti-Nerve Growth Factor Monoclonal Antibodies ............................................................................... 38 
1.5.2.5 Stem Cell Therapy .................................................................................................................................. 39 
1.5.3 Structure-Modifying Osteoarthritis Agents and Nutraceuticals ..................................................... 39 
1.5.4 Weight Management ...................................................................................................................... 41 
1.5.5 Environmental and Activity Modulation ......................................................................................... 42 
1.5.6 Physical Therapies ........................................................................................................................... 44 
1.5.7 Surgical Management ..................................................................................................................... 44 
1.5.7.1 Excision Arthroplasty ............................................................................................................................. 44 
1.5.7.2 Total Joint Replacement ........................................................................................................................ 45 
1.5.7.3 Arthrodesis ............................................................................................................................................. 45 
1.5.8 Complementary Therapies .............................................................................................................. 46 
1.6 THESIS OBJECTIVES ................................................................................................................................... 47 
2. STUDY ONE: RISK FACTORS FOR OWNER-REPORTED SIGNS OF EARLY DEGENERATIVE JOINT DISEASE AT 
SIX YEARS OF AGE .......................................................................................................................................... 48 
2.1 AIMS AND OBJECTIVES .............................................................................................................................. 48 
2.2 HYPOTHESIS ............................................................................................................................................ 48 
2.3 MATERIALS AND METHODS ........................................................................................................................ 48 
2.3.1 Study Design ................................................................................................................................... 48 
2.3.2 Participants ..................................................................................................................................... 49 
2.3.3 Data Collection ................................................................................................................................ 50 
2.3.4 Explanatory Variables ..................................................................................................................... 51 
vii 
 
2.3.5 Statistical Analysis .......................................................................................................................... 60 
2.4 RESULTS ................................................................................................................................................. 61 
2.4.1 Participants ..................................................................................................................................... 61 
2.4.1.1 Breed Classifications .............................................................................................................................. 62 
2.4.1.2 Neuter Status at Six Months of Age ....................................................................................................... 63 
2.4.1.3 Owner-reported Body Condition Score at All Timepoints ...................................................................... 63 
2.4.1.4 Diagnosis of Chronic Kidney Disease at Six Years of Age........................................................................ 66 
2.4.1.5 Dental Health at Six Years of Age ........................................................................................................... 66 
2.4.1.6 Vaccination History at All Timepoints .................................................................................................... 67 
2.4.1.7 Trauma Incidence at All Timepoints ....................................................................................................... 68 
2.4.2 Logistic Regression Analysis ............................................................................................................ 71 
2.4.2.1 Outcome Variable .................................................................................................................................. 71 
2.4.2.2 Explanatory Variables ............................................................................................................................ 71 
2.4.2.3 Univariable Models ................................................................................................................................ 73 
2.4.2.4 Multivariable Model .............................................................................................................................. 75 
2.4.2.5 Additional Investigations on the Effect of Body Condition Score at Six Years of Age on the Initial 
Logistic Regression Model ......................................................................................................................................... 76 
2.5 DISCUSSION ............................................................................................................................................ 82 
2.6 CONCLUSION ........................................................................................................................................... 86 
3. STUDY TWO: ORTHOPAEDIC EXAMINATION, QUALITY OF LIFE ASSESSMENT AND ACTIVITY 
MONITORING OF CATS WITH OWNER-REPORTED SIGNS OF DEGENERATIVE JOINT DISEASE OVER SIX YEARS 
OF AGE........................................................................................................................................................... 87 
3.1 AIMS AND OBJECTIVES .............................................................................................................................. 87 
3.2 HYPOTHESES ........................................................................................................................................... 87 
3.3 MATERIALS AND METHODS ........................................................................................................................ 88 
3.3.1 Study Design ................................................................................................................................... 88 
3.3.2 Study Size ........................................................................................................................................ 88 
3.3.3 Setting ............................................................................................................................................. 88 
3.3.4 Participants ..................................................................................................................................... 89 
viii 
 
3.3.5 Data Collection ................................................................................................................................ 93 
3.3.5.1 Bias ......................................................................................................................................................... 93 
3.3.5.2 Pre-visit Measures ................................................................................................................................. 93 
3.3.5.3 Visit Protocol .......................................................................................................................................... 94 
3.3.5.4 Outcome Measures ................................................................................................................................ 97 
3.3.6 Variables ......................................................................................................................................... 97 
3.3.7 Statistical Analysis ........................................................................................................................ 100 
3.4 RESULTS ............................................................................................................................................... 103 
3.4.1 Participants ................................................................................................................................... 103 
3.4.2 Pre-visit Measures......................................................................................................................... 104 
3.4.3 Visit Measures ............................................................................................................................... 104 
3.4.3.1 Temperament Assessment .................................................................................................................. 104 
3.4.3.2 Body Condition Score (Assessed by Veterinary Surgeon) .................................................................... 105 
3.4.3.3 Orthopaedic Examination .................................................................................................................... 106 
3.4.4 Group Comparisons ...................................................................................................................... 109 
3.4.4.1 Participants .......................................................................................................................................... 109 
3.4.4.2 Pre-visit Measures ............................................................................................................................... 110 
3.4.4.3 Visit Measures ...................................................................................................................................... 111 
3.4.4.4 Accelerometry ...................................................................................................................................... 116 
3.5 DISCUSSION .......................................................................................................................................... 118 
3.6 CONCLUSION ......................................................................................................................................... 122 
4. CONCLUSIONS AND FUTURE WORK ..................................................................................................... 123 
5. REFERENCES ........................................................................................................................................ 124 
6. APPENDICES ........................................................................................................................................ 145 
APPENDIX A FELINE MUSCULOSKELETAL PAIN INDEX ............................................................................. 146 
APPENDIX B SUMMARY OF ACTIVITY MONITORS AND RELEVANT LITERATURE ...................................... 151 
APPENDIX C BRISTOL CAT STUDY QUESTIONNAIRE ................................................................................ 154 
APPENDIX D TRAUMA-RELATED KEYWORDS FOR FREE TEXT MINING ..................................................... 178 
ix 
 
APPENDIX E STUDY ONE: BREED INFORMATION .................................................................................... 179 
APPENDIX F RECRUITMENT E-MAILS AND ADVERTISEMENTS ................................................................. 180 
APPENDIX G COLLAR HABITUATION INSTRUCTIONS ............................................................................... 183 
APPENDIX H ONLINE INCLUSION QUESTIONNAIRE .................................................................................. 185 
APPENDIX I STUDY PARTICIPANT INFORMATION SHEET ........................................................................ 192 
APPENDIX J STUDY PARTICIPANT CONSENT FORM ................................................................................ 196 
APPENDIX K ONLINE FELINE MUSCULOSKELETAL PAIN INDEX QUESTIONNAIRE ..................................... 199 
APPENDIX L ONLINE VETMETRICA QUESTIONNAIRE ............................................................................... 206 
APPENDIX M ORTHOPAEDIC EXAMINATION SHEET ................................................................................. 229 
APPENDIX N ACCELEROMETER OWNER DIARY ........................................................................................ 230 
APPENDIX O TESTS OF NORMALITY AND TRANSFORMATIONS................................................................ 231 
APPENDIX P HOLM-BONFERRONI METHOD CALCULATIONS ................................................................... 241 
APPENDIX Q ACCELEROMETER MISSING DATA POINTS ........................................................................... 242 
 
5. LIST OF TABLES 
TABLE 1.1: SUMMARY FINDINGS OF THE REPORTED PREVALENCE OF RADIOGRAPHIC APPENDICULAR FELINE DEGENERATIVE JOINT 
DISEASE .......................................................................................................................................................... 10 
TABLE 1.2: SUMMARY FINDINGS OF THE REPORTED PREVALENCE OF RADIOGRAPHIC AXIAL FELINE DEGENERATIVE JOINT DISEASE .. 11 
TABLE 1.3: LIST OF RECOGNISED AND POSTULATED PRIMARY AND SECONDARY CAUSES OF FELINE DEGENERATIVE JOINT DISEASE .. 12 
TABLE 1.4: SUMMARY FINDINGS OF THE REPORTED PREVALENCE OF FELINE HIP DYSPLASIA WITH/WITHOUT DEGENERATIVE JOINT 
DISEASE .......................................................................................................................................................... 13 
TABLE 1.5: PREVIOUSLY INVESTIGATED RISK FACTORS FOR FELINE DEGENERATIVE JOINT DISEASE ............................................. 17 
TABLE 1.6: SUMMARY OF RADIOGRAPHIC APPEARANCE OF APPENDICULAR FELINE DEGENERATIVE JOINT DISEASE ....................... 22 
TABLE 1.7: SUMMARY OF RADIOGRAPHIC APPEARANCE OF AXIAL FELINE DEGENERATIVE JOINT DISEASE ................................... 23 
x 
 
TABLE 2.1: EXPLANATORY VARIABLES CONSIDERED FOR UNIVARIABLE ANALYSIS OF RISK FACTORS FOR FELINE DEGENERATIVE JOINT 
DISEASE IN SIX-YEAR-OLD CATS ........................................................................................................................... 51 
TABLE 2.2: ADDITIONAL EXPLANATORY VARIABLES TO INVESTIGATE THE EFFECT OF BODY CONDITION SCORE AT SIX YEARS OF AGE ON 
THE INITIAL LOGISTIC REGRESSION MODEL ............................................................................................................. 58 
TABLE 2.3: DEMOGRAPHIC DATA FOR N = 799 CATS ....................................................................................................... 61 
TABLE 2.4: OWNER-REPORTED BODY CONDITION SCORE FOR N = 799 CATS AT ALL TIMEPOINTS ............................................. 64 
TABLE 2.5: OWNER-REPORTED VACCINATIONS AT ALL TIMEPOINTS .................................................................................... 67 
TABLE 2.6: INCIDENCE OF OWNER-REPORTED ROAD TRAFFIC ACCIDENTS UNTIL THE AGE OF 2.5 YEARS .................................... 69 
TABLE 2.7: OWNER-REPORTED INCIDENCE OF DIFFERENT TYPES OF TRAUMA UNTIL THE AGE OF SIX YEARS ................................ 70 
TABLE 2.8: LIST OF EXPLANATORY VARIABLES CONSIDERED FOR UNIVARIABLE ANALYSIS OF RISK FACTORS FOR FELINE DEGENERATIVE 
JOINT DISEASE IN SIX-YEAR-OLD CATS ................................................................................................................... 72 
TABLE 2.9: UNIVARIABLE LOGISTIC REGRESSION MODELS OF RISK FACTORS FOR FELINE DEGENERATIVE JOINT DISEASE IN SIX-YEAR-
OLD CATS ........................................................................................................................................................ 74 
TABLE 2.10: MULTIVARIABLE LOGISTIC REGRESSION MODEL OF RISK FACTORS FOR FELINE DEGENERATIVE JOINT DISEASE IN SIX-
YEAR-OLD CATS ................................................................................................................................................ 76 
TABLE 2.11: CHANGES IN BODY CONDITION SCORE BETWEEN SIX-YEAR-OLD CATS AND CATS OF ALL OTHER AGES ..................... 77 
TABLE 2.12: ADDITIONAL BODY CONDITION SCORE-RELATED VARIABLES CONSIDERED FOR UNIVARIABLE ANALYSIS OF RISK FACTORS 
FOR FELINE DEGENERATIVE JOINT DISEASE IN SIX-YEAR-OLD CATS .............................................................................. 78 
TABLE 2.13: RESULTS FROM ADDITIONAL UNIVARIABLE LOGISTIC REGRESSION MODELS OF RISK FACTORS FOR FELINE DEGENERATIVE 
JOINT DISEASE IN SIX-YEAR-OLD CATS ................................................................................................................... 80 
TABLE 2.14: RESULTS FROM FINAL MULTIVARIABLE REGRESSION MODEL OF RISK FACTORS FOR FELINE DEGENERATIVE JOINT DISEASE 
IN SIX-YEAR-OLD CATS ....................................................................................................................................... 81 
TABLE 3.1: INCLUSION AND EXCLUSION CRITERIA FOR STUDY RECRUITMENT ......................................................................... 89 
TABLE 3.2: NUMBER OF CATS AND ASSOCIATED REASONS FOR STUDY EXCLUSION ................................................................. 91 
TABLE 3.3: VARIABLES USED FOR ANALYSIS OF ORTHOPAEDIC EXAMINATION, QUALITY OF LIFE ASSESSMENT AND ACTIVITY 
MONITORING OF CATS WITH OWNER-REPORTED SIGNS OF DEGENERATIVE JOINT DISEASE OVER SIX YEARS OF AGE ............ 97 
TABLE 3.4: DEMOGRAPHIC DATA FOR N = 57 CATS ....................................................................................................... 103 
TABLE 3.5: PRE-VISIT MEASURES FOR N = 57 CATS ....................................................................................................... 104 
TABLE 3.6: TEMPERAMENT ASSESSMENT FOR N = 57 CATS ............................................................................................. 105 
xi 
 
TABLE 3.7: BODY CONDITION SCORE (ASSESSED BY VETERINARY SURGEON) FOR N = 57 CATS ............................................... 105 
TABLE 3.8: PREVALENCE OF ABNORMALITIES DETECTED DURING ORTHOPAEDIC EXAMINATION OF THE APPENDICULAR AND AXIAL 
SKELETON IN N = 56 CATS ................................................................................................................................ 106 
TABLE 3.9: PREVALENCE OF BILATERAL PAIN IN EACH JOINT TYPE IN N = 56 CATS ............................................................... 108 
TABLE 3.10: GROUP COMPARISONS FOR DEMOGRAPHIC DATA IN N = 57 CATS .................................................................. 110 
TABLE 3.11: GROUP COMPARISONS FOR PRE-VISIT MEASURES IN N = 57 CATS .................................................................. 110 
TABLE 3.12: GROUP COMPARISONS FOR TEMPERAMENT ASSESSMENT IN N = 57 CATS ........................................................ 111 
TABLE 3.13: GROUP COMPARISONS FOR BODY CONDITION SCORE (ASSESSED BY VETERINARY SURGEON) IN N = 57 CATS .......... 112 
TABLE 3.14: GROUP COMPARISONS FOR TOTAL PAIN AND MANIPULATION SCORES IN N = 56 CATS ....................................... 113 
TABLE 3.15: GROUP COMPARISONS FOR THE PREVALENCE OF BILATERAL PAIN IN N = 56 CATS .............................................. 114 
TABLE 3.16: PREVALENCE OF BILATERAL PAIN IN DIFFERENT JOINTS FOR N = 30 CASE AND N = 27 CONTROL CATS.................... 115 





6. LIST OF FIGURES 
FIGURE 1.1: COMPONENTS OF A FELINE STIFLE JOINT ......................................................................................................... 3 
FIGURE 1.2: SCHEMATIC ILLUSTRATION OF THE SIX TYPES OF SYNOVIAL JOINTS AND THE TYPES OF JOINT MOVEMENT. ................... 4 
FIGURE 1.3: SCHEMATIC ILLUSTRATION OF ADAPTIVE PAIN ................................................................................................. 5 
FIGURE 1.4: SCHEMATIC ILLUSTRATION OF MALADAPTIVE PAIN ........................................................................................... 6 
FIGURE 1.5: CELLULAR MECHANISMS IN DEGENERATIVE JOINT DISEASE. ................................................................................ 8 
FIGURE 1.6: MODEL OF THE NOCICEPTIVE SYSTEM OF THE JOINT AND MAJOR PROCESSES LIKELY TO UNDERLIE DJD-RELATED JOINT 
PAIN................................................................................................................................................................. 9 
FIGURE 1.7: MULTIDIMENSIONAL APPROACH TO DIAGNOSING DEGENERATIVE JOINT DISEASE ................................................. 20 
FIGURE 2.1: BREED CLASSIFICATION ACCORDING TO CEPHALIC INDEX FOR N = 793 CATS ........................................................ 62 
FIGURE 2.2: BREED CLASSIFICATION ACCORDING TO BODY SIZE FOR N = 793 CATS ................................................................ 63 
FIGURE 2.3: OWNER-REPORTED BODY CONDITION SCORE AT ALL TIMEPOINTS ..................................................................... 65 
FIGURE 2.4: OWNER-REPORTED NUMBERS OF NOT OVERWEIGHT AND OVERWEIGHT/OBESE CATS AT ALL TIMEPOINTS ............... 65 
FIGURE 2.5:  DENTAL HEALTH AT SIX YEARS OF AGE (ASSESSED BY VETERINARY SURGEON AND REPORTED BY OWNERS) .............. 66 
FIGURE 2.6: OWNER-REPORTED VACCINATIONS AT ALL TIMEPOINTS ................................................................................... 68 
FIGURE 2.7: OWNER-REPORTED INCIDENCE OF TRAUMA ACCORDING TO SEVERITY ................................................................ 70 
FIGURE 2.8: OWNER-REPORTED MOBILITY SCORE FOR N = 238 CASE CATS .......................................................................... 71 
FIGURE 2.9: SPEARMAN RANK CORRELATION MATRIX OF ALL EXPLANATORY VARIABLES CONSIDERED FOR UNIVARIABLE ANALYSIS OF 
RISK FACTORS FOR FELINE DEGENERATIVE JOINT DISEASE IN SIX-YEAR-OLD CATS .......................................................... 73 
FIGURE 2.10: CHANGES IN BODY CONDITION SCORE BETWEEN SIX-YEAR-OLD CATS AND CATS OF ALL OTHER AGES ................... 77 
FIGURE 2.11: SPEARMAN RANK CORRELATION MATRIX OF ALL CONFIRMED AND ADDITIONAL EXPLANATORY VARIABLES CONSIDERED 
FOR UNIVARIABLE ANALYSIS OF RISK FACTORS FOR FELINE DEGENERATIVE JOINT DISEASE IN SIX-YEAR-OLD CATS ................ 79 
FIGURE 3.1: RECRUITMENT AND ENROLMENT FLOWCHART ............................................................................................... 92 
FIGURE 3.2: STUDY PARTICIPANT WEARING THE COLLAR-MOUNTED ACTIVITY MONITOR ........................................................ 95 
FIGURE 3.3: REPRESENTATIVE GRAPH ILLUSTRATING ACTIVITY COUNTS AS GENERATED BY THE ACTIVITY MONITOR ...................... 96 
FIGURE 3.4: DIAGRAM ILLUSTRATING THE PRE-PROCESSING PIPELINE AND THE STEPS FOLLOWED FOR MACHINE LEARNING ANALYSIS 
OF THE ACCELEROMETER DATA .......................................................................................................................... 102 
FIGURE 3.5:  BODY CONDITION SCORE (ASSESSED BY VETERINARY SURGEON) FOR N = 57 CATS ............................................. 105 
xiii 
 
FIGURE 3.6: SUMMARY OF ABNORMALITIES DETECTED DURING ORTHOPAEDIC EXAMINATION OF THE APPENDICULAR SKELETON IN N 
= 56 CATS ..................................................................................................................................................... 107 
FIGURE 3.7: PREVALENCE OF PAIN DETECTED DURING ORTHOPAEDIC EXAMINATION OF THE AXIAL SKELETON IN N = 56 CATS ..... 107 
FIGURE 3.8: TOTAL NUMBER OF JOINTS AFFECTED WITH BILATERAL PAIN IN N = 56 CATS ..................................................... 109 
FIGURE 3.9: OWNER-REPORTED MOBILITY SCORE FOR N = 30 CASE CATS .......................................................................... 109 
FIGURE 3.10: GROUP COMPARISONS FOR VETMETRICA DOMAIN SCORES IN N = 57 CATS .................................................... 111 
FIGURE 3.11: GROUP COMPARISONS FOR TEMPERAMENT ASSESSMENT IN N = 57 CATS ....................................................... 112 
FIGURE 3.12: BODY CONDITION SCORE (ASSESSED BY VETERINARY SURGEON) IN N = 57 CATS .............................................. 112 
FIGURE 3.13: GROUP COMPARISONS FOR TOTAL PAIN SCORE IN N = 57 CATS .................................................................... 113 
FIGURE 3.14: GROUP COMPARISONS FOR THE PREVALENCE OF BILATERAL PAIN IN N = 56 CATS ............................................ 114 
FIGURE 3.15: GROUP COMPARISONS FOR THE NUMBER OF JOINTS AFFECTED WITH BILATERAL PAIN IN N = 56 CATS ................. 116 






7. LIST OF ABBREVIATIONS 
-2LL Log likelihood-ratio statistic 
BC Bristol Cats 
BCS Body condition score 
CCL Cranial cruciate ligament 
CKD Chronic kidney disease 
C.L.A.W.S. Cat Longitudinal Analysis of Welfare Study 
CMI Clinical metrology instruments 
COX Cyclooxygenase 
CSOM Client Specific Outcome Measures 
Cx Coxofemoral 
df Degrees of Freedom 
DHA Docosahexaenoic acid 
DJD Degenerative joint disease 
DLH Domestic long hair 
DSH Domestic short hair 
EPA Eicosapentaenoic acid 
ETA Eicosatetraenoic acid 
EWB Emotional wellbeing 
FeLV Feline leukaemia virus 
FET Fisher’s exact test 
FPFF Feline Physical Function Formula 
FeSFV Feline syncytia-forming virus 
FHNE Femoral head and neck excision arthroplasty 
FET Fisher's exact test 
xv 
 
FIV Feline immunodeficiency virus 
FMPI Feline Musculoskeletal Pain Index 
FPFF Feline Physical Function Formula 
GLM Green lipid mussel 
HD Hip dysplasia 
HRQoL Health related quality of life 
IL Interleukin 
IQR Interquartile range 
LS Lumbosacral 
mAb Monoclonal antibody 
Mdn Median 
MI-CAT(C) Montreal Instrument for Cat Arthritis Testing – Caretaker/Owner 
MI-CAT(V) Montreal Instrument for Cat Arthritis Testing – Veterinarian 
MS Mobility score 
N/A Not applicable 
nBC Non-Bristol Cats 
NGF Nerve growth factor 
NMDA N-methyl-D-aspartate 
NSAIDS Non-steroidal anti-inflammatory drugs 
OBW Owner Behaviour Watch 
OR Odds ratio 
PPS Pentosan polysulfate 
PSGAG Polysulfated glycosaminoglycan 
PSW Pressure-sensitive walkways 
QoL Quality of life 
xvi 
 
QST Quantitative sensory testing 
RTA Road traffic accident 
ROM Range of motion 
SFO Scottish Fold osteochondrodysplasia 
STT Soft tissue trauma 
S&P Scale and polish 
STMOAD Structure-modifying osteoarthritis drugs 
TNF-α Tumour necrosis factor α 
UK United Kingdom 










1.1 General Background 
Feline degenerative joint disease (DJD) is one of the most common causes of chronic pain in cats, with 
prevalence increasing with age and prevalence estimates in radiographical studies ranging from 61% 
(Slingerland et al., 2011) to as high as 99% in cats of all ages (Lascelles et al., 2010b). Despite the high 
prevalence, little is known about risk factors predisposing cats to this condition, with increasing age being the 
only identified risk factor for feline DJD to date (Lascelles et al., 2010b, Slingerland et al., 2011). Similarly to 
humans where DJD has been shown to lead to reduced mobility and pain (Schaible, 2012), unpublished data 
suggest that approximately 40% of cats with radiographic DJD have an impaired mobility and experience pain 
secondary to DJD (Lascelles et al., 2010b). Cats are increasingly considered more of a family member than a 
pet (Turner, 2017), however some owners have a poor understanding of cat welfare needs (Rioja-Lang et al., 
2019) and the impact of DJD on the cats’ quality of life (QoL) has not been fully established.  
Diagnosis of DJD requires combining information obtained from the owner, physical examination, and 
radiography, nevertheless it primarily depends on owners detecting changes in their cat’s activity and 
behaviour, then seeking veterinary advice. Unfortunately, given the insidious onset and the subtlety of the 
clinical signs associated with DJD (Bennett and Morton, 2009, Clarke et al., 2005, Hardie et al., 2002, Klinck et 
al., 2012, Lascelles et al., 2007c) as well as the ability of cats to mask signs of disease (Gowan and Iff, 2016), it 
is likely that the disease is not recognised in a significant number of cats. Diagnosis is far from straightforward 
even in the consulting room as the stress that cats are subjected to when removed from their home 
environment can affect physiological parameters (Quimby et al., 2011), and possibly how cats exhibit pain 
within the consult room. In addition, cats may not allow clinicians to perform an orthopaedic examination or, 
even if they do, it is not always clear if resistance to joint palpation is due to pain or fear of handling (Clarke 
and Bennett, 2006, Lascelles et al., 2012). Radiographic findings may also not always correspond to orthopaedic 
findings, making feline DJD quite challenging to diagnose (Clarke and Bennett, 2006, Lascelles et al., 2007c). 
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Activity monitors have been used successfully to differentiate healthy cats from cats with DJD (Guillot et al., 
2012, Lascelles et al., 2007c, Lascelles et al., 2008a), and these devices may also have the potential to 
objectively detect early signs of DJD in cats where the diagnosis has not yet been established.   
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1.2 The Feline Joint 
1.2.1 Physiology 
Joints are the connections between two bones that allow body parts to move, and are comprised of adjacent 
bones, subchondral bone, articular cartilage, ligaments, and tendons (Figure 1.1). 
 
Figure 1.1: Components of a Feline Stifle Joint 
(Taken from MSD Veterinary Manual, 2019) 
 
Structurally, feline joints are divided into fibrous, cartilaginous, and synovial joints. Adjacent bones are joined 
by fibrous connective tissue in fibrous joints and by cartilage in cartilaginous joints. Cartilage is a more flexible 
type of connective tissue, allowing more movement between bones in cartilaginous than fibrous joints. Neither 
the bones of fibrous nor of cartilaginous joints have a joint cavity between them. On the other hand, synovial 
joints have a membrane that lines the joint and forms a cartilage-lined cavity filled with synovial fluid, a 
lubricating liquid secreted by the synovial membrane. Some synovial joints additionally have a fibrocartilage 
structure between the articulating surfaces of bones termed articular disc or meniscus, depending on its shape. 
The joint capsule connects the adjacent bones indirectly to each other, resulting in increased mobility. Synovial 
joints are further classified based on the shape of the bones’ articulating surfaces into plane, hinge, pivot, ball-





Figure 1.2: Schematic Illustration of the Six Types of Synovial Joints and the Types of Joint Movement.  
A: Plane, B: Hinge, C: Pivot, D: Ball-and-socket E: Condyloid, F: Saddle 
(Adapted from Study.com, 2019)  
 
1.2.2 Joint Disorders 
Joint disorders can be of inflammatory or non-inflammatory origin. Inflammatory joint disorders can be 
infectious or immune-mediated, affecting one (monoarthritis) or multiple (polyarthritis) joints. A plethora of 
bacterial, viral, fungal and rickettsial infectious agents is responsible for inflammatory joint disorders of 
infectious origin in cats (Lemetayer and Taylor, 2014). Non-inflammatory joint disorders are more common, 
and include developmental, degenerative, neoplastic, and traumatic causes. Irrespective of the instigating 
cause, all joint disorders are associated with varied degrees of pain and discomfort. 
 
1.2.3 Physiology of Pain 
Pain is classified as an unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage (Merskey and Bogduk, 1994). Nociception refers to the 
physiologic component of pain consisting of the processes of transduction, transmission, and modulation of 
neural signals generated in response to an external noxious stimulus (Mathews et al., 2014). Pain is a complex 
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multi-dimensional experience that involves sensory, affective and functional components and is unique to the 
individual; not all animals may experience pain in response to nociception (Mathews et al., 2014). 
Pain had traditionally been categorised as acute or chronic based on its duration, with chronic pain defined in 
human medicine as any pain that lasts more than three to six months (Merskey and Bogduk, 1994). More 
recently, the terms adaptive and maladaptive have been adopted to better describe pain (Woolf et al., 2004). 
Adaptive pain includes nociceptive and inflammatory pain (Figure 1.3). Nociceptive pain occurs in response to 
a noxious stimulus that may or may not cause tissue injury, whereas inflammatory pain follows tissue injury 
and is accompanied by an inflammatory response and inflammatory mediators that sensitise neural pathways. 
Both types of pain are reversible and considered protective.  
 
 
Figure 1.3: Schematic Illustration of Adaptive Pain  




Maladaptive pain, on the other hand, can develop from poorly treated adaptive pain and is the result of 
physical changes occurring in the brain and spinal cord (Figure 1.4). Maladaptive pain includes neuropathic 
pain, where direct damage to the neural tissue has occurred, and functional pain, where there is a dysfunction 
of the nociceptive system. Pivotal to the development of maladaptive pain are peripheral and central 
sensitisation (Adrian et al., 2017). In peripheral sensitisation, cell damage to an area causes the release of 
chemical mediators that sensitise nerve terminals or directly activate nociceptors, resulting in an increased 
sensitivity to afferent nerve stimuli. Central sensitisation involves the nervous system undergoing cellular wind-
up then remaining autonomously in a high excitability state, thus lowering pain threshold. Two clinical 
phenomena are the hallmark of peripheral and central sensitisation: hyperalgesia and allodynia. Hyperalgesia 
is a stronger and prolonged pain response to a stimulus that would normally be painful, whereas allodynia is a 
pain response to a normally innocuous stimulus. 
 
 
Figure 1.4: Schematic Illustration of Maladaptive Pain  
(Taken from Adrian et al., 2017)  
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1.3 Feline Degenerative Joint Disease 
1.3.1 Definition 
Degenerative joint disease is a type of non-inflammatory joint disease that results from the gradual destruction 
of one or more joint components. This disease develops in all mammals and can affect synovial and 
cartilaginous, but not fibrous, joints.  
Although the terms DJD and osteoarthritis have been used interchangeably, osteoarthritis refers to the 
degenerative process affecting synovial joints only. For the purposes of this thesis, the term appendicular DJD 
will be used to refer to degenerative pathology affecting synovial joints and the term axial DJD to refer to 
degenerative pathology affecting the spine. 
 
1.3.2 Pathophysiology of Degenerative Joint Disease 
The gradual loss of articular cartilage is considered one of the earliest markers of DJD progression (Eyre et al., 
2006). Although there are repair mechanisms within the cartilage, it is likely that they decline with age which 
could partially explain the increased prevalence of DJD with age (Li et al., 2013). Since the mechanical 
properties of articular cartilage are directly linked to its biochemical composition, the weakening of its repair 
mechanisms also affects other joint components and destabilises the joint further, causing mechanical cartilage 
injury (Renberg, 2005). This results in cartilage ulceration, subchondral sclerosis and formation of subchondral 
cysts, periarticular osteophyte formation, interarticular mineralisation and periarticular tissue inflammation 
(Dedrick et al., 1993). Proposed cellular mechanisms in DJD are shown in Figure 1.5. Although there is a paucity 
of feline-specific studies investigating the pathophysiology of DJD, studies to date support these findings 




Figure 1.5: Cellular Mechanisms in Degenerative Joint Disease. 
Cyclo-oxygenase (COX); interleukin (IL); inducible nitric oxide synthase (iNOS); matrix metalloproteinase (MMP); nitric oxide 
(NO); tissue inhibitor of metalloproteinase (TIMP); tumour necrosis factor α (TNF-α).  
(Adapted from  Abercromby et al., 2018) 
 
1.3.2.1 Pathophysiology of Degenerative Joint Disease-related Pain 
In humans, nerve growth factor (NGF) is considered a key molecule for nociceptor biology since clinical studies 
demonstrated that antibodies against NGF provided significant pain relief in patients with DJD (Schaible, 2012). 
Cytokines are also believed to play an important role; these are signalling proteins secreted by specific cells of 
the immune system that mediate inflammation among other things. Specifically, some cytokines such as 
tumour necrosis factor (TNF)-α, interleukin (IL)-6 and IL-1β seem to be involved in inflammation and 
destruction in DJD (Schaible, 2012).  
Clinical studies in human patients have documented that central sensitisation occurs in DJD and that DJD has 
a complex pain state, involving adaptive (nociceptive, inflammatory) as well as maladaptive (neuropathic) pain 
components (Schaible, 2012). Figure 1.6 displays a model of the joint nociceptive system indicating major 




Figure 1.6: Model of the Nociceptive System of the Joint and Major Processes Likely to Underlie DJD-related Joint Pain 
(Taken from Schaible, 2012) 
 
The pathophysiology of DJD-related pain has not been elucidated in cats, however DJD has been established 
as a clinical condition that results in long-term pain in this species (Robertson and Lascelles, 2010). Central 
sensitisation has also been shown to occur in cats with DJD (Guillot et al., 2013). Consequently, multimodal 




Multiple studies have investigated the prevalence of radiographic DJD in cats. Appendicular DJD has been 
studied more extensively, with prevalence ranging from 22% to 74% and 61% to 91% in retrospective and 
prospective studies investigating all joints, respectively (Table 1.1). Bilateral disease is a common finding, 
occurring in 46% to 91% of cats with appendicular DJD depending on if it was estimated based on radiography 
(Godfrey and Vaughan, 2018, Kimura et al., 2020) or combined orthopaedic and radiographic findings (Clarke 
and Bennett, 2006, Godfrey, 2005, Lascelles et al., 2010b, Slingerland et al., 2011). 
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Mean age  
(years) 
% of cats with 
DJD in ≥ 1 joint 
Most commonly  
affected joint 
Reference 
PC Cx 2.5 19 - (Langenbach et al., 1998) 
RS Cx 2.8 6.3 - (Keller et al., 1999) 
RCS Stifles 3.3 68 - (Loughin et al., 2006) 
RS All 15.2 64 Elbow (17%) (Hardie et al., 2002) 
RS All 6.5 (10.2 
median) 
16.5 Cx (51%) (Clarke et al., 2005) 
RS All 8.2 22 Elbow (21.8%) (Godfrey, 2005) 
RS All 10.1 57 Cx (34%), Elbow (24%), 
Shoulder (21%), Stifle (19%), Tarsus 
(17%), Carpus (3%) 
(Godfrey, 2008) 
PC All 11 
(median) 
- Elbow (45%), 
Cx (38%) 
(Clarke and Bennett, 2006) 
PC All 9.5 91 Cx (65%), Stifle (50%), Tarsus (40%), 
Elbow (35%) 
(Lascelles et al., 2010b) 
PC All 11 61 Shoulder, Elbow, Cx , Tarsus (Slingerland et al., 2011) 
RS All 7.8 74 Stifle (53%), Cx (46%), Elbow (42%), 
Tarsus (30%) 
(Godfrey and Vaughan, 2018) 
RS All 9.8 74.3 Elbow, Stifle (Kimura et al., 2020) 
Coxofemoral (Cx); Degenerative Joint Disease (DJD); Prospective cohort (PC); Retrospective case series (RCS); Retrospective 
survey (RS). Median. 
 
With regards to axial DJD, prevalence ranges from 21% to 80% in retrospective studies and from 55% to 92% 
in prospective studies (Table 1.2). The thoracic and lumbosacral regions are the most commonly and most 
severely affected areas, respectively. 
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Table 1.2: Summary Findings of the Reported Prevalence of Radiographic Axial Feline Degenerative Joint Disease 
Study  
Design 
Mean age  
(years) 







RS Unknown (older) 58 Thoracic (T7-8) - (Beadman, 1964) 
RS 15 80 - Lumbosacral (Hardie et al., 2002) 
RS 6.5 21 Thoracic (T6-7, 9-10) Lumbar (Clarke et al., 2005) 
PC 11 - Thoracic Thoracic (Clarke and Bennett, 2006) 
PC 14 92 Thoracic - (Lascelles et al., 2007b) 
PC 9.5 55 Thoracic Lumbosacral (Lascelles et al., 2010b) 
RS 9.8 40.6 Lumbosacral Lumbosacral (Kimura et al., 2020) 
Degenerative Joint Disease (DJD); Prospective cohort (PC); Retrospective survey (RS). Median 
 
Prevalence differences between retrospective and prospective studies most likely reflect different study 
designs. Estimating DJD prevalence based on retrospective radiographical studies for example is difficult for 
several reasons. Firstly, the age between study populations differs greatly and is not equally distributed, which 
makes drawing firm conclusions difficult. In addition, due to the retrospective nature of these studies, not all 
radiographs were obtained with the intent to study the joints, some views were missing, and sometimes 
routine thoracic or abdominal radiographs were used to estimate prevalence. Another confounding factor in 
comparing results from different studies irrespective of their design is the fact that each study used different 
radiographical criteria to grade DJD according to severity (Clarke and Bennett, 2006, Clarke et al., 2005, 
Godfrey, 2005, Hardie et al., 2002, Slingerland et al., 2011).  
 
1.3.4 Causes 




Table 1.3: List of Recognised and Postulated Primary and Secondary Causes of Feline Degenerative Joint Disease 
Primary 
• Scottish Fold osteochondrodysplasia (Gandolfi et al., 2016, Malik et al., 1999) 
• Mucopolysaccharidosis VI (Crawley et al., 2003, Macri et al., 2002) 
• Age-related cartilage degeneration (Lascelles, 2010) 
Secondary 
• Congenital / Developmental 
o Hip dysplasia (Keller et al., 1999, Langenbach et al., 1998, Loder and Todhunter, 2018) 
o Patellar luxation (Langenbach et al., 1998, Loughin et al., 2006, Smith et al., 1999) 
o Elbow dysplasia (Freire et al., 2014, Freire et al., 2011, Staiger and Beale, 2005) 
o Elbow luxation (Rossi et al., 2003, Valastro et al., 2005) 
• Traumatic 
o Cranial cruciate ligament injury (Harasen, 2005, Herzog et al., 1993, Leumann et al., 
2019, Wessely et al., 2017, Wu et al., 2000) 
o Other trauma (Clarke and Bennett, 2006, Clarke et al., 2005, Godfrey, 2005, Hardie et 
al., 2002, Johnston, 1997) 
• Nutritional – Hypervitaminosis A (Polizopoulou et al., 2005) 
• Endocrine – Hypersomatotropism (Peterson et al., 1990, Wassenaar et al., 2009) 
• Neoplastic 
o Synovial osteochondromatosis (Tan et al., 2010, Tas et al., 2013) 
o Osteosarcoma (Godfrey, 2005) 
• Immune-mediated (Gao et al., 2013, Lemetayer and Taylor, 2014) 
o Erosive polyarthropathies 
 Feline periosteal proliferative polyarthritis 
 Feline rheumatoid-like arthritis 
o Non-erosive polyarthropathies  
 Primary or idiopathic 
 Secondary (Reactive polyarthritis, systemic lupus erythematosus) 
• Infectious (Lemetayer and Taylor, 2014) 
o Mycoplasma spp (Liehmann et al., 2006, Moise et al., 1983, Zeugswetter et al., 2007) 
o Bartonella spp (Tomas et al., 2015) 
o Histoplasma capsulatum (Wolf, 1987) 
o Cryptococcus neoformans (Tisdall et al., 2007) 
o Feline leukaemia virus (Oohashi et al., 2010, Pedersen et al., 1980) 
o Feline syncytia-forming virus (Inkpen, 2015, Pedersen et al., 1980) 
 
Primary or idiopathic DJD is suggested to occur without an apparent initiating cause. Scottish Fold 
osteochondrodysplasia (SFO) and mucopolysaccharidosis are considered primary forms of DJD in cats. Briefly, 
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SFO is a  dominantly inherited disorder which results from a generalised defect in cartilage metabolism, causing 
malformations in the distal forelimbs, distal hindlimbs and tail as well as progressive appendicular joint 
destruction (Gandolfi et al., 2016, Malik et al., 1999). Mucopolysaccharidosis VI is a recessively inherited 
disease that has been identified in Siamese and domestic shorthair (DSH) cats, with affected cats exhibiting 
malformations of the skull, vertebrae and joints, resulting in arthropathies (Crawley et al., 2003, Macri et al., 
2002). Nevertheless, neither SFO nor mucopolysaccharidosis are commonly encountered in practice, and most 
cases with DJD have no obvious initiating cause. This has been termed age-related cartilage degeneration 
(Lascelles, 2010) and, as primary DJD is a diagnosis of exclusion, it is possible that factors that have yet to be 
recognised are responsible for the occurrence of DJD in these cats. Secondary DJD occurs as a result of a specific 
disease process and a plethora of recognised and postulated factors of congenital, traumatic, nutritional, 
endocrine, infectious, and immune-mediated origin have been linked with its development. 
Hip dysplasia (HD) is a developmental disease that has been established to result in secondary DJD (Keller et 
al., 1999, Langenbach et al., 1998, Loder and Todhunter, 2018). It has a reported incidence ranging from 7% to 
32%, with secondary DJD reported in 60% to 95.5% of cases and with Maine Coon, Persian and Himalayan being 
the most commonly affected breeds (Table 1.4).  
 








Breed Cats  
with HD 
Cats  
with HD + DJD 
Reference 
PC 78 2.5 22% DSH,  
78% purebred 
25 (32%) 15 (60%) (Langenbach et al., 1998) 
RS 684 2.8 88% DSH,  
12% purebred 
45 (6.6%) 43 (95.5%) (Keller et al., 1999) 
RS 2548 0.5 – 2.5 Maine Coon 635 (24.9%) - (Loder and Todhunter, 2018) 




Patella luxation is another developmental disease that has been established as a cause of secondary DJD in 
both pedigree and non-pedigree cats (Smith et al., 1999). In a more recent study, variable degrees of DJD were 
seen in 64% of stifle joints with patella luxation, and the cats that exhibited the most severe DJD also had a 
grade 4 luxation, which could suggest that the severity of DJD in the stifle increases in response to the increase 
in patella luxation severity (Loughin et al., 2006). In the same study, an association was also found between HD 
and patellar luxation, with 43% of cats suffering from both conditions. This substantiates the findings of a 
previous study where 24% of cats had both conditions and cats were three times more likely to suffer from 
both than from either condition alone (Langenbach et al., 1998).  
Elbow dysplasia has also been suggested to result in secondary DJD (Staiger and Beale, 2005). However, in 
subsequent studies evaluating elbow DJD neither fractured medial coronoid process nor osteochondritis 
dissecans, the most common forms of elbow dysplasia in dogs, were shown to play a role in the development 
of feline DJD (Freire et al., 2014, Freire et al., 2011). Elbow luxation is unlikely to be a cause of secondary DJD 
based on the only two published case reports (Rossi et al., 2003, Valastro et al., 2005). 
Trauma has been historically postulated to be a cause of DJD (Hardie et al., 2002, Johnston, 1997) and has been  
suggested to be a secondary cause of DJD in both retrospective and prospective studies of cats with DJD (Clarke 
and Bennett, 2006, Clarke et al., 2005, Godfrey, 2005). However, to the researcher’s knowledge, the occurrence 
of DJD following joint trauma has not been evaluated. Transection of the cranial cruciate ligament (CCL) has 
been shown to lead to secondary DJD in experimental models (Herzog et al., 1993, Leumann et al., 2019, Wu 
et al., 2000), but the aetiopathogenesis of feline CCL disease has not been elucidated. One case study with 17 
cats suggested both a traumatic and a degenerative aetiology, although only a single CCL was examined 
histologically (Harasen, 2005), whereas a more recent case study examined 19 ruptured CCL and did not find 
any histological evidence to support a degenerative process (Wessely et al., 2017).  
Hypervitaminosis A has been reported in cats whose diet predominantly consists of liver and is rarely seen 
nowadays since most cats are mainly fed nutritionally complete commercial diets (Polizopoulou et al., 2005). 
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The increased risk of developing DJD secondarily to hypersomatotropism (acromegaly) is well recognised in 
human patients, with DJD-related clinical signs being present in 50% to 70% of patients at diagnosis (Wassenaar 
et al., 2009). Secondary DJD in acromegalic cats has only been reported in one case study (Peterson et al., 
1990), with 42.9% of cats with acromegaly exhibiting DJD-related radiographical changes in their shoulder, 
elbow, carpus, stifle, digits and spine. Although this study reported the concurrent presence of both disease 
processes, the causal effect was not evaluated. Consequently, since all study cats were middle-aged or older, 
it is possible that the cats were suffering from age-related cartilage degeneration rather than secondary DJD 
as a result of acromegaly. 
With regards to neoplasia as a secondary cause of DJD, another suggested cause is synovial 
osteochondromatosis. However, these benign lesions reportedly occur less likely as a primary entity, but more 
commonly represent a degenerative condition of synovial epithelium near joints affected by DJD (Tan et al., 
2010, Tas et al., 2013). Appendicular DJD was also reported secondarily to a single case of osteosarcoma in a 
retrospective study (Godfrey, 2005), however an association between joint malignant neoplasia and secondary 
DJD has not been reported elsewhere to the researcher’s knowledge. 
An immune-mediated aetiopathogenesis has been proposed for several forms of secondary DJD. These were 
initially termed ‘chronic progressive arthritis’ (Pedersen et al., 1980), but then it became clear that different 
forms existed (Bennett and Nash, 1988). More recently, differences were found in the immune responses 
between cats with DJD and age-matched controls, suggesting that an impaired immune response could cause 
and/or exacerbate DJD (Gao et al., 2013). Immune-mediated polyarthropathies are presently classified as 
erosive or non-erosive based on clinical and radiographic findings (Lemetayer and Taylor, 2014). Erosive 
polyarthropathies include feline periosteal proliferative polyarthritis and feline rheumatoid-like arthritis, 
whereas non-erosive polyarthropathies occur as a primary or idiopathic disorder, secondarily to antigenic 
stimulation (reactive polyarthritis) or as a feature of systemic lupus erythematosus (Gao et al., 2013). 
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Infectious agents such as Bartonella spp (Tomas et al., 2015), Mycoplasma gatae (Moise et al., 1983, 
Zeugswetter et al., 2007), Mycoplasma felis (Liehmann et al., 2006), Histoplasma capsulatum (Wolf, 1987), 
Cryptococcus neoformans (Tisdall et al., 2007), Feline leukemia virus (Oohashi et al., 2010, Pedersen et al., 
1980) and Feline syncytia-forming virus (Inkpen, 2015, Pedersen et al., 1980) have also been postulated to be 
instigating factors in the development of secondary DJD. Bacterial arthritis as a result of direct inoculation with 
bacteria or haematogenous spread has been occasionally reported in the literature as a cause of DJD in cats 
(Lemetayer and Taylor, 2014), with Godfrey (2005) first reporting appendicular DJD occurring secondarily to 
osteomyelitis. Contrary to a study in dogs where an association between Bartonella spp. seropositivity and 
disease states was established (Henn et al., 2005), Bartonella spp. seropositivity was associated with decreased 
severity of DJD in a recent study (Tomas et al., 2015). 
 
1.3.5 Risk Factors 
Age is the only identified risk factor for feline DJD (Lascelles et al., 2010b, Slingerland et al., 2011), with one 
prospective study showing that the expected total DJD score (which reflects the severity of the disease) 
increased by approximately 14% for each 1-year increase in a cat’s age (Lascelles et al., 2010b). Only one study 
found no association between age and DJD severity (Hardie et al., 2002); however, this study’s population 
included cats exclusively over the age of 12 which may have resulted in the inability to observe this association. 
The association between obesity and the development of DJD has been established in humans (Vina and Kwoh, 
2018) and in dogs (Zoran, 2010). It has been postulated that obesity is a risk factor for the development of 
secondary DJD in cats; nevertheless, a causal relationship has yet to be shown. Overweight cats were more 
likely to be diagnosed with a locomotor disease in a retrospective study (Ohlund et al., 2018), whereas 
overweight and obese cats were, respectively, approximately three and five times more likely to develop 
lameness requiring veterinary care in a prospective study of approximately 1,500 cats (Scarlett and Donoghue, 
1998). In the later study, it was speculated that cartilage damage and appendicular DJD could have been caused 
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by excess bodyweight or a generalised abnormality in lipid metabolism which is in line with the proposed 
biomechanical mechanisms in humans (Guilak, 2011) and dogs (Marshall et al., 2009). Unfortunately, the cause 
of lameness and, consequently, a possible association with DJD was not evaluated. No significant association 
between weight or BCS and appendicular DJD severity (Slingerland et al., 2011) or radiographic signs of DJD 
(Clarke et al., 2005) was found in two retrospective studies. In a prospective study, bodyweight and BCS were 
not associated with appendicular DJD either, but a negative association was found with axial DJD severity 
(Lascelles et al., 2010b). The authors suggested this could be explained by the effect of age on bodyweight 
since older cats have been demonstrated to have increased maintenance energy requirements which results 
in a decreased weight and BCS (Laflamme, 2005). Apart from increasing age, none of the other proposed 
variables were found to be significantly associated with the development of DJD (Table 1.5). 
 






















hlund et al., 2018
 C 
Age        
BCS        
Sex        
Neuter status        
Breed        
Time spent outdoors        
Vaccination status        
FeLV/FIV status        
Use of flea/tick prevention        
Body Condition Score (BCS); Feline leukaemia virus (FeLV); Feline immunodeficiency virus (FIV).  
Study design marked as Cross-sectional (C); Prospective cohort (PC); Retrospective survey (RS). 
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Hardie and others (2002) did not find any association between DJD severity and a plethora of diseases, such as 
diabetes mellitus, hyperthyroidism, neoplasia (other than thyroid neoplasia), dental disease, gastrointestinal 
disease, urinary tract disease, cardiovascular disease, ocular disease, and skin disease. Notwithstanding the 
lack of association between neurological signs and appendicular DJD severity, there was a significant 
association between neurological signs and axial DJD severity.  
A number of haematologic, serum biochemical and urinalysis variables were initially found to be significant 
predictors of DJD and DJD severity when considered individually (Lascelles et al., 2010b). None of these 
variables were however significantly associated with the presence of DJD or DJD severity once age was 
accounted for. Nevertheless, the authors speculated that some of the investigated variables may be associated 
with DJD and that the same pathological process may be observed in DJD and, for example, chronic kidney 
disease. Interestingly, a recent retrospective study reported that approximately 70% of cats with DJD had 
concurrent CKD and that concurrent CKD was associated with higher levels of feline DJD pain, supporting the 
notion of a common pathway (Chiu et al., 2019). This newer finding could also possibly explain the very strong 
association found between lipase and DJD in the study by Lascelles and others (2010b), since the decreased 
renal function observed in CKD would also decrease lipase clearance. Dental disease is another chronic 
inflammatory process associated with age, and an independent association between the severity of dental 
disease and the development of CKD has been found (Finch et al., 2016). This additional finding further 
endorses the concept of a common pathway linking chronic inflammatory processes such as dental disease, 
CKD and DJD. 
 
1.3.6 Clinical Signs 
Domestic cats have retained the instinctive behaviour of wild cats to hide overt signs of pain and disease from 
potential predators (Gowan and Iff, 2016). Although this has resulted in DJD-associated clinical signs being 
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subtle, owners are generally able to recognise them when appropriately directed by the veterinary surgeon 
(Bennett and Morton, 2009b, Klinck et al., 2012).  
Owner observations are extremely useful in veterinary medicine as they provide veterinary surgeons with 
insight on the cat’s mobility and behaviour in their natural environment, away from the stress associated with 
visiting the clinic. Lameness is the most cardinal sign of DJD in dogs (Pettitt and German, 2015), however it is 
rarely the presenting complaint in cats as it is only reported in 4% to 17.5% of cats with DJD (Clarke et al., 2005, 
Hardie et al., 2002). This may be explained by the fact that bilateral disease is quite common in cats with DJD, 
and therefore the gait asymmetry that is needed for lameness to be observed is not present. It is also possible 
that lameness is not a major feature of feline DJD. Indeed, no lameness was observed during the 1-year 
duration of an experimental study involving a feline cruciate transection model of DJD despite progression of 
radiographic DJD (Suter et al., 1998). Studies to date agree that the most common owner-reported changes 
seen in cats suffering from DJD-associated pain relate to mobility (altered jumping frequency and height, 
altered stair use, altered gait), followed by decreased activity levels, decreased grooming as well as changes in 
social behaviour and litter box use (Bennett and Morton, 2009, Klinck et al., 2012, Lascelles et al., 2007c, 
Slingerland et al., 2011). Cats with DJD also display increased vocalisation, resistance to handling, changes in 
play and hunting behaviour (Hardie et al., 2002, Klinck et al., 2012). 
 
1.3.7 Diagnostic Methods 
Diagnosis of DJD requires combining information obtained from the owner, physical examination, and 




Figure 1.7: Multidimensional Approach to Diagnosing Degenerative Joint Disease 
 
1.3.7.1 History Evaluation and Owner Observations 
The index of suspicion for the presence of DJD may be raised if veterinary surgeons identify a) known primary 
or secondary causes of DJD whilst evaluating a cat’s medical record, or b) previously described DJD-related 
clinical signs during history taking. 
 
1.3.7.2 Physical Examination 
In addition to obtaining information from the owner about changes in the cat’s mobility and behaviour, 
veterinary surgeons should also perform a physical examination. The stress that cats are subjected to when 
removed from their home environment and taken to the veterinary practice has been shown to affect 
physiological parameters (Quimby et al., 2011). This may also affect how cats exhibit pain within the consult 
room and thereby make the interpretation of the orthopaedic examination more difficult. Visual gait analysis 
involves subjectively observing an animal’s gait and should ideally be undertaken before the orthopaedic 
examination takes place. Nevertheless, a low agreement was shown between visual and objective gait analysis 
in dogs with orthopaedic disease (Quinn et al., 2007), disputing its diagnostic value. In cats, it is likely that the 
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agreement is even lower, not only due to the high prevalence of bilateral disease and resulting lack of gait 
asymmetry, but also due to the unwillingness of the species to walk within the consult room.  
An orthopaedic examination involves manipulating individual joints and assessing the degree of pain, crepitus, 
effusion and thickening associated with each joint (Lascelles et al., 2012). Resistance to joint palpation and 
manipulation is a common finding in cats with DJD; however, this may often be due to fear of handling, which 
would result in overestimating the number of clinically affected joints. Conversely, some cats may not tolerate 
the orthopaedic examination and their reaction may not necessarily reflect that the assessed joint was painful 
(Clarke and Bennett, 2006, Lascelles et al., 2012), which would in turn result in underestimating the number of 
clinically affected joints. 
 
1.3.7.3 Radiography 
Computed tomography and magnetic resonance imaging are powerful imaging modalities but are not routinely 
used to confirm the presence of DJD. Radiography has historically been performed to support orthopaedic 
examination findings, further raising the degree of suspicion, or confirming the presence of DJD.  
Nevertheless, radiographic findings may not always correspond to orthopaedic findings and vice versa. 
Radiographic findings agreed with orthopaedic findings in 66% of joints with DJD in one prospective study 
(Clarke and Bennett, 2006), whereas in another prospective study only 33% of joints with radiographic signs of 
DJD were found to be painful on orthopaedic examination (Lascelles et al., 2007c). Nevertheless, Lascelles and 
others (2012) suggested that absence of pain, crepitus, effusion or thickening in conjunction with normal 
goniometry (joint angle measurement) can be used to confidently rule out the presence of radiographic DJD 
and, at the same time, detecting crepitus, effusion and thickening will increase the likelihood of radiographic 
DJD being present. 
With regards to the radiographic criteria of feline DJD, Allan (2000) suggested that the radiographic signs of 
appendicular DJD in cats are similar to those seen in dogs. Following this, Hardie and others (2002) used a 
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scoring system that considered both the presence and the severity of DJD-associated radiographic features 
(Morgan, 1999). The same criteria were used in both studies by Clarke (Clarke and Bennett, 2006, Clarke et al., 
2005). In his earlier studies (Godfrey, 2008, Godfrey, 2005), Godfrey considered appendicular DJD present if 
some of the criteria described by Hardie and others were present. A few years later, it was suggested that the 
radiographic appearance of feline DJD differs from canine DJD, and a group of board certified veterinary 
radiologists and surgeons established their own criteria for the evaluation of radiographic signs of feline 
appendicular DJD (Freire et al., 2011, Lascelles et al., 2010b). The same criteria were later used by Godfrey and 
Vaughan (2018), although before that Slingerland and others (2011) chose to use some of the criteria suggested 
by Hardie and others (2002) instead. The different radiographic criteria used to describe the radiographic 
appearance of appendicular DJD are listed in Table 1.6.  






Hardie et al., 2002 
G
odfrey, 2005 
Clarke et al., 2005 




Lascelles et al., 2010 





Osteophytes           
Enthesophytes 
          
Periarticular new bone formation           
New bone formation (tarsal joint)           
Joint-associated mineralisation         ¥  
Intra-articular mineralisation 
          
Sclerosis 
          
Joint effusion 
          
Subchondral bone erosions/cysts 
          
Subluxation coxofemoral joint           
Described as periarticular bone formation within the text. ¥Described as soft tissue mineralisation within the text. Described 
as increased subchondral bone density within the text. 
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With regards to the radiographic features of axial DJD, these have not been researched as extensively. 
Morgan’s scoring system was used in two studies (Clarke et al., 2005, Hardie et al., 2002) before the same 
group that established radiographic criteria in feline appendicular DJD did so for axial DJD (Lascelles et al., 
2010b). The different radiographic criteria used to describe the radiographic appearance of axial DJD are listed 
in Table 1.7. 
 





Hardie et al., 2002 
Clarke et al., 2005 
Lascelles et al., 2010 
Osteophytes 
   
Enthesiophytes 
   
Spondylosis    
Disc-associated degeneration 
   




1.4 Chronic Pain Assessment in Feline Degenerative Joint Disease  
All animals experience pain; however, response to pain depends on the animal’s age and species (Epstein et 
al., 2015). Pain assessment in cats with DJD is challenging not only due to the species’ ability to mask signs of 
pain, but also because pain-related behavioural changes such as aggression, avoidance of handling and lack of 
responsiveness to human attention (Lascelles and Waterman, 1997) are sometimes considered part of the 
natural ageing process by owners (Merola and Mills, 2016). 
 
1.4.1 Subjective Outcome Measures of Chronic Pain 
1.4.1.1 Clinical Metrology Instruments 
Clinical metrology instruments (CMI) are tools that can be used for the assessment of pain and take the form 
of questionnaires. There are two types of CMIs, those that are completed by owners and those that are 
completed by veterinary surgeons. 
Owner assessments comprise the mainstay of chronic pain assessment in veterinary medicine given the 
inability of animals to assess and self-report pain. One of the main advantages of using CMIs is that they 
facilitate assessment in the home environment where cats are not subjected to the stress of visiting the clinic. 
In addition, they are easy to use and cost effective. There are several CMIs aimed at owners available for the 
assessment of chronic pain in cats suffering from DJD: the Zamprogno Question Bank (ZQB), the Feline 
Musculoskeletal Pain Index (FMPI), the Owner Behaviour Watch (OBW), the Feline Physical Function Formula 
(FPFF), the Montreal Instrument for Cat Arthritis Testing – Caretaker/Owner (MI-CAT(C)) and the Client Specific 
Outcome Measures (CSOM).  
The ZQB contains items identified as essential after the authors showed that behaviours linked to activity 
differed between cats with DJD and DJD-free cats (Zamprogno et al., 2010); this was later used to construct the 
FMPI. The FMPI (Appendix A) is a general subjective outcome measure where the ability of cats to perform 17 
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activities compared to a normal cat is rated by their owners on a Likert scale; it has been shown to have 
discriminatory validity and good repeatability (Benito et al., 2013a, Benito et al., 2013b, Gruen et al., 2015). 
This CMI has been used in clinical studies evaluating pain relief for DJD-associated pain (Gruen et al., 2014, 
Gruen et al., 2016), as well as the management of pantarsal arthrodesis (Alza Salvatierra et al., 2018), tibial 
fractures (Craig et al., 2018) and cranial cruciate ligament disease (Boge et al., 2019). The OBW is also a general 
subjective outcome measure where the ability of cats to perform activities assigned to four domains (mobility, 
activity, grooming, temperament) is compared to a normal cat, and their overall problem severity is rated by 
their owners on a Likert scale. This CMI was constructed to evaluate treatment response in cats with DJD 
receiving meloxicam (Bennett and Morton, 2009) and was later used to evaluate treatment response in cats 
with DJD receiving both meloxicam and glucosamine/chondroitin sulphate (Sul et al., 2014). The MI-CAT(C) is 
a newer general subjective outcome measure that contains 38 items relating to a cat’s ability, behaviour and 
physical condition; these are again rated by owners on a Likert scale (Klinck et al., 2018a). Following content 
validation and piloting (version one), the researchers conducted a randomised, blinded, placebo-controlled 
study, producing version two. The FPFF is another general subjective outcome measure which was based on 
the OBW and has been evaluated in one study (Stadig et al., 2019). The CSOM on the other hand is an 
individualised subjective outcome measure where three activities are selected by owners and the ability of 
their cats to perform them is rated on a Likert scale (Benito et al., 2013a, Gruen et al., 2015, Lascelles et al., 
2007c). This CMI has been used exclusively to evaluate the DJD in cats, and in particular pain relief for DJD-
associated pain (Gruen et al., 2017b, Gruen et al., 2014, Gruen et al., 2016, Guedes et al., 2018b) and a 
therapeutic diet (Lascelles et al., 2010a). Only FMPI, MI-CAT(C) and CSOM have been tested in blinded, placebo-
controlled studies (Gruen et al., 2014, Gruen et al., 2015, Gruen et al., 2016, Lascelles et al., 2007c), with Klinck 
and others (2018a) suggesting that further refinement and testing in a larger sample of cats is necessary for 
MI-CAT(C). The results of a more recent study compared different CMIs (ZQB, OBW, FPFF, FMPI) and suggested 
that FMPI is the best CMI to use in a clinical setting (Stadig et al., 2019). Indeed, the FMPI is also the researcher’s 
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preferred general CMI due to its proven validity and reliability, ease of completion and repeated use in clinical 
studies.  
The Montreal Instrument for Cat Arthritis Testing – Veterinarian (MI-CAT(V)) is the only CMI to date that can 
be completed by veterinary surgeons in conjunction with the physical examination. In the preliminary study 
which was conducted in a laboratory colony of cats, only the items assessing gait and body posture were 
promising, but no scale items distinguished healthy cats from cats suffering from DJD in the follow up 
evaluation (Klinck et al., 2015). The revised MI-CAT(V), also tested on laboratory cats, was able to detect 
naturally occurring DJD, but not treatment effects (Klinck et al., 2018b). Consequently, further studies are 
needed to confirm the instrument’s performance in client-owned cats. 
 
1.4.1.2 Quality of Life 
In human medicine, the importance of patient-reported outcomes is widely recognised, as they provide 
important information relating to health outcome endpoint data, such as clinical signs, quality of life (QoL) and 
health related QoL (HRQoL) as well as treatment adherence (Arpinelli and Bamfi, 2006). The World Health 
Organisation defines QoL as an individual's perception of their position in life in the context of the culture and 
value systems in which they live, and in relation to their goals, expectations, standards and concerns (World 
Health Organisation, 1995). Since QoL is a broad, complex, and multidimensional concept, HRQoL attempts to 
focus on the QoL aspects which are affected by disease and can possibly be modified by treatment. In animals, 
HRQoL is also a multidimensional concept, including both physical and non-physical factors, such as 
comfort/discomfort and feelings, respectively (Mullan, 2015). Assessment of QoL in animals has similar 
challenges to chronic pain assessment; it relies on owners identifying issues that are affecting their animals’ 
QoL since animals are unable to self-report. Measurement of HRQoL can be used to identify or highlight QoL 
concerns that had not been previously perceived by the owner or to monitor changes in QoL over time in an 
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animal suffering from a chronic disease (Yeates and Main, 2009). Consequently, it can be a valuable tool for 
veterinary surgeons as it can help influence treatment decisions. 
 
1.4.1.2.1 Assessment Using Quality of Life Instruments 
There are numerous instruments which attempt to quantify QoL and HRQoL in veterinary medicine. Some are 
disease-specific, focusing on an individual condition, whilst others are generic, designed to be used more 
broadly. Disease-specific instruments can be more sensitive in recognising clinical changes, however generic 
instruments may be preferred when an animal is suffering from more than one disease, such as in the case of 
older cats. 
A plethora of disease-specific HRQoL instruments have been developed for cats, focusing on cardiac disease 
(Freeman et al., 2012, Reynolds et al., 2010, Rush et al., 2015), diabetes mellitus (Niessen et al., 2010), 
hyperthyroidism (Boland et al., 2014), feline infectious peritonitis (Fischer et al., 2011), skin disease (Noli, 2019, 
Noli et al., 2016), as well as neoplasia and use of chemotherapy (Lynch et al., 2011, Thornton et al., 2018, 
Tzannes et al., 2008, Vols et al., 2017). With regards to DJD-associated pain, an initial design of a questionnaire 
to assess DJD-associated pain and QoL in cats (Benito et al., 2012, Zamprogno et al., 2010) was followed by the 
development of the FMPI CMI (Benito et al., 2013a, Benito et al., 2013b, Gruen et al., 2015, Zamprogno et al., 
2010). 
Four generic HRQoL instruments have been published in cats. The first psychometric generic HRQoL to be 
developed and validated in cats was the CatQoL which contains 16 items (Bijsmans et al., 2016). In the second 
part of this study, the CatQoL was also used to compare the HRQoL of healthy young cats, healthy older cats, 
and cats with chronic kidney disease (CKD). The Cat HEalth and Wellbeing (CHEW) Questionnaire contains 33 
items and was shown to have good validity as well as internal and test-retest reliability (Freeman et al., 2016). 
Nevertheless, as all but eight out of 1303 cats were considered perfectly healthy by their owners, the authors 
suggested that further research is needed to verify its usefulness in a non-healthy cat population. Another 
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HRQoL instrument containing 16 items was validated and was shown to have good reliability, internal 
consistency and test-retest reliability in healthy cats (Tatlock et al., 2017). The VetMetrica instrument was the 
most recent and first web-based generic HRQoL instrument to be developed (Noble et al., 2019), containing 20 
items that are allocated in three domains (vitality, comfort and emotional wellbeing [EWB]). Following 
qualitative analysis of interview data, content validity index scores for relevance and clarity which had been 
assigned to each item were used to evaluate the content validity of included items, with the prototype 
VetMetrica instrument containing 39 items. After the first field test, the remaining 20 items were interpreted 
as part of the vitality, comfort, and EWB domains. Using these data, factor analysis was conducted by Noble 
and others (2019), with the model adopted accounting for 72% of the variability in the owner response data, 
confirming construct validity. A scoring algorithm was also developed as some items loaded to more than one 
domain. Following the second field test which compared sick versus healthy cats, linear discriminant analysis 
(LDA) showed that the instrument was able to correctly classify 89% of sick cats and 71% of healthy cats, 
whereas test-retest reliability was moderate for the vitality domain and good for the comfort and EWB 
domains. 
In the researcher’s opinion, VetMetrica is currently the best suited generic HRQoL available for assessing QoL 
in cats with DJD, with or without comorbidities, for several reasons. First, VetMetrica was used in healthy cats 
as well as in cats with at least one chronic disease, with DJD reported in 56% and 57% of cats in the first and 
second field test, respectively. Although CatQoL was able to differentiate between healthy cats and cats with 
CKD, its validity in cats with other diseases has not yet been established. Secondly, veterinary surgeons verified 
the health status of all cats in the VetMetrica study. Given that approximately 30% of cats considered healthy 
by the owners were found to be unhealthy by the veterinary surgeons, owner judgement may be unreliable 
(Noble et al., 2019). Consequently, this might be an issue for all the other instruments where recruited cats 
were considered healthy based on their owners’ perception, with the exception of cats with CKD in CatQoL 
where the diagnosis was made by a veterinary surgeon. Finally, the VetMetrica instrument is web-based and 
thus allows automatic data capture, preventing owners from changing their answers to previous questions. 
29 
 
1.4.2 The Placebo Effect in Feline Degenerative Joint Disease 
There are three types of placebo effects. The term “placebo effect” is generally used to describe the placebo 
effect on the patients themselves. This describes the beneficial response of a patient to an inert treatment 
which is the result of their psychological state as well as the context with which it is administered, rather than 
the treatment itself (Benedetti, 2013). The caregiver placebo effect refers to effects that can improve the 
ratings of the subjective assessment provided by caregivers or clinicians, but not objective measures. In turn, 
the subjective assessment and behaviour of caregivers can affect the patients themselves, further enhancing 
the placebo effect in a phenomenon termed the placebo-by-proxy effect; this, however, can also affect 
objective measures (Kossowsky and Kaptchuk, 2015). 
A recent study discovered a profound caregiver placebo effect in cats with DJD participating in clinical trials, 
with 50% to 70% of placebo-receiving cats showing clinical improvement based on the results of both general 
and specific CMIs (Gruen et al., 2017b). In this study, suggested causes for the caregiver placebo effect included 
the better care effect, where owner assessed ratings are improved as a result of more follow-ups, as well as 
the owner’s wish for the trial to work and the desire to please the investigator. Although a placebo-by-proxy 
effect has not been established in cats, the authors suggested theories on how it could impact on the results 
of both subjective and objective outcome measures in clinical trials (Gruen et al., 2017b). It was proposed that 
owners may pay more attention and interact more frequently with their cats, thereby increasing their cat’s 
activity levels and improving their own subjective assessments, or that their own positive disposition may result 





1.4.3 Objective Outcome Measures of Chronic Pain 
1.4.3.1 Gait Analysis 
Kinetic gait analysis is a technique used to objectively describe locomotion and the forces produced during the 
gait cycle in order to study musculoskeletal disease. Kinetic gait analysis in cats requires ground reaction force 
measurement which has been undertaken using force plates and pressure-sensitive walkways (PSW).  
A number of studies have used force plates for gait assessment in healthy cats (Corbee et al., 2014, Lavoie et 
al., 1995), in experimental models of CCL transection (Leumann et al., 2019, Suter et al., 1998), and in cats 
undergoing total hip replacement (Kalis et al., 2012). Kinetic gait analysis using PSW has been investigated 
more extensively, with studies to date evaluating its use in healthy cats (Corbee et al., 2014, Lascelles et al., 
2007b, Schnabl-Feichter et al., 2017, Stadig and Bergh, 2015, Verdugo et al., 2013), cats undergoing 
onychectomy (Robinson et al., 2007, Romans et al., 2004), and cats with DJD (Carroll et al., 2011, Guillot et al., 
2012, Guillot et al., 2013, Monteiro et al., 2016, Moreau et al., 2013). One limitation in using force plates in 
cats is the fact that they are usually difficult to direct onto the force plate and are not accustomed to a walking 
on a lead. Moreover, force plates cannot assess all limbs simultaneously or during several step cycles which 
can be an issue in cats with DJD given the high prevalence of bilateral disease. The most commonly calculated 
parameters using force plates and PSW are Peak Vertical Force and Vertical Impulse. Force plates can 
additionally assess craniocaudal and mediolateral forces, however vertical force is considered the component 
of greatest magnitude and lowest variability (Schnabl and Bockstahler, 2015).  
In summary, ground reaction forces can be used to objectively detect gait changes in healthy cats and, more 
importantly, in cats with DJD, also serving as an outcome measure in evaluating treatment efficacy (Moreau et 






Activity monitors such as accelerometers are monitoring devices that have been used in humans, cats, dogs, 
and other species as a surrogate measure of spontaneous activity, but also to assist with the assessment of 
other health-related aspects. These devices measure changes that are generated proportionally to the intensity 
and duration of change in acceleration by using a piezoelectric sensor, then convert them into counts for the 
chosen measurement period (John and Freedson, 2012). Accelerometers are worn on the animal’s collar or 
harness and are classified as uniaxial, biaxial, triaxial or omnidirectional based on the number of axes used to 
measure acceleration. Some accelerometers provide real-time data, whilst others need to be removed from 
the animal in order to export and analyse that data. Accelerometry is a valid objective outcome measure of 
DJD-related chronic pain in companion animal veterinary medicine (Brown et al., 2010, Lascelles et al., 2008a), 
enabling the non-invasive assessment of an animal’s daily activity within the home environment, away from 
the stress of the clinic. There are multiple devices marketed to researchers, veterinary surgeons, and the 
general public, but few are supported by scientific studies (Appendix B). 
Actical (Hansen et al., 2007) and Actigraph GT3-X (Yam et al., 2011) were the first accelerometers validated as 
a measure of activity and distance moved in dogs. Actical was also shown to be a valid outcome assessment 
tool for evaluating treatment response in dogs with DJD (Brown et al., 2010). Four more devices have been 
compared against Actical since then. There was a strong correlation between the activity counts of Actical and 
Whistle (Yashari et al., 2015), Heyrex (Mejia et al., 2019) and Actrigraph wGT3X+ (Belda et al., 2018), whereas 
a moderate correlation was observed between Actical and PetPace (Belda et al., 2018).  
Actical is the only accelerometer validated in cats not only as a measure of activity and distance moved in 
healthy cats and in cats with DJD (Lascelles et al., 2007c, Lascelles et al., 2008a), but also as a modality to 
differentiate between cats with DJD and disease-free cats (Guillot et al., 2012). It has therefore been used in a 
plethora of studies investigating activity levels as well as the treatment effect of different therapeutic 
interventions in cats with DJD (Gruen et al., 2017a, Gruen et al., 2014, Gruen et al., 2016, Guedes et al., 2018b, 
Guillot et al., 2013, Lascelles et al., 2010a). ActiWatch-Mini has been used in two studies investigating the 
32 
 
treatment effect of meloxicam and tramadol in cats with DJD (Monteiro et al., 2016, Monteiro et al., 2017), 
however it has not been validated as a measure of activity and distance moved in cats or compared against 
Actical. To the researcher’s knowledge, no studies have been conducted on the use of any other 
accelerometers for the evaluation of activity levels in cats. 
 
1.4.3.3 Goniometry 
Goniometric joint measurements have been shown to be repeatable and valid in orthopaedically normal cats 
(Jaeger et al., 2007). The sole study evaluating goniometry in cats with DJD demonstrated that increased range 
of motion (ROM) measurements were associated with decreased odds of radiographic DJD being present, 
thereby suggesting that it may be useful in ruling out the presence of DJD (Lascelles et al., 2012). 
 
1.4.3.4 Quantitative Sensory Testing 
Quantitative sensory testing (QST) measures mechanical and thermal sensory thresholds to assess 
somatosensory abnormalities such as hyperalgesia, allodynia and enhanced temporal summation which occur 
as a result of peripheral and central sensitisation (Adrian et al., 2017). Different devices such as the von Frey 
anaesthesiometer have been used to assess QST in healthy cats (Addison and Clements, 2017, Machin et al., 
2019). Two studies demonstrated that QST was able to successfully differentiate between cats suffering from 
DJD-associated pain, cats suffering from pain not associated with DJD and non-painful cats (Guillot et al., 2013, 
Guillot et al., 2014), suggesting that QST may be a valuable diagnostic tool in the clinical setting. 
 
1.4.3.5 Biological Markers 
Biological markers, or biomarkers, are defined as characteristics that can be objectively measured and 
evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to a 
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therapeutic intervention (Biomarkers Definitions Working, 2001). Biochemical and genetic markers have been 
investigated in addition to physical and imaging DJD markers. In human medicine, cytokines and chemokines 
such as tumour necrosis factor alpha (TNF-α) and interleukins (IL-1β, IL-6) have been associated with DJD-
related structural joint damage, inflammation and pain (Imamura et al., 2014, Schaible, 2012). A study in cats 
with DJD demonstrated higher serum concentrations of IL-4 and IL-8 in cats with higher radiographic DJD 
scores, and higher concentrations of IL2, IL-8, and TNF-α in cats with higher orthopaedic exam pain scores 
(Gruen et al., 2017c). Unfortunately, no single cytokine or group of cytokines was able to reliably differentiate 
between cats with and without DJD-associated pain and, as the samples were not age-matched against control 
samples, the increase in IL-8 could be the result of increasing age rather than DJD. Interestingly, a study 
investigating the genetic and proteomic profiles of cats with DJD suggested that the differentially expressed 
genes in cats with DJD were related to the disease itself as well as aging (Gao et al., 2013). Leptin, a cytokine 
produced by adipose tissue, has also been implicated in the development of DJD in humans (Yan et al., 2018) 
and, possibly, dogs (Kleine et al., 2019), but not cats. 
 
1.4.3.6 Other Objective Measures 
Other objective measures have been described in literature; however, these may not be feasible in a clinical 
setting. One study detected brain changes in cats with DJD-related pain using Positron Emission Tomography, 
confirming the previous belief that central sensitisation occurs in cats with the disease (Guillot et al., 2015a). 
Another study evaluating coxofemoral joint kinematics using fluoroscopic images suggested that the ROM of 
the coxofemoral joint could be used as a marker of DJD-associated impairment (Guillot et al., 2015b).  The use 
of thermographic imaging may also be promising in clinical practice according to a study that showed it can 




1.5 Management of Degenerative Joint Disease 
1.5.1 Advantages of Early Detection 
Earlier DJD detection allows veterinary professionals to adopt a multimodal approach to manage the disease, 
thereby delaying or halting DJD progression and improving the cats’ QoL.  
 
1.5.2 Pharmacological Pain Management 
Multimodal analgesia involves using a combination of different groups of medications to achieve adequate 
pain relief and is generally recommended in cats with DJD. By combining drugs that act synergistically and on 
different levels of the pain pathway, smaller doses of an individual drug are needed, thus reducing the potential 
for adverse effects. 
 
1.5.2.1 Non-Steroidal Anti-Inflammatory Drugs 
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used analgesic in veterinary medicine for 
the alleviation of both acute and chronic pain and have antipyretic, anti-inflammatory and analgesic effects. 
They act on two cyclooxygenase (COX) isoforms, COX-1 and/or COX-2, or COX and lipoxygenase enzymes, 
inhibiting the production of prostaglandins from arachidonic acid (Warner and Mitchell, 2004). COX-1 has an 
important role for many physiological functions, resulting in the production of prostaglandins that regulate 
gastroprotection, vascular homeostasis and blood clotting, whereas COX-2 is expressed in sites of inflammation 
and neoplasia (Warner and Mitchell, 2004). Adverse side effects can be seen even with NSAIDs that selectively 
inhibit COX-2 with a minimal effect on COX-1, and other factors such as tissue concentration, dosing, and 
individual characteristics (e.g. age) need to be considered.  
A plethora of NSAIDs have been studied in cats. The clinical use of acetaminophen is contraindicated, but the 
administration of appropriate doses of acetylsalicylic acid, carprofen, deracoxib, firocoxib, flunixin, ketoprofen, 
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meloxicam, piroxicam, robenacoxib, tepoxalin, tolfenamic acid and vedaprofen is generally considered safe 
(Brondani et al., 2009, Charlton et al., 2013, Lascelles et al., 2007a, Papich, 2008). Carprofen, ketoprofen, 
meloxicam, robenacoxib, and tolfenamic acid are the only NSAIDs licensed for cats in the United Kingdom. All 
are licensed for a short course of one to four days, however meloxicam and robenacoxib are also licensed for 
long-term use. Meloxicam is a selective COX-2 inhibitor and the first NSAID licenced for the management of 
chronic pain associated with feline DJD. The safety and efficacy of meloxicam in alleviating DJD-associated pain 
in cats has been evaluated not only subjectively, but also objectively using accelerometers and kinetic gait 
analysis in double-blinded, placebo controlled randomised studies (Gruen et al., 2014, Gruen et al., 2015, 
Guillot et al., 2013, Lascelles et al., 2007c). An oral transmucosal spray formulation of meloxicam was shown 
to be as effective as oral meloxicam in a randomised, blinded study (Monteiro et al., 2016), but has since been 
withdrawn from the market. Robenacoxib is a “coxib” type of NSAID, demonstrating highly selective and 
targeted inhibition of COX-2. It is also licensed for the management of chronic pain associated with feline DJD 
in the UK, with in vitro and in vivo studies attesting to its safety and efficacy (King et al., 2016, Kongara and 
Chambers, 2018). More recently, the effect of robenacoxib was evaluated objectively in a double-blinded, 
placebo controlled randomised study using accelerometers (Adrian et al., 2019).  
The most common adverse effects associated with long-term NSAID administration in cats receiving meloxicam 
or robenacoxib are of gastrointestinal nature, primarily vomiting (Gowan et al., 2011, King et al., 2016). With 
regards to a possible link between chronic NSAID administration and the development of acute kidney injury 
or chronic kidney disease (CKD), two retrospective studies evaluating the safety of meloxicam administration 
in older cats with DJD and with or without stable CKD reported no development or progression of CKD when 
that was administered once daily for six to twelve months (Gowan et al., 2012, Gowan et al., 2011). 
Nevertheless, the mean dose administered in those studies was lower than the licensed dose in the UK or the 
doses that have been described as efficacious (Guillot et al., 2013, Gunew et al., 2008, Lascelles et al., 2007c). 
A prospective, randomised and blinded study evaluating the safety of robenacoxib administration in a similar 
population of cats with DJD and with or without stable CKD also reported no clinically detected evidence of 
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development or progression of CKD, respectively; however, the drug was only administered for one month 
which may not be a sufficient time period to appreciate possible adverse effects on kidney function (King et 
al., 2016). There are currently no data on the potential adverse effects of chronic NSAID administration on cats 
with cardiovascular or chronic liver disease in cats (Kongara and Chambers, 2018, Lascelles et al., 2007a, Papich, 
2008, Sparkes et al., 2010). 
 
1.5.2.2 Piprants 
Grapiprant is part of a new class of drugs, the piprants, which block prostaglandin E2 receptors (Vito 
et al., 2016). Grapiprant selectively blocks the EP4 receptor of prostaglandin E2, one of the key mediators of 
inflammation and pain (Woodward et al., 2011) which was also shown to be involved in central sensitisation 
and chronic pain in humans and animals (Lin et al., 2006, Nakao et al., 2007). The safety and efficacy of 
grapiprant was evaluated in a prospective, randomised, placebo-controlled study where owners and veterinary 
surgeons assessed the pain-relieving effect of grapiprant in dogs with DJD (Rausch-Derra et al., 2016). In a more 
recent study evaluating an induced model of acute arthritis in dogs using force plates (de Salazar Alcala et al., 
2019), however, no significant difference was found in lameness reduction between dogs receiving grapiprant 
and untreated controls. The safety (Rausch-Derra and Rhodes, 2016) and pharmacokinetics (Lebkowska-
Wieruszewska et al., 2017) of grapiprant administration have been evaluated in healthy cats, nevertheless 
there are no studies to date evaluating its efficacy in the treatment of cats with DJD. 
 
1.5.2.3 Centrally Acting Drugs 
Centrally acting drugs, such as amantadine, amitriptyline, gabapentin, opioids and tramadol, have been used 
as adjunctive analgesic drugs to NSAIDs in humans (Dworkin et al., 2007). Some of these have been used in 
cats with DJD through extrapolation from humans or, more recently, backed by scientific data; nevertheless, 
none are licensed in the UK for the management of chronic DJD-associated pain. 
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Amantadine is a non-competitive N-methyl-D-aspartate (NMDA) antagonist that has been used in humans with 
neuropathic pain (Dworkin et al., 2007) and was demonstrated to attenuate hyperalgesia and allodynia in 
animal models of neuropathic pain (Robertson and Lascelles, 2010). The pharmacokinetics of experimental 
amantadine administration in cats have been documented (Siao et al., 2011), however the efficacy of 
amantadine as an adjunct to a NSAID (meloxicam) has only been evaluated in dogs with DJD (Lascelles et al., 
2008b). Consequently, there are currently no clinical data supporting or refuting the use of amantadine in cats.  
Gabapentin, a structural analogue of the neurotransmitter γ-aminobutyric acid (GABA), is also commonly used 
in human medicine for the management of chronic neuropathic pain (Moore et al., 2014). The 
pharmacokinetics of gabapentin in cats have been documented in two experimental studies (Adrian et al., 
2018, Siao et al., 2010). Positive results were seen following long-term use of gabapentin in a case study of 
three cats exhibiting chronic pain; DJD was confirmed in one of these cats (Lorenz et al., 2013). Gabapentin 
administration was significantly associated with improvement in owner-identified impaired activities (Guedes 
et al., 2018b) in a recent blinded, placebo-controlled, randomised crossover-design study in cats with DJD. 
Nevertheless, a decrease in activity levels was observed using accelerometry; this was attributed to sedation, 
the most common adverse effect seen with gabapentin administration (Adrian et al., 2018, Guedes et al., 
2018b). Opioids such as fentanyl, buprenorphine and tramadol are used for the management of maladaptive 
and DJD-associated pain in humans (Schaefert et al., 2015), however their role in the management of chronic 
pain in cats has not been elucidated. Transdermal use of fentanyl, a full μ-agonist, has been evaluated in cats 
undergoing ovariohysterectomy (Davidson et al., 2004) and onychectomy (Wilson and Pascoe, 2016), but not 
in cats with DJD-associated chronic pain. The use of buprenorphine, a partial μ-agonist and κ-antagonist, has 
been evaluated in multiple studies in cats, although they were also mainly focused on acute rather than chronic 
pain (Steagall et al., 2014). The most reliable routes of buprenorphine administration are the intravenous and 
the intramuscular route, but neither can be used for the management of chronic pain. Although there are no 
clinical studies to date, the oral transmucosal route was experimentally demonstrated to be as effective as 
intravenous administration and lasting up to six hours (Robertson et al., 2005). On the other hand, the rectal 
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route of administration has recently been reported to be unreliable (Schroers et al., 2018). Subcutaneous 
administration of a new high-concentration formulation of buprenorphine was also recently shown to be 
promising and lasting over 24 hours (Doodnaught et al., 2017); unfortunately, this formulation is not presently 
available in the UK.  
Tramadol is a partial μ-agonist and serotonin antagonist whose pharmacokinetics (Pypendop and Ilkiw, 2008) 
as well as analgesic effect use peri- and intra-operatively (Brondani et al., 2009, Ko et al., 2008) have been 
documented. In a study where oral tramadol was administered in addition to oral transmucosal meloxicam in 
cats with DJD, there was a reported decrease in central hypersensitivity, but no other evident positive benefit 
was demonstrated over meloxicam alone (Monteiro et al., 2016). Two additional prospective, randomised, 
blinded, controlled, crossover trials evaluated the efficacy of tramadol in feline DJD using subjective as well as 
objective outcome measures (Guedes et al., 2018a, Monteiro et al., 2017). Although both studies reported a 
beneficial effect of oral tramadol administration, the activity data analysis was limited in the study by Guedes 
and others (2018a), and adverse effects (sedation, hypersalivation, gastrointestinal signs) were commonly 
reported in all three studies. Consequently, the use of tramadol as an adjunctive analgesic drug to meloxicam 
is not presently supported, and more studies can attest to its efficacy for use in cats with DJD. 
 
1.5.2.4 Anti-Nerve Growth Factor Monoclonal Antibodies 
Nerve growth factor (NGF) is a neurotrophic factor critical for the normal development of certain neurons 
which has been shown to play an important role in nociceptor sensitisation both in acute and chronic pain 
scenarios in humans, cats and dogs  (Enomoto et al., 2019, Schnitzer and Marks, 2015). To this end, species-
specific anti-NGF monoclonal antibodies (mAbs) have been manufactured in humans (Schnitzer and Marks, 
2015), dogs (Lascelles et al., 2015) and, more recently, cats (Gearing et al., 2016). The study of 
pharmacokinetics and safety of frunevetmab, the felinised anti-NGF mAb, was followed by a pilot proof of 
concept study in cats with DJD-related pain and mobility impairment (Gruen et al., 2016). In this study, a 
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positive treatment effect using subjective and objective measures was seen for six weeks following a single 
subcutaneous injection and no adverse effects were reported. In addition, this was the first time that owners 
were able to detect the benefit of a therapeutic intervention over a placebo in a blinded, parallel group design 
study. Nevertheless, an increased incidence of serious adverse events such as osteonecrosis was seen in human 
patients concurrently receiving NSAIDs and the humanised monoclonal anti-NGF antibodies, tanezumab and 
fulranumab (Hochberg, 2015). The potentially deleterious effect of concurrent exposure to NSAIDs and mAbs 
was also suggested in a study in mice where a significant inhibition of NGF expression was demonstrated 
following NSAID administration (Park et al., 2019). 
 
1.5.2.5 Stem Cell Therapy 
Stem cells can differentiate into other types of cells and have potent immunomodulatory properties, which 
explains the interest in using them in the management of degenerative diseases such as DJD. One approach is 
to use autologous adult stem cells, with the three known accessible sources being bone marrow, adipose tissue, 
and blood. In veterinary medicine, adipose tissue is surgically harvested under general anaesthesia and sent 
for processing; following this, the stem cells are injected intravenously or into the affected joints. Positive 
outcomes have been reported in three studies of dogs with DJD (Black et al., 2008, Black et al., 2007, Vilar et 
al., 2013). To date, there are studies investigating the use of stem cell therapy in cats with kidney disease 
(Quimby, 2019) and gingivostomatitis (Arzi et al., 2016), but not in cats with DJD. 
 
1.5.3 Structure-Modifying Osteoarthritis Agents and Nutraceuticals  
Structure-modifying Osteoarthritis Agents and Nutraceuticals (STMOADs) are drugs with the potential to alter 
the underlying pathophysiological process of cartilage degradation that occurs in DJD.  
40 
 
The STMOADs pentosan polysulfate (PPS) and polysulfated glycosaminoglycan (PSGAG) have been suggested 
to stimulate articular cartilage growth and limit cartilage degeneration in dogs, however only a moderate level 
of comfort exists that these relationships are scientifically valid (Aragon et al., 2007). The safety and efficacy of 
nutraceuticals such as omega-3 fatty acids (eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA], and 
eicosatetraenoic acid [ETA]), green lipid mussel (GLM) as well as glucosamine and chondroitin sulfate, either 
on their own or as a part of a diet, has been evaluated in numerous studies over the past decade in dogs. 
Unfortunately, it is very hard to evaluate the evidence provided by these studies as they report different 
therapy durations, sometimes include other active ingredients, and the drugs used are produced by different 
manufacturers, thereby having different compositions. Consequently, the evidence of nutraceutical efficacy in 
alleviating DJD-related clinical signs in dogs is poor, with the exception of omega-3 fatty acids (Bhathal et al., 
2017, Vandeweerd et al., 2012). With regards to GLM, three studies reported an improvement whilst one study 
did not; however, since GLM contains ETA, it was suggested that part of its effect was due to that (Vandeweerd 
et al., 2012). Interestingly, a later study also reported an objectively-assessed beneficial effect of a GLM-
enriched diet using objective primary outcomes (Rialland et al., 2012), however the evidence regarding GLM is 
still controversial. The administration of PCSO-524, a compound rich in omega-3 fatty acids extracted from the 
New Zealand GLM, was recently reported to have a beneficial effect when administered in addition to 
carprofen (Kwananocha et al., 2016) and firocoxib (Vijarnsorn et al., 2019) in dogs with DJD. 
Unfortunately, there is a paucity for nutraceutical studies in cats with DJD. To the researcher’s knowledge, 
there are no studies investigating the use of either PPS or PSGAG and, although the safety of PCSO-524 was 
evaluated in clinically-healthy, normal cats (Pusoonthornthum, 2017), no further studies have been published 
to date. A prospective, blinded, randomised, controlled clinical study evaluating a feline DJD diet rich in EPA, 
DHA and supplemented with GLM and glucosamine/chondroitin sulphate showed significantly increased 
activity using both subjective and objective measures in the test-diet group compared to the control-diet group 
(Lascelles et al., 2010a). Although it cannot be said with certainty that these effects were attributable to 
increased EPA and DHA levels rather than concomitant additional nutritional modifications, a more recent 
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randomised, double-blinded, placebo-controlled, crossover-design study supported the beneficial clinical 
effect of EPA and DHA omega-3 fatty acids based on owner perception (Corbee et al., 2013). Another study 
comparing the efficacy of meloxicam to a supplement containing glucosamine/chondroitin sulphate 
demonstrated that cats receiving the supplement appeared to improve during study duration, although that 
was not statistically significant (Sul et al., 2014). In summary, there is some evidence for the administration of 
omega-3 fatty acids, but not for any other nutraceuticals, in cats with DJD. 
 
1.5.4 Weight Management 
In overweight patients with knee osteoarthritis, a 3.1% weight loss was not able to affect pain or improve 
function in one study (Jenkinson et al., 2009), however in a more recent study, a 10% – 20% weight loss was 
successful in improving pain levels, function and HRQoL (Messier et al., 2018). In a study evaluating dogs with 
hip dysplasia resulting in secondary DJD, an 11% – 18% weight reduction of initial body weight resulted in 
reduction of the observed clinical lameness (Impellizeri et al., 2000). In a more recent prospective study 
evaluating exclusively obese dogs with hip and/or elbow osteoarthritis using kinetic gait analysis, a noticeable 
improvement was noted after only a 6% – 9% reduction in body weight (Marshall et al., 2010). The results from 
these studies confirm that, in dogs, weight loss is associated with clinical improvement and, likely, pain 
reduction.  
There is a paucity of clinical studies evaluating the effect of weight loss in cats with DJD. In a study evaluating 
a therapeutic diet for cats with DJD, and after controlling for weight and change in weight, the group fed the 
test-diet showed increased activity levels whereas the group fed the control-diet showed decreased activity 
levels (Lascelles et al., 2010a). The authors proposed two theories; either that the cats fed the test-diet felt 
more comfortable, which resulted in increased activity levels and more weight loss, or that the weight loss 
itself resulted in more activity in the test-diet group, suggesting that weight loss was more important than pain 
relief. Although weight loss was not significantly different between groups, Lascelles and others (2010a) 
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advocated that the weight loss observed in the test-diet group could be a combination of increased activity 
levels and the test-diet itself which was rich in DHA and EPA. Indeed, diets high in DHA and EPA have been 
shown to decrease adipose tissue mass and supress the development of obesity in rodents (Madsen et al., 
2005). In any case, the relationship between weight loss, activity and pain relief has not been elucidated in cats 
with DJD. 
 
1.5.5 Environmental and Activity Modulation 
Environmental modulation in the context of a cat suffering from DJD refers to adding or modifying one or more 
factors within its environment in order to improve its physical and psychological welfare that has been affected 
by the disease (Ellis, 2009, Robertson and Lascelles, 2010). These factors refer to aspects of the cat’s 
environment, and can be organised into five “systems”: physical resource, nutritional, elimination, social and 
behavioural (Herron and Buffington, 2010). 
• Physical resource system: Cats need to have unrestricted access to resting areas and vantage points 
where stressors are minimised and/or where they can feel safe at (Herron and Buffington, 2010). The 
importance of vertical space cannot be overlooked in a cat with DJD, and therefore adding steps or 
ramps in the environment for cats that have difficulty jumping will facilitate access to raised beds, 
window ledges and other surfaces (Ellis, 2009, Lascelles and Robertson, 2010, Robertson and Lascelles, 
2010). Cat flaps should also be modified for cats with outdoor access. In addition, cats prefer 
comfortable resting options such as pillows or fleece beds, and a source of heat plays an important 
role in their choice of a resting place (Ellis, 2009, Robertson and Lascelles, 2010). Consequently, a range 
of options and a heat source such as a heat mat can greatly improve the comfort of a cat with DJD. 
• Nutrition system: Food and water bowls should also be easily accessible. Moreover, cats are natural 
predators and their hunting behaviour needs to be encouraged in order to provide them with physical 
and mental stimulation (Ellis, 2009, Herron and Buffington, 2010). This can be achieved by having 
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multiple food bowls, hiding the food bowl, and using puzzle toys or food trails (Bennett et al., 2012b, 
Ellis, 2009). 
• Elimination system: At least one easily accessible litterbox should be available to all cats irrespective 
of their lifestyle (indoor or outdoor). This should be of generous size, and with at least one low side to 
allow easy access and positioning for a cat with DJD-associated pain (Bennett et al., 2012b, Lascelles 
and Robertson, 2010). 
• Social system: Free-ranging cats have been reported to spend approximately 14% of their time 
grooming (Panaman, 1981). Cats with DJD-related pain may not groom themselves sufficiently, 
therefore owners should groom their cats providing they don’t find it aversive (Robertson and 
Lascelles, 2010). Grooming as well as actively interacting with the cat and providing play opportunities 
will not only strengthen the human-animal bond, but is also believed to release neurotransmitters that 
help cats cope with DJD-related pain (Bennett et al., 2012b, Ellis, 2009). 
• Behavioural system: An enriched indoor environment and active involvement from the owner with 
regards to providing appropriate outlets for play are essential for normal behaviour display in cats. 
One of these behaviours is scratching, and different substrates will appeal to each cat. As cats tend to 
scratch more often when stretching following rest, scratching facilities should be placed in proximity 
to the resting places of cats with DJD (Bennett et al., 2012b). 
Offering cats with DJD a complex three-dimensional environment and opportunities to display their natural 
behaviours, with or without owner interaction, will provide them with mental stimulation and encourage more 
movement (Ellis, 2009). This has been shown to help maintain muscle tone and mass as well as minimise DJD-





1.5.6 Physical Therapies 
In the context of DJD, physical therapy aims to alleviate muscular pain and improve mobility in affected joints 
by utilising a range of modalities such as manual therapy, exercise therapy as well as electrophysical and 
thermal treatments (Lindley et al., 2010, Sharp, 2012a). There is good evidence for the use of physical therapy 
in humans, and several canine studies have shown positive results (Dycus et al., 2017, Marsolais et al., 2002, 
Monk et al., 2006). Although there are no published studies in cats to date, it has been proposed that the same 
principles and benefits would apply to cats (Sharp, 2012a). In manual therapy, mobilisations and manipulations 
are used to reduce pain and improve joint ROM, whereas massage and passive movements help maintain 
muscle mass and tone as well as alleviate pain (Sharp, 2012a). Therapeutic exercise can be land-based or water-
based (hydrotherapy), and electrophysical therapies include laser, ultrasound, neuromuscular electrical 
simulation, and transcutaneous electrical nerve stimulation. Electrophysical therapies as well as heat and cold 
therapy in conjunction with manual therapy and therapeutic exercise have been shown to have an anti-
inflammatory and analgesic effect in humans and dogs with DJD (Sharp, 2012a, Sharp, 2012b). Although the 
same effect could possibly be seen in cats, there are no published clinical studies to support this to date. 
 
1.5.7 Surgical Management 
Surgical management is undertaken when non-surgical management options do not provide adequate pain 
relief. Depending on the affected joint, surgical techniques include excision arthroplasty, total joint 
replacement, arthrodesis and, when no other option can be explored, amputation.  
 
1.5.7.1 Excision Arthroplasty 
Femoral head and neck excision arthroplasty (FHNE) is indicated for the management of chronic coxofemoral 
luxation, coxofemoral DJD, failed total hip replacement (THR), and highly comminuted femoral head, neck, or 
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acetabular fractures (Harper, 2017) as well as hip dysplasia in cats (Perry, 2016). Case reports to date suggest 
good to excellent functionality both medium-term and long-term following FHNE, although few cats were 
suffering from DJD (Berzon et al., 1980, Off and Matis, 2010, Yap et al., 2015). In addition, direct comparison 
between study outcomes is not without issues given the lack of objective measures and the lack of follow-up 
and/or postoperative radiographs in some cases. 
 
1.5.7.2 Total Joint Replacement 
The indications for THR in cats are similar to those for FHNE (Liska, 2010, Perry, 2016) and it has also been used 
following failed FHNE procedures (Fitzpatrick et al., 2012, Liska et al., 2010). The majority of published case 
reports, however, evaluate the outcome in cats that have suffered trauma rather than cats suffering from DJD 
(Kalis et al., 2012, Liska, 2010, Liska et al., 2009, Marino et al., 2012, Witte et al., 2010).  Excellent outcomes 
are generally reported at least in the short-term following THR in the few studies to date (Fitzpatrick et al., 
2012, Liska, 2010, Liska et al., 2009, Liska et al., 2010). There are currently no studies in cats comparing THR 
and FHNE, however measured peak vertical force and impulse returned after THR (Budsberg et al., 1996), but 
not after FHNE in dogs (Planté et al., 1997). 
To the author’s knowledge, there are currently no studies evaluating elbow or stifle replacement in cats. 
 
1.5.7.3 Arthrodesis 
Arthrodesis is the surgical fusion of two bones at a functional angle across a joint and is indicated when there 
is unmanageable joint pain or instability, non-reconstructible articular fractures and sepsis (Pettitt, 2018). 
Arthrodesis has mainly been reported in literature following trauma rather than management of painful DJD. 
Pancarpal arthrodesis is indicated following carpal hyperextension, intra-articular fractures, severe shearing 
injuries, some peripheral nerve injuries and severe DJD (Basa and Johnson, 2019). Only two and one cats  
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underwent partial or pancarpal arthrodesis (Calvo et al., 2009, Mathis and Voss, 2015) and pantarsal 
arthrodesis (Alza Salvatierra et al., 2018, DeCamp et al., 1993, Mathews et al., 1995), respectively, due to 
painful DJD in published case reports to date. The sole case report on stifle arthrodesis also concerns a cat that 
suffered trauma (Belch et al., 2012), and there are no published studies on elbow or shoulder arthrodesis in 
cats. 
 
1.5.8 Complementary Therapies 
Complementary and alternative therapies such as acupuncture and herbal medicine have been criticised both 
in human and veterinary medicine for not being evidence-based and for potentially causing harm (McKenzie, 
2012). The analgesic mechanism of acupuncture is not fully understood and the results of clinical studies in 
dogs with DJD are considered controversial (Kapatkin et al., 2006, McKenzie, 2012, Shmalberg et al., 2019, Silva 
et al., 2017). A scoping review identified 843 citations of acupuncture use in cats, dogs and horses which 
included 179 experimental studies and 175 case reports/series; out of these, only 17 were in cats (Rose et al., 
2017). Although there are studies investigating the use of acupuncture in cats undergoing ovariohysterectomy 
(Nascimento et al., 2019, Ribeiro et al., 2017), there are no studies supporting the use of acupuncture for the 




1.6 Thesis Objectives 
As discussed, the prevalence of DJD is high in cats of all ages and it is likely that the QoL of cats suffering from 
DJD is impaired. Moreover, little is known about risk factors predisposing cats to DJD apart from advancing age, 
and there are multiple obstacles that prevent veterinary surgeons from diagnosing DJD in a timely manner. 
Elucidating the risk factors predisposing cats to this condition and detecting changes early in the development 
of DJD is important as these changes may still be reversible and, consequently, a preventative multimodal 
approach could be adopted to delay or reverse further disease progression, thereby improving the QoL of cats 
with DJD. 
The first overall objective of this thesis was therefore to identify new risk factors associated with the occurrence 
of feline DJD as well as to evaluate previously investigated risk factors identified in the literature. This would 
be accomplished by examining prospectively collected data from a large-scale longitudinal cohort study of pet 
cats (“Bristol Cats”; BC). 
The second overall objective of this thesis was to evaluate some of the available tools for diagnosing feline DJD, 
and to ascertain the effect of early DJD-related pain on the QoL of affected cats. Although we are not yet able 
to directly measure the subjective and emotional experience of chronic pain in cats, we are able to assess the 
physical dysfunction resulting from chronic pain. Subjective owner assessment questionnaires, orthopaedic 
examination, and accelerometers would be used in the BC study cohort to a) identify differences in the activity 
profiles of cats with early DJD-related changes in owner-reported mobility when compared to cats without 
owner-reported mobility changes, b) establish whether joint health as evaluated by orthopaedic examination 
reflected early DJD-related changes in owner-reported mobility, c) investigate changes in the QoL of cats with 
early DJD-related changes in owner-reported mobility, and d) determine whether accelerometry was able to 
detect early DJD-related changes in owner-reported mobility. 
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2. STUDY ONE: RISK FACTORS FOR OWNER-REPORTED SIGNS 
OF EARLY DEGENERATIVE JOINT DISEASE AT SIX YEARS OF 
AGE 
This study was approved by University of Bristol’s Health Sciences Faculty Research Ethics Committee (69041; 
04/07/2018) and the Animal Welfare and Ethical Review Body (VIN/18/026; 09/08/2018). 
 
2.1 Aims and Objectives 
The specific aim of this study was to utilise data from the BC study cohort relating to husbandry and health in 
order to not only identify novel risk factors associated with the occurrence of feline DJD, but also to evaluate 
previously investigated risk factors. 
 
2.2 Hypothesis 
We hypothesised that early risk factors in the life of cats would influence the development of owner-reported 
mobility changes related to DJD later in life. 
 
2.3 Materials and Methods 
2.3.1 Study Design 
A study was designed to identify risk factors for feline DJD in 6-year-old cats by examining prospective data 
from a longitudinal cohort study, the BC study.  
Briefly, the BC study (http://www.bristol.ac.uk/vet-school/research/projects/cats/) is an ongoing longitudinal 
study of health, behaviour and environment of client-owned cats where data is being collected prospectively 
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from owners and veterinary surgeons via the use of questionnaires and the sharing of clinical records (with 
owner permission), respectively. The BC study has been approved by the Ethics of Human Research Committee 
and by the Animal Welfare and Ethical Review Body (UIN/13/026). A total of 2203 kittens (aged 8-16 weeks) 
were registered by their owners between June 2010 – December 2013. Questionnaires are being completed 
by owners at specific intervals during their cat’s life; questionnaires one (Q1) at 2-4 months, two (Q2) at six 
months, three (Q3) at 12 months, four (Q4) at 18 months, five (Q5) at 2.5 years, six (Q6) at four years, then 
annually thereafter. These questionnaires include information such as cat and owner demographics, cat 
behaviour, clinical signs of disease and veterinary treatment. The BC study and published findings to date have 
been described extensively elsewhere (Murray et al., 2017). During 2014-2015, an additional 241 cats 
registered on another cohort study (Cat Longitudinal Analysis of Welfare Study [C.L.A.W.S.]) were transferred 
onto the BC study. The C.L.A.W.S. cats were adopted as kittens from rehoming organisations, mainly Cats 
Protection, and were recruited between May 2012 – May 2013 (http://www.bristol.ac.uk/vet-
school/research/projects/claws/). The cohort was designed to investigate early-life risk factors of feline obesity 
at two years of age (Rowe et al., 2017), and owners completed a series of five questionnaires until that age, 
with some questions identical to those used for the BC study. After completing the last C.L.A.W.S. questionnaire 
at two years of age, owners were offered the opportunity to join the BC study, completing their first BC 
questionnaire when their cats reached 2.5 years of age. With the addition of the C.L.A.W.S. cohort, the total 
number of the BC study cohort increased to 2444 cats. 
 
2.3.2 Participants 
Participants included the entire BC study cohort of 2444 cats, which comprised of 2203 cats from the original 
BC study cohort and 421 cats from the C.L.A.W.S cohort. 
Cats from the BC study were considered for this study if their owners had completed the BC study questionnaire 
(Appendix C) which was distributed when their cat turned six years of age (Q8). Twelve mobility-related 
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questions were selected from Q8 (Section E2) based on changes that were most likely to occur as a result of 
DJD rather than other disease processes. In these questions, owners were asked to rate their agreement to 
statements relating to their cat’s ability to perform different activities with the options “yes”, “maybe”, “no” 
and “not applicable”. These questions were used to classify cats as Cases or Controls, and owners additionally 
needed to have completed at least ten out of twelve questions (~80%), answering “not applicable” in less than 
50% of those. “Not applicable” was not given a score and the remaining answers were assigned on an integer 
scale from 0 to 2, with 0 = “no”, 1 = “maybe”, and 2 = “yes”. The total mobility score (MS) was the sum of scores 
for each question with a range of 0-24. Control cats were required to have no owner-assessed mobility 
impairment (MS = 0), whereas cats with owner-assessed mobility impairment (MS > 1) were assigned to the 
Case group. A MS of 1 corresponded to a “maybe” answer to a single question and was excluded to eliminate 
uncertain answers to a single aspect of mobility which could also have reflected a different disease process to 
DJD. Conversely, the score of two and above corresponded to one “yes” answer or two “maybe” answers and 
it was felt that it could reflect early mobility impairment. Finally, cats were not excluded if they were not 
healthy or if they were currently receiving any analgesic or anti-inflammatory medications. 
A total of 986 owners completed the BC study questionnaire which was distributed when their cat turned six 
years of age (Q8). Thirty-five cats were excluded either because their owners answered less than ten out of 
twelve questions (< ~80%) or because more than 50% of these were answered with “not applicable”. An 
additional 152 cats were excluded due to having a MS = 1, leaving 799 cats for analysis. 
 
2.3.3 Data Collection 
Data on potential early risk factors were obtained from questionnaires completed between the age of 2-4 
months and five years (Q1-Q7 inclusive), whereas data on present husbandry and health were obtained from 
the questionnaire completed at six years of age (Q8). An example of the questionnaires used in this study can 
be found in Appendix C. 
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2.3.4 Explanatory Variables 
Participating cats were identified using their unique BC study identification number. Variables suggested in the 
literature to be early life risk factors associated with the occurrence of DJD were considered as predictors in a 
logistic regression model and are listed in Table 2.1. Keywords used for free text mining of trauma-related 
injuries are listed in Appendix D. 
 
Table 2.1: Explanatory Variables Considered for Univariable Analysis of Risk Factors for Feline Degenerative Joint 






















“What is the breed 
of your kitten?” 
Q1 
DSH DSH, DLH and 
their crossbreeds DLH 






“What is the breed 
of your kitten?” 
Q1 
British shorthair, 
Burmilla, Exotic shorthair, 
Persian, Scottish Fold 
Brachycephalic 
Korat, Oriental, Siamese, 
Somali, Tonkinese 
Dolichocephalic 





“What is the breed 
of your kitten?” 
Q1 
Devon Rex, Oriental, 
Russian Blue, Singapura 
Small/Toy 
Bengal, Birman, British 
shorthair, Exotic 






All other breeds Medium 
















at Six Months 
of Age 





at Six Years  
of Age 
Categorical 









“Which of these 
statements best 








Inside only – cat only 
goes out into enclosed 
run or on a lead 
Outdoor access 
Inside and outside 
Outside only – cat is not 




“Please assess the 










Categorical As above Q4 
1 






Categorical As above Q5 
1 






Categorical As above Q6 
1 
Not overweight 2 
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CKD Diagnosis  Categorical 
“Has a veterinary 
surgeon diagnosed 




Dental Health Categorical 
“During the last 12 
months, has a 
veterinary 
surgeon/nurse 
commented on the 
health of your cat's 
teeth and mouth?” 
Q8 
Advised that teeth and 
mouth are in good health 
Good 
Advised that cat has 
some dental/oral disease 
and that dental 
treatment (under 
anaesthetic) may be 
necessary in the future 
Dental disease 
present 
Advised that that cat has 
a S&P (under anaesthetic) 
Advised that cat has 
dental/oral disease and 
recommended that 
dental treatment under 
anaesthetic (excluding 
S&P only) was needed 
No comment on 
teeth/mouth made Answers treated 
as missing data 
and not analysed 
N/A – has not seen a vet 
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attention for: Dog 
bite, Cat bite and/or 
abscess, Lameness / 
limb problem 
(including broken or 
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“Has your cat had 
any of the following 
injuries which you 
felt were not 
serious enough to 
seek veterinary 
attention for: Dog 
bite, Cat bite and/or 
abscess, Lameness / 
limb problem?” 









Body condition score (BCS); Chronic kidney disease (CKD); Domestic short hair (DSH); Domestic long hair (DLH); Not applicable 
(N/A); Road traffic accident (RTA); Scale and polish (S&P). 
 
With regards to their breed, cats were organised in two additional categories. The first category was according 
to the cephalic index, the ratio between the width and length of a cat’s skull, with cats grouped as 
brachycephalic, mesocephalic and dolichocephalic (Farnworth et al., 2018). British short hair, Burmilla, Exotic 
shorthair, Persian and Scottish Fold cats were considered brachycephalic, and Korat, Oriental, Siamese, Somali 
and Tonkinese and were considered dolichocephalic. The remaining cat breeds were classified as mesocephalic. 
The second category was based on average breed body size, with cats classified as small/toy, medium and 
large/giant (Purina, 2020). Bengal, Birman, British shorthair, Exotic shorthair, Maine Coon, Norwegian Forest, 
Persian, Ragamuffin, Ragdoll, Siamese, Siberian and Somali cats were classified as large/giant, and Devon Rex, 
Oriental, Russian Blue, and Singapura were classified as small/toy. The remaining breeds were considered of 
medium size. 
Taking into account the outdoor access of each cat and the level of exercise it permitted, cats were grouped 
for analysis as having “no outdoor access” (“inside only – the cat is not allowed outside”) or having “outdoor 
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access” (“inside only – cat only goes out into enclosed run or on a lead”, “inside/outside”, and “outside only – 
cat is not allowed in the house”). 
As data were sparse for the lower BCS using the 5-point system (Laflamme, 1997), cats were grouped for further 
analysis as “overweight/obese” for BCS 4–5, which included both overweight (4) and obese (5) cats, or “not 
overweight” for BCS 1–3, which included underweight (1–2) cats and cats of ideal weight (3). 
Data were also sparse for some dental health categories, and thus these were collapsed for analysis as 0 = 
“good health” (“advised that teeth and mouth are in good health”) or 1 = “dental disease” (“advised that cat 
has some dental/oral disease and that dental treatment (under anaesthetic) may be necessary in the future”, 
“advised that cat has a S&P (under anaesthetic)”, “advised that cat has dental/oral disease and recommended 
that dental treatment under anaesthetic (excluding a S&P only) was needed”), whilst 2 = “no comment on 
teeth/mouth made” and “N/A – has not seen a veterinary surgeon/nurse in the past 12 months” were treated 
as missing data and were not analysed. 
The question relating to whether the cat had been vaccinated was categorised as 0 = No and 1 = Yes for each 
questionnaire. In order to be analysed, answers to these questions were grouped into the following categories 
according to previous research (Finch et al., 2016): a) Never vaccinated, b) Primary vaccinations only, c) 
Occasional vaccination (> 2-year interval), d) Frequent or annual vaccination (every 1-2 years), and e) Unknown 
vaccination status. An unknown vaccination status was given to cats with missing data in > 50% of possible 
answers with the remaining being negative; these were treated as missing data and were not analysed. As data 
were sparse for some categories, they were collapsed as follows: 0 = “Never vaccinated / Primary vaccinations 
only”, 1 = “Occasional vaccination”, and 2 = “Frequent or annual vaccination”, with cats of unknown vaccination 
status again treated as missing data and not analysed. 
The RTA-related question (“Has your cat been hit by a vehicle since you have owned him/her?”) was coded as 
follows: 0 = No (“No”), 1 = Unsure (“Unsure”), 2 = Yes (“Yes – at my current address” and “Yes – at my previous 
address”). Due to the nature of the positive answer, data prior to any positive answer were examined to ensure 
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no RTA was counted twice and were then collapsed as 0 = No (“No”) and 1 = Yes (“Yes” and “Unsure”). 
Additional trauma-related information was acquired by free text mining as well as analysing two more 
questions relating to injuries that received veterinary treatment and injuries that the owners deemed were not 
serious enough to seek veterinary attention for. All trauma-related information was used to classify trauma as 
RTA, fall from height, fracture/dislocation, dog or cat bite and abscess, and soft tissue trauma (STT). When the 
exact nature of lameness was unclear, it was classified as STT. Following this, the researcher obtained advice 
from an orthopaedic surgeon with regards to categorising trauma further. Answers to questions pertaining to 
sustained trauma were grouped into the following categories in order of severity from least to most severe: a) 
STT, b) Dog or cat bites and abscesses, and c) RTAs/Falls from height/Fractures/Dislocations. In addition, only 
the most severe injury was retained for cats that had sustained more than one type of injury, and only the 
oldest injury was retained for cats that had sustained the same type of injury multiple times. In the end, all 
trauma-related data were collapsed for analysis to reflect if trauma had occurred or not (0 = No, 1 = Yes) since 
data were sparse for some trauma categories. Data from Q8 were not used to collect trauma-related 
information as it was felt that it would not have caused a chronic inflammatory process such as DJD to develop 
in such a short time. 
The age when the oldest and most severe trauma occurred was also noted based on the questionnaire where 
it was reported, with possible answers being 6 months, 12 months, 18 months, 2.5 years, 4 years, and 5 years. 
Following construction of the final model, a subsequent logistic regression model was formulated to investigate 
the effect of BCS at six years of age on the initial model. These additional composite variables described the 
change in BCS between cats aged 6 years and 12 months, 18 months, 2.5 years, 4 years and 5 years, 
respectively, and had possible outcomes of -2 = lost two BCS units, -1 = lost one BCS unit, 0 = no BCS change, 1 
= gained one BCS unit, 2 = gained two BCS units and 3 = gained 3 BCS units (Table 2.2). They were grouped for 




Table 2.2: Additional Explanatory Variables to Investigate the Effect of Body Condition Score at Six Years of Age 
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2.3.5 Statistical Analysis 
Analyses were performed using SPSS (version 24.0.0.2, IBM Corporation, USA). An alpha value of ≤ 0.05 was 
set for statistical significance in all analyses, and an exact significance (2-tailed) is reported. 
The cat’s status reflected the absence (Control = 0) or presence (Case = 1) of owner-reported early DJD-related 
signs at six years of age and was the outcome variable. 
All explanatory variables were of categorical (ordinal or nominal) nature. A correlation matrix was initially 
constructed in order to test for multicollinearity between all explanatory variables. If two or more explanatory 
variables were highly correlated (Spearman’s ρ > |0.8|), only one was taken forward to the univariable models. 
Univariable analysis was conducted using binomial logistic regression models to examine the association of all 
potential explanatory variables with the outcome of owner-reported presence of early DJD-related signs at six 
years of age; only variables with a Wald test p < 0.2 were considered for inclusion in the multivariable model. 
A multivariable model was then constructed to explore and quantify the presence of independent associations 
between different predictor variables and the odds of a cat having owner-reported early DJD-related signs at 
six years of age. The multivariable model was built using a backwards elimination method, and removal of 
variables was undertaken based on minimising the log likelihood-ratio statistic (-2LL). The Hosmer and 
Lemeshow test (R2L) was used to assess the fit of the model whilst Cox-Snell’s and Nagelkerke’s R2 were used 






2.4.1  Participants 
At the time of Q8 completion, all 799 included cats were six years of age, 423 (53.1%) were male, and 787 
(99.1%) were spayed/castrated (Table 2.3). 
 
Table 2.3: Demographic Data for n = 799 Cats 
 N (%) of cats 
Sex 
Male 423 (53.1%) 
Female 374 (46.9%) 
Total 797 (99.5%) 
Missing 2 (0.3%) 
Neuter Status  
at Six Years of Age 
Entire 7 (0.9%) 
Neutered 787 (99.1%) 
Total 794 (99.4%) 
Missing 5 (0.6%) 
Breed 
Category 
DSH, DLH and their crossbreeds  637 (80.3%) 
Purebred 156 (19.7%) 
Total 793 (99.2%) 
Missing 6 (0.8%) 
Outdoor  
Access 
No – Inside only 92 (11.5%) 
Yes – Only in an enclosed run or on a lead 86 (10.8%) 
Yes – Inside and outside 618 (77.5%) 
Yes – Outside only 1 (0.1%) 
Total 797 (99.7%) 
Missing  2 (0.3%) 
Domestic shorthair (DSH); Domestic longhair (DLH). 
 
There was missing information concerning the breed of six (0.8%) cats. The majority of the remaining 793 
(99.2%) cats (n = 637, 80.3%) were DSH, domestic longhair (DLH) and their crossbreeds (Appendix E). Most cats 
(n = 553, 69.2%) lived in a single-cat household, whereas 214 (26.8%), 24 (3%), and 8 (1%) cats lived in a 
household with a total of two, three and four cats, respectively. Two (0.25%) and nine (1.12%) cats were 
receiving joint supplements or medication on a long-term basis, respectively; six cats were receiving steroids, 
and three cats were receiving NSAIDs. 
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2.4.1.1 Breed Classifications 
When classified according to their cephalic index, most cats were mesocephalic (n = 713, 89.9%), followed by 



































Figure 2.1: Breed Classification according to Cephalic Index for n = 793 Cats 
 
When classified according to their body size, most cats were of medium body size (n = 661, 83.4%), followed 































Figure 2.2: Breed Classification according to Body Size for n = 793 Cats 
 
Neither breed classification according to cephalic index nor body size were analysed statistically as two 
categories in each variable had a very small number of cats. 
 
2.4.1.2 Neuter Status at Six Months of Age 
There was missing information in 35 (4.4%) cats. Out of the included 764 (95.6%) cats, 653 (85.5%) cats had 
been neutered whereas 111 (14.5%) cats remained entire when Q2 was completed at six months of age. 
 
2.4.1.3 Owner-reported Body Condition Score at All Timepoints 
Using the 5-point system, owner-reported BCS ranged from 1 to 5 with a median of 3 at all timepoints, whereas 
interquartile range (IQR) was 3 in cats aged 12 months, 18 months, 2.5 years, 4 years and 5 years, and 3 – 4 in 




Table 2.4: Owner-reported Body Condition Score for n = 799 Cats at All Timepoints 
 N (%) of cats 
BCS from Q3 
(12 months) 
1 6 (0.9%) 
2 36 (5.6%) 
3 546 (85.6%) 
4 47 (7.4%) 
5 3 (0.5%) 
Total 638 (79.8%) 
Missing  161 (20.2%) 
BCS from Q4 
(18 months) 
1 2 (0.3%) 
2 21 (3.3%) 
3 531 (84.7%) 
4 69 (11.0%) 
5 4 (0.6%) 
Total 627 (78.5%) 
Missing  172 (21.5%) 
BCS from Q5 
(2.5 years) 
1 5 (0.7%) 
2 29 (4.1%) 
3 560 (79.8%) 
4 99 (14.1%) 
5 9 (1.3%) 
Total 702 (87.9%) 
Missing  97 (12.1%) 
BCS from Q6 
(4 years) 
1 1 (0.2%) 
2 42 (6.5%) 
3 491 (75.7%) 
4 110 (16.9%) 
5 5 (0.8%) 
Total 649 (81.2%) 
Missing  150 (18.8%) 
BCS from Q7 
(5 years) 
1 2 (0.3%) 
2 35 (5.5%) 
3 469 (73.7%) 
4 128 (20.1%) 
5 2 (0.3%) 
Total 636 (79.6%) 
Missing  163 (20.4%) 
BCS from Q8 
(6 years) 
1 4 (0.5%) 
2 37 (4.8%) 
3 539 (69.5%) 
4 184 (23.7%) 
5 12 (1.5%) 
Total 776 (97.1%) 
Missing  23 (2.9%) 
Body condition score (BCS). 
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Figure 2.3: Owner-reported Body Condition Score at All Timepoints 
Body Condition Score (BCS). 
 
When grouped according to their BCS, the number of overweight/obese cats increased with age, with 50 (7.8%) 
12-month-old, 73 (11.6%) 18-month-old, 108 (15.4%) 2.5-year-old, 115 (17.7%) 4-year-old, 130 (20.4%) 5-year-

































Figure 2.4: Owner-reported Numbers of Not Overweight and Overweight/Obese Cats at All Timepoints 
Body Condition Score (BCS). 
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2.4.1.4 Diagnosis of Chronic Kidney Disease at Six Years of Age 
There was missing information on whether cats had been diagnosed with CKD in 285 (35.7%) cats. Out of the 
included 514 (64.3%) cats, only 4 (0.8%) cats had been diagnosed with CKD and thus it was not possible to 
analyse this variable statistically. 
 
2.4.1.5 Dental Health at Six Years of Age 
There was missing information on the dental health assessment of 19 (2.4%) cats, whilst no comment was 
made in 143 (17.9%) cats and 134 (16.8%) cats hadn’t seen a veterinary surgeon or nurse in 12 months, bringing 
the number of cats treated as missing data to 296 (37%). Out of the included 503 (63%) cats, good dental health 
was reported in the majority of cats (n = 376, 74.8%), and dental disease was reported in the remaining 127 
(25.2%) cats. Specifically, some dental disease was noted in 104 (20.7%) cats, whereas a scale and polish (S&P) 














































Figure 2.5:  Dental Health at Six Years of Age (Assessed by Veterinary Surgeon and Reported by Owners) 
Scale and Polish (S&P). 
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2.4.1.6 Vaccination History at All Timepoints 
The incidence of owner-reported vaccinations obtained from each questionnaire is shown in Table 2.5 and 
Figure 2.6. 
 
Table 2.5: Owner-reported Vaccinations at All Timepoints 
 N (%) of cats 
Reported Vaccination from Q2 
(6 months) 
No 22 (3%) 
Yes 712 (96.9%) 
Total 734 (91.9%) 
Missing  65 (8.1%) 
Reported Vaccination from Q3 
(12 months) 
No 103 (58.2%) 
Yes 74 (41.8%) 
Total 177 (22.2%) 
Missing  622 (77.8%) 
Reported Vaccination from Q4 
(18 months) 
No 324 (42.5%) 
Yes 438 (57.5%) 
Total 762 (95.4%) 
Missing  37 (4.6%) 
Reported Vaccination from Q5 
(2.5 years) 
No 290 (39.7%) 
Yes 441 (60.3%) 
Total 731 (91.5%) 
Missing  68 (8.5%) 
Reported Vaccination from Q6 
(4 years) 
No 0 (0.0%) 
Yes 520 (100.0%) 
Total 520 (65.1%) 
Missing  279 (34.9%) 
Reported Vaccination from Q7 
(5 years) 
No 191 (28.9%) 
Yes 469 (71.1%) 
Total 660 (100.0%) 
Missing  139 (17.4%) 
Reported Vaccination from Q8 
(6 years) 
No 0 (0.0%) 
Yes 446 (100.0%) 
Total 446 (55.8%) 

























Figure 2.6: Owner-reported Vaccinations at All Timepoints 
 
When grouped according to how frequently vaccinations had been administered, it was possible to determine 
the vaccination history of all but 16 (2%) cats. Of the remaining 783 (98%) cats, most had been occasionally 
vaccinated in intervals longer than two years (n = 337, 48.1%), followed by frequent or annual vaccination (n = 
308, 39.3%). Primary vaccinations only had been given in 85 (10.9%) cats, whilst 13 (1.7%) cats had never been 
vaccinated. 
 
2.4.1.7 Trauma Incidence at All Timepoints 
The RTA-related question asked the owners if their cat was involved or was suspected to have been involved 
in an RTA at their current or at their past address, and thus 15 duplicate positive answers were removed. The 
incidence of owner-reported RTAs until the age of 2.5 years is listed in Table 2.6.   
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Table 2.6: Incidence of Owner-reported Road Traffic Accidents Until the Age of 2.5 Years 
 N (%) of cats 
Road Traffic Accidents from Q2 
(6 months) 
Yes 2 (0.5%) 
Suspected 0 (0.0%) 
No 432 (99.5%) 
Total 434 (54.3%) 
Missing 365 (45.7%) 
Road Traffic Accidents from Q3 
(12 months) 
Yes 9 (1.9%) 
Suspected 1 (0.2%) 
No 471 (97.9%) 
Total 481 (60.2%) 
Missing 318 (39.8%) 
Road Traffic Accidents from Q4 
(18 months) 
Yes 8 (1.7%) 
Suspected 5 (1.1%) 
No 462 (97.3%) 
Total 475 (59.4%) 
Missing 324 (40.6%) 
Road Traffic Accidents from Q5 
(2.5 years) 
Yes 18 (3.9%) 
Suspected 4 (0.9%) 
No 437 (95.2%) 
Total 459 (57.4%) 
Missing 340 (42.6%) 
 
Additional trauma-related data was mined from Q6 (four years) and Q7 (five years), and the incidence of 
different types of trauma until the age of six years is shown in Table 2.7. A small number of cats had suffered 
serious injuries such as an RTA (n = 32, 4%), a fracture/dislocation (n = 11, 1.4%) or a fall from a height (n = 7, 
0.9%). Dog bites were also rare (n = 8, 1%). Cat bites and/or abscesses were the most commonly reported injury 




Table 2.7: Owner-reported Incidence of Different Types of Trauma Until the Age of Six Years 
 
N (%) of cats 
Road Traffic Accident No 767 (96.0%) 
Once 32 (4.0%) 
Fracture/Dislocation No 788 (98.6%) 
Once 11 (1.4%) 
Fall from Height No 792 (99.1%) 
Once 7 (0.9%) 
Cat Bite and/or Abscess No 692 (86.6%) 
Once 89 (11.1%) 
Twice 16 (2.0%) 
Three times 2 (0.3%) 
Dog Bite No 791 (99.0%) 
Once 8 (1.0%) 
Soft Tissue Trauma No 737 (92.2%) 
Once 54 (6.8%) 
Twice 8 (1.0%) 
       
Following retention of only the oldest and most severe injury for each cat, trauma was reported in 206 (25.8%) 
cats (Figure 2.7) and, when grouped according to their severity, over half (n = 110, 53.4%) were dog/cat bites 












































Figure 2.7: Owner-reported Incidence of Trauma According to Severity 
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For the 206 cats that suffered trauma, this occurred in most cats at the age of 2.5 (n = 64, 31.1%) or 4 (n = 49, 
23.8%) years followed by the age of 12 months (n = 27, 13.1%), whereas for 22 cats (10.7%) trauma occurred 
at the age of 6 months, 18 months, or 5 years.  
 
2.4.2 Logistic Regression Analysis 
2.4.2.1 Outcome Variable 
Mobility score ranged from 0 to 15 (Figure 2.8) with a median of 0 (IQR = 0 – 2). All 561 Control cats had a MS 
of 0 and the 238 Case cats had a median MS of 2 (IQR = 2 – 4). 




















Figure 2.8: Owner-reported Mobility Score for n = 238 Case Cats 
 
2.4.2.2 Explanatory Variables 
Where original explanatory variables had low numbers for some categories, these were combined to form new 
derived variables (Table 2.1). Two composite variables were additionally created by combining information 
concerning each cat’s vaccination and trauma history, respectively. Only 7 (0.9%) cats were entire and thus this 
variable was not analysed statistically. Thirteen variables were considered for univariable analysis (Table 2.8). 
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Table 2.8: List of Explanatory Variables Considered for Univariable Analysis of Risk Factors for Feline Degenerative 





All Cats  
N (%) of Cats 
Cases (MS > 1)  
N (%) of Cats 
Controls (MS = 0) 
N (%) of Cats 
Sex 
Male 423 (53.2%) 121 (51.1%) 302 (54.0%) 
Female 372 (46.8%) 117 (49.4%) 257 (46.0%) 
Total 795 (99.5%) 237 (99.6%) 559 (99.6%) 
Neuter Status  
at Six Months of Age 
Entire 111 (14.5%) 43 (19.0%) 68 (12.6%) 
Neutered 653 (85.5%) 183 (81.0%) 470 (87.4%) 
Total 764 (95.6%) 226 (95.0%) 538 (95.9%) 
Breed  
Category 
DSH, DLH and their crossbreeds  637 (80.3%) 186 (78.5%) 451 (81.1%) 
Purebred 156 (19.7%) 51 (21.5%) 105 (18.9%) 
Total 793 (99.2%) 237 (99.6%) 556 (99.1%) 
Outdoor  
Access 
No outdoor access 92 (11.5%) 21 (8.9%) 71 (12.7%) 
Outdoor access 705 (88.5%) 216 (91.1%) 489 (87.3%) 
Total 797 (99.7%) 237 (99.6%) 560 (99.8%) 
BCS  
(6-year-old) 
Not Overweight 580 (74.7%) 157 (68.0%) 423 (77.6%) 
Overweight/Obese 196 (25.3%) 74 (32.0%) 122 (22.4%) 
Total 776 (97.1%) 231 (97.1%) 545 (97.1%) 
BCS  
(5-year-old) 
Not Overweight 506 (79.6%) 145 (76.7%) 361 (80.8%) 
Overweight/Obese 130 (20.4%) 44 (23.3%) 86 (19.2%) 
Total 636 (79.6%) 189 (79.4%) 447 (79.7%) 
BCS  
(4-year-old) 
Not Overweight 534 (82.3%) 148 (77.9%) 386 (84.1%) 
Overweight/Obese 115 (17.7%) 42 (22.1%) 73 (15.9%) 
Total 649 (81.2%) 190 (79.8%) 459 (81.8%) 
BCS  
(2.5-year-old) 
Not Overweight 594 (84.6%) 174 (84.1%) 420 (84.8%) 
Overweight/Obese 108 (15.4%) 33 (15.9%) 75 (15.2%) 
Total 702 (87.9%) 207 (87.0%) 495 (88.2%) 
BCS  
(18-month-old) 
Not Overweight 554 (88.4%) 172 (86.4%) 382 (89.3%) 
Overweight/Obese 73 (11.6%) 27 (13.6%) 46 (10.7%) 
Total 627 (78.5%) 199 (83.6%) 428 (76.3%) 
BCS  
(12-month-old) 
Not Overweight 588 (92.2%) 186 (91.2%) 402 (92.6%) 
Overweight/Obese 50 (7.8%) 18 (8.8%) 32 (7.4%) 
Total 638 (79.8%) 204 (85.7%) 434 (77.4%) 
Dental  
Health  
Good health 376 (74.8%) 112 (74.7%) 264 (74.8%) 
Dental disease 127 (25.2%) 38 (25.3%) 89 (25.2%) 
Total 503 (63.0%) 150 (63.0%) 353 (62.9%) 
Vaccination  
History 
Never / Primary vaccinations only 98 (12.5%) 34 (14.7%) 64 (11.6%) 
Occasional vaccination  377 (48.1%) 115 (49.6%) 262 (47.5%) 
Frequent or annual vaccination 308 (39.3%) 83 (35.8%) 225 (40.8%) 
Total 783 (98.0%) 232 (97.5%) 551 (98.2%) 
Trauma  
Incidence 
None reported 593 (74.2%) 157 (66.0%) 436 (77.7%) 
Reported 206 (25.8%) 81 (34.0%) 125 (22.3%) 
Total 799 (100.0%) 238 (100.0%) 561 (100.0%) 
Body Condition Score (BCS); Domestic longhair (DLH); Domestic shorthair (DSH). 
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2.4.2.3 Univariable Models 
Prior to univariable analysis, a Spearman Rank correlation matrix was constructed (Figure 2.9); no significant 
collinearity (Spearman’s ρ > |0.8|) was detected between variables and therefore all were taken forward to 
univariable analysis. 
 
Figure 2.9: Spearman Rank Correlation Matrix of All Explanatory Variables Considered for Univariable Analysis of 
Risk Factors for Feline Degenerative Joint Disease in Six-year-old Cats 
Spearman’s ρ values range from 0 to 1, with higher values indicating a stronger relationship between the two examined variables 
on the x and y axis. The sign of Spearman’s ρ indicates the direction of association between the two variables; a positive coefficient 
suggests that if one variable increases, the other variable tends to do the same, and a negative coefficient suggests that if one 
variable increases, the other variable tends to decrease. In this case, no two variables were considered highly correlated as all 





Out of the thirteen variables that were taken forward to univariable analysis, five were significant at p < 0.2 
and therefore retained for multivariable analysis (Table 2.9). These were: neuter status at six months of age (p 
= 0.023), outdoor access (p = 0.125), BCS at four (p = 0.061) and six (p = 0.005) years of age, and trauma 
incidence (p = 0.001). 
 
Table 2.9: Univariable Logistic Regression Models of Risk Factors for Feline Degenerative Joint Disease in Six-year-
old Cats 
 N Categories B S.E. Wald df Sig. OR (CI) -2LL 
Sex 797 
Male Reference 971.167 
Female 0.128 0.155 0.679 1 0.41 1.136 (0.839, 1.54) 
Neuter Status at 
Six Months of Age 767 
Neutered Reference 922.899 
Entire 0.485 0.213 5.162 1 0.023* 1.624 (1.069, 2.468) 
Breed 
Category 793 
Purebred Reference 966.580 
Mixed -0.164 0.192 0.729 1 0.393 0.849 (0.583, 1.236) 
Outdoor 
Access 797 
No outdoor access Reference 967.647 
Outdoor access 0.401 0.261 2.353 1 0.125* 1.493 (0.895, 2.493) 
BCS 
(12-month-old) 638 
Not Overweight Reference 799.247 
Overweight/Obese 0.195 0.308 0.403 1 0.526 1.216 (0.665, 2.222) 
BCS 
(18-month-old) 627 
Not Overweight Reference 782.576 
Overweight/Obese 0.265 0.259 1.046 1 0.306 1.304 (0.784, 2.167) 
BCS 
(2.5-year-old) 702 
Not Overweight Reference 851.395 
Overweight/Obese 0.06 0.228 0.07 1 0.791 1.062 (0.68, 1.659) 
BCS 
(4-year-old) 649 
Not Overweight Reference 781.345 
Overweight/Obese 0.406 0.216 3.515 1 0.061* 1.501 (0.982, 2.294) 
BCS 
(5-year-old) 636 
Not Overweight Reference 772.635 
Overweight/Obese 0.242 0.21 1.33 1 0.249 1.274 (0.844, 1.922) 
BCS 
(6-year-old) 776 
Not Overweight Reference 937.213 
Overweight/Obese 0.491 0.174 7.924 1 0.005* 1.634 (1.161, 2.301) 
Dental 
Health 503 
Good health Reference 612.996 
Dental disease 0.006 0.224 0.001 1 0.977 1.006 (0.649, 1.562) 
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 N Categories B S.E. Wald df Sig. OR (CI) -2LL 
Vaccination 
History 783 
Frequent 2.398 2 0.302 Reference 949.259 
Never / Primary only 0.365 0.248 2.162 1 0.141 1.44 (0.886, 2.342) 
Occasional 0.174 0.17 1.042 1 0.307 1.19 (0.852, 1.661) 
Trauma 
Incidence 799 
None Reference 961.581 
Yes 0.588 0.17 11.9 1 0.001* 1.8 (1.289, 2.513) 
Body Condition Score (BCS); Degrees of Freedom (df); Log likelihood-ratio statistic (-2LL); Odds ratio (OR). 
*Variables with p < 0.2 Bootstrap 95% confidence intervals (CI) results are based on 1000 bootstrap samples and are shown in 
brackets. 
 
2.4.2.4 Multivariable Model 
The initial model included only the intercept, had a -2LL of 897.197, and classified correctly 70.5% of cats. The 
final model (Table 2.10) included 740 cats and four parameters: neuter status at six months of age, outdoor 
access, BCS at six years of age, and trauma incidence. In addition, the final model had a -2LL of 866.849, a 
goodness-of-fit R2L = 1.237 (p = 0.872), classified correctly 70.9% of cats and, according to Nagelkerke’s R2, had 
an effect size of 0.057, explaining 5.7% of the variability in the model. Outdoor access was retained in the 
model as it resulted in a 3.524 change in -2LL and explained an additional 0.8% variability. 
Independence of errors was confirmed by evaluating the dispersion parameter, φ, which was less than 1. It 
was not necessary to check the linearity of the logit assumption as none of the explanatory variables were 
continuous. Additional diagnostics were run to evaluate the presence of influential cases or outliers. None of 
the studendised and less than 5% of the standardised residuals (n = 6, 0.8%) lay outside ±2, suggesting that the 
multivariable model included no significant outliers. Although 91 cats (12.3%) in the dataset had leverage 
values that were more than 2-3 times the average leverage value of 0.0067, Cook’s distance and DFBeta values 





Table 2.10: Multivariable Logistic Regression Model of Risk Factors for Feline Degenerative Joint Disease in Six-
year-old Cats 
 B S.E. Wald df Sig. Odds Ratio (95% CI) 
Included 
Neuter Status at  
Six Months of Age 
Neutered Reference 
Entire 0.678 0.226 8.974 1 0.003* 1.97 (1.264, 3.071) 
Outdoor Access 
No outdoor access Reference 
Outdoor access 0.513 0.283 3.298 1 0.069 1.671 (0.96, 2.907) 
BCS (6-year-old) 
Not Overweight Reference 
Overweight/Obese 0.485 0.184 6.964 1 0.008* 1.624 (1.133, 2.328) 
Trauma Incidence 
None Reference 
Yes 0.613 0.179 11.759 1 0.001* 1.846 (1.3, 2.62) 
Intercept  -1.745 0.284 37.61 1 0* 0.175 
Not Included 
BCS (4-year-old) 
Not Overweight Reference 
Overweight/Obese -0.023 0.285 0.007 1 0.935 0.977 (0.559, 1.707) 
Body Condition Score (BCS); Confidence intervals (CI), Degrees of Freedom (df).  
R2= 1.237 (Hosmer–Lemeshow), 0.040 (Cox–Snell), 0.057 (Nagelkerke). Model χ2(4) = 30.348, p < 0.001. *p < 0.05. 
 
2.4.2.5 Additional Investigations on the Effect of Body Condition Score at Six Years of 
Age on the Initial Logistic Regression Model 
A subsequent logistic regression model was formulated to investigate the effect of BCS at six years of age on 
the initial model using additional composite BCS-related variables (Table 2.2). 
 
2.4.2.5.1 Changes in Body Condition Score 
Changes in BCS between cats aged 6 years and 12 months, 18 months, 2.5 years, 4 years, and 5 years are shown 




Table 2.11: Changes in Body Condition Score Between Six-Year-Old Cats and Cats of All Other Ages 
 
Range Median IQR Total Cats 
N (%) of Cats 
Missing Data 
N (%) of Cats 
BCS Change Between 6- and 5-year-old Cats -2 to 3 0 0 628 (78.6%) 171 (21.4%) 
BCS Change Between 6- and 4-year-old Cats -2 to 2 0 0 634 (79.3%) 165 (20.7%) 
BCS Change Between 6- and 2.5-year-old Cats -2 to 2 0 0 687 (86.0%) 112 (14%) 
BCS Change Between 6-year- and 18-month-old Cats -2 to 2 0 0 610 (76.3%) 189 (23.7%) 
BCS Change Between 6-year- and 12-month-old Cats -2 to 3 0 0 – 1 623 (78.0%) 176 (22%) 
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Figure 2.10: Changes in Body Condition Score Between Six-Year-Old Cats and Cats of All Other Ages 
Body Condition Score (BCS). 
 
2.4.2.5.1.1 Additional Explanatory Variables 
All additional explanatory variables had low numbers for some categories and were combined to form new 
derived variables (Table 2.12). 
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Table 2.12: Additional Body Condition Score-related Variables Considered for Univariable Analysis of Risk Factors 
for Feline Degenerative Joint Disease in Six-year-old Cats 
  All Cats  
N (%) of Cats 
Cases (MS > 1)  
N (%) of Cats 
Controls (MS = 0) 
N (%) of Cats 
BCS Change Between 6-  
and 5-year-old Cats 
No change 480 (76.4%) 133 (71.5%) 347 (78.5%) 
Decrease 54 (8.6%) 21 (11.3%) 33 (7.5%) 
Increase 94 (15.0%) 32 (17.2%) 62 (14.0%) 
Total 628 (78.6%) 186 (78.2%) 442 (78.8%) 
BCS Change Between 6-  
and 4-year-old Cats 
No change 492 (77.6%) 139 (74.7%) 353 (78.8%) 
Decrease 41 (6.5%) 15 (8.1%) 26 (5.8%) 
Increase 101 (15.9%) 32 (17.2%) 69 (15.4%) 
Total 634 (79.3%) 186 (78.2%) 448 (79.9%) 
BCS Change Between 6-  
and 2.5-year-old Cats 
No change 498 (72.5%) 135 (66.2%) 363 (75.2%) 
Decrease 60 (8.7%) 23 (11.3%) 37 (7.7%) 
Increase 129 (18.8%) 46 (22.5%) 83 (17.2%) 
Total 687 (86.0%) 204 (85.7%) 483 (86.1%) 
BCS Change Between 6-year-  
and 18-month-old Cats 
No change 445 (73.0%) 130 (67.0%) 315 (75.7%) 
Decrease 44 (7.2%) 18 (9.3%) 26 (6.3%) 
Increase 121 (19.8%) 46 (23.7%) 75 (18.0%) 
Total 610 (76.3%) 194 (81.5%) 416 (74.2%) 
BCS Change Between 6-year-  
and 12-month-old Cats 
No change 418 (67.1%) 124 (62.3%) 294 (69.3%) 
Decrease 43 (6.9%) 16 (8.0%) 27 (6.4%) 
Increase 162 (26.0%) 59 (29.6%) 103 (24.3%) 
Total 623 (78.0%) 199 (83.6%) 424 (75.6%) 
Body Condition Score (BCS). 
 
2.4.2.5.1.2 Additional Univariable Models 
Prior to conducting additional univariable analysis, a Spearman Rank correlation matrix was constructed (Figure 
2.11); no significant collinearity (Spearman’s ρ > |0.8|) was detected between variables and therefore all were 







Figure 2.11: Spearman Rank Correlation Matrix of All Confirmed and Additional Explanatory Variables 
Considered for Univariable Analysis of Risk Factors for Feline Degenerative Joint Disease in Six-year-old Cats 
Body Condition Score (BCS). 
 
Out of the five additional explanatory variables, three were significant at p < 0.2 and therefore retained for the 
additional multivariable model (Table 2.13). These were: BCS change between 6- and 5-year-old cats (p = 
0.142), BCS change between 6- and 2.5-year-old cats (p = 0.053), and BCS change between 6-year- and 18-




Table 2.13: Results from Additional Univariable Logistic Regression Models of Risk Factors for Feline Degenerative 
Joint Disease in Six-year-old Cats 
 N Categories B S.E. Wald df Sig. OR (CI) -2LL 
BCS Change Between 6-  
and 5-year-old Cats 618 
No BCS change  3.911 2 0.142* Reference 759.309 
BCS decrease 0.507 0.297 2.91 1 0.088 1.66 (0.927, 2.973) 
BCS increase 0.298 0.24 1.533 1 0.216 1.347 (0.841, 2.157) 
BCS Change Between 6-  
and 4-year-old Cats 634 
No BCS change  1.576 2 0.455 Reference 765.784 
BCS decrease 0.382 0.339 1.267 1 0.26 1.465 (0.753, 2.849) 
BCS increase 0.164 0.236 0.48 1 0.488 1.178 (0.741, 1.871) 
BCS Change Between 6-  
and 2.5-year-old Cats 687 
No BCS change  5.889 2 0.053* Reference 829.947 
BCS decrease 0.514 0.284 3.271 1 0.07 1.671 (0.958, 2.916) 
BCS increase 0.399 0.21 3.621 1 0.057 1.49 (0.988, 2.248) 
BCS Change Between 
6 and 18-month-old Cats 610 
No BCS change  5.171 2 0.075* Reference 757.864 
BCS decrease 0.517 0.324 2.552 1 0.11 1.678 (0.889, 3.165) 
BCS increase 0.396 0.214 3.417 1 0.065 1.486 (0.976, 2.262) 
BCS Change Between 
6 and 12-month-old Cats 623 
No BCS change  3.03 2 0.22 Reference 777.531 
BCS decrease 0.34 0.333 1.042 1 0.307 1.405 (0.731, 2.699) 
BCS increase 0.306 0.195 2.458 1 0.117 1.358 (0.926, 1.991) 
Body Condition Score (BCS); Degrees of Freedom (df); Log likelihood-ratio statistic (-2LL); Odds ratio (OR).                         
*Variables with p < 0.2 Bootstrap 95% confidence intervals (CI) results are based on 1000 bootstrap samples and are shown in 
brackets. 
 
2.4.2.5.1.3 Final Multivariable Model 
None of the additional explanatory variables improved the previously constructed model; the results of the 





Table 2.14: Results from Final Multivariable Regression Model of Risk Factors for Feline Degenerative Joint Disease 
in Six-year-old Cats 
 B S.E. Wald df Sig. Odds Ratio (95% CI) 
Included 
Neuter Status at 
Six Months of Age 
Neutered Reference 
Entire 0.678 0.226 8.974 1 0.003* 1.97 (1.264, 3.071) 
Outdoor 
Access 
No outdoor access Reference 
Outdoor access 0.513 0.283 3.298 1 0.069 1.671 (0.96, 2.907) 
BCS 
(6-year-old) 
Not Overweight Reference 




Yes 0.613 0.179 11.759 1 0.001* 1.846 (1.3, 2.62) 
Intercept  -1.745 0.284 37.61 1 0* 0.175 
Not included 
BCS Change Between 
6 and 5-year-old Cats 
No change 1.275 2 0.529 Reference 
BCS decrease 0.329 0.355 0.86 1 0.354 1.39 (0.693, 2.786) 
BCS increase -0.184 0.297 0.381 1 0.537 0.832 (0.465, 1.491) 
BCS Change Between 
6 and 2.5-year-old 
Cats 
No change 0.175 2 0.916 Reference 
BCS decrease 0.062 0.379 0.026 1 0.871 1.064 (0.506, 2.236) 
BCS increase 0.109 0.277 0.156 1 0.693 1.115 (0.648, 1.918) 
BCS change between 
6 and 18-month-old 
cats 
No change 0.014 2 0.993 Reference 
BCS decrease -0.002 0.444 0 1 0.997 0.998 (0.418, 2.384) 
BCS increase -0.037 0.317 0.014 1 0.907 0.964 (0.518, 1.792) 
Body Condition Score (BCS); Confidence intervals (CI), Degrees of Freedom (df). 




Previous studies have failed to identify risk factors for feline DJD other than age. Nevertheless, this study 
identified four risk factors that were associated with owner-reported early DJD-related signs at six years of age 
(Table 2.10); entire neuter status at six months of age, sustained trauma before the age of six years, outdoor 
access at six years of age, and overweight/obese status according to owner-assessed BCS at six years of age. 
Cats that were entire at six months of age were twice as likely to have owner-reported early DJD-related signs 
than cats that were neutered before that age. No studies to date have established a relationship between 
neutering and the incidence of musculoskeletal problems (Howe et al., 2000) or long bone fractures (Spain et 
al., 2004) which could result in secondary DJD later in life; however, these retrospective cohort studies only 
had a median follow-up time of approximately three years. This is the first study where the occurrence of feline 
DJD in relation to neutering has been assessed. Neutering has been shown to result in delayed physeal closure 
of long bones in cats and dogs of both sexes (Kustritz, 1999). In dogs neutered earlier than six months, the 
increased incidence of genetically mediated musculoskeletal problems such as HD, CCL and elbow dysplasia, 
all of which can result in secondary DJD, has been attributed to delayed physeal closure (Howe, 2015). Primary 
DJD in dogs has also been linked to neutering and specifically post-neutering weight gain (Sanderson, 2012), 
something which has not been shown in cats. Consequently, the postulated explanations for the effect of 
neutering in dogs do not appear to apply in cats. On the other hand, the immunosuppressive effect of 
testosterone during the early stages of development has been recognised in humans and other species of both 
sexes (Martin, 2000, Nunn et al., 2009). In one study, cats that were neutered before the age of 5.5 months 
were less likely to suffer from feline asthma and gingivitis compared to cats that were neutered later in life 
(Spain et al., 2004). The effect of early neutering on the immune system of cats has not been elucidated, and 
neutering has not been established as a risk factor for the development of chronic inflammatory processes 
such as feline asthma, gingivitis, CKD and DJD. Nevertheless, the protective effect of neutering before the age 
of six months demonstrated in this study could be explained by the fact that it resulted in reduced circulating 
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levels of androgens during that developmental period, thereby decreasing the incidence of owner-reported 
early DJD-related signs at six years of age.  
Cats that had sustained trauma were twice as likely to have owner-reported early DJD-related signs than cats 
that had not sustained trauma. In humans, trauma is a confirmed risk factor for the development of secondary 
DJD (Felson et al., 2000), however there is little evidence to support this in dogs (Anderson et al., 2018) or cats 
(Lascelles, 2010). This is the first study where the occurrence of feline DJD following joint trauma has been 
evaluated. Trauma occurred in approximately a quarter of this study’s cats and was therefore higher than the 
12.9% reported for the UK pet cat population (O'Neill et al., 2014). Nevertheless, the study by O’Neil and others 
(2014) only involved cats that attended primary-care veterinary practices, whilst the present study additionally 
included injuries that the owners felt were not serious enough to seek veterinary attention. On the other hand, 
the reported prevalence of RTAs for the UK pet population is 60% (O'Neill et al., 2015), and therefore 
considerably higher than the prevalence of RTAs in this study (~6%). It should be noted, however, that the 
present study exclusively involved non-fatal RTAs. Unfortunately, there were not enough cats per trauma 
category to analyse them separately in this study; nevertheless, this relationship appeared to be driven by the 
most severe injuries (RTAs, fractures/dislocations, falls from height). Approximately a quarter of sustained 
trauma in this study comprised of severe injuries which have been shown to result in direct joint trauma; 
indeed, skeletal fractures/dislocations were reported in 60% and 68.9% of cats that were alive on arrival 
following RTAs (Rochlitz, 2004) or falls from height (Vnuk et al., 2004), respectively. Cat and dog bites and/or 
resulting abscesses accounted for approximately half of this study’s traumatic injuries and could have 
contributed to the development of early signs of DJD in two manners. Cat bites can puncture soft tissue deeply 
and even penetrate joints due to the sharp nature of cats’ teeth, whereas dog bites can cause severe STT and 
fractures as a result of the crush injury delivered by dogs’ jaws (Dendle and Looke, 2009). Cat and dog bite 
wounds also contain a plethora of aerobic and anaerobic bacteria with Pasteurella species being the most 
common isolates (Talan et al., 1999). Consequently, in addition to direct joint trauma, cat and dog bites may 
lead to secondary DJD by instigating bacterial arthritis either by direct inoculation, if they occur close to joints, 
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or by haematogenous spread. The remainder of sustained trauma in this study was attributed to STS. It is 
unlikely that a single STT could have contributed to the development of DJD. Nevertheless, this category may 
have included other types of more severe trauma that were not witnessed, resulting in owners only reporting 
the lameness rather than the cause of the lameness.  
Cats with outdoor access were twice as likely to have owner-reported early DJD-related signs than indoor only 
cats. The proportion of cats that had an exclusively indoor lifestyle in this study (~11%) was similar to the 
previously reported 9.1% for the UK pet cat population (Murray and Gruffydd-Jones, 2012). It should be noted, 
however, that not all cats in this study would have necessarily had outdoor access for the entirety of their lives. 
Studies to date have not demonstrated a relationship between outdoor access and feline DJD (Hardie et al., 
2002, Lascelles et al., 2010b), however these studies evaluated the presence of radiographic DJD rather than 
the presence of signs of mobility impairment as reported by owners. Outdoor access has been hypothesised to 
increase the risk of fighting and accidental injury in cats (Buffington, 2002), thus increasing the risk of 
developing secondary DJD; nevertheless, there was no multicollinearity between outdoor access and trauma 
incidence in this study. A possible explanation for this is that cats with outdoor access may be more likely to 
undergo repetitive microtrauma that goes unnoticed, thereby resulting in owners not reporting any lameness. 
Repetitive microtrauma has indeed been shown to result in altered biomechanics that lead to DJD in dogs 
(Marcellin-Little et al., 2007), horses (Magnusson and Ekman, 2001) as well as professional athletes and dancers 
(Rehmani et al., 2015, Yang et al., 2012). 
This study found that overweight/obese cats were approximately twice as likely to have owner-reported early 
DJD-related signs compared to cats that were not overweight. In humans and dogs, obesity has been 
established as a cause of abnormal joint loading which alters the mechanical and biochemical properties of 
articular cartilage, thus initiating the DJD process (Guilak, 2011, Marshall et al., 2009). Interestingly, DJD has 
also been shown to develop in the non-weight bearing joints of obese patients (Cicuttini et al., 1996), indicating 
that obesity-related biochemical factors may also be involved in the development of DJD. Circulating levels of 
leptin reflect body fat mass and have been shown to be increased in overweight cats, dogs and humans (Radin 
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et al., 2009). In humans, the levels of serum and synovial fluid leptin were demonstrated to be higher in patients 
with DJD compared to patients without DJD, with the expression of leptin and its receptor being positively 
correlated with the severity of DJD (Yan et al., 2018). Studies in dogs revealed that the levels of synovial fluid 
leptin were higher in dogs with secondary DJD due to CCL injury (Schmidli et al., 2018) and in dogs with owner-
reported signs of impaired mobility (Kleine et al., 2019), thereby supporting the proinflammatory role of leptin 
in the development of DJD in dogs. Although there is a paucity of studies investigating the role of mechanical 
and biochemical factors in the relationship between obesity and feline DJD, it is reasonable that these 
postulations could also apply to cats, therefore explaining this study’s link between obesity and DJD. Additional 
BCS-derived variables were not able to explain the increased proportion of overweight/obese cats from less 
than 10% at one year of age to approximately a quarter of cats at six years of age, and future studies are needed 
to dissect the effect of BCS at six years of age on the development of DJD. 
Cohort studies have the ability to assess causality and can thus provide the strongest scientific evidence 
compared to cross-sectional and case-control studies which are prone to non-response and recall bias, 
respectively (Song and Chung, 2010). Nonetheless, this study also has potential limitations. The population of 
the present study was generally similar to what has previously been reported in a large cross-sectional UK study 
(O'Neill et al., 2015), suggesting that it represented the general owned UK cat population. The only difference 
was the higher proportion of purebred cats in this study (~20%) than the reported 11%. This is most likely 
explained by the fact that a pedigree breeder was a more common source of cats for the BC study cohort 
(Wilson et al., 2017) compared to the UK population (Murray and Gruffydd-Jones, 2012). It should however be 
noted that the studies by O’Neil (2015) and Murray and Gruffydd-Jones (2012) may be less representative of 
the general owned UK cat population than the BC study as they only included cats that were registered with or 
attended primary care veterinary practices. Conversely, both these studies and the BC study may have 
exclusively included more motivated owners; the former only including owners that registered with or 
attended a primary care veterinary practice, and the later consisting of owners that had voluntarily participated 
in a six-year-long study. One of the limitations of this study’s design was the fact that it depended on owner-
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reported data, possibly introducing reporting bias. This bias could have been mitigated if clinical information 
pertaining to BCS, vaccination history, dental health and trauma incidence was compared against veterinary 
records, however that was unfortunately not possible within the study’s time frame. With regards to the BCS 
variable, it is accepted that owners tend to underestimate the BCS of their cats (Cave et al., 2012, Colliard et 
al., 2009), and indeed a similar attitude has been reported in the BC cohort (Rowe et al., 2017). Consequently, 
the prevalence of obesity in this study may be an underestimation, which would indicate that the relationship 
between obesity and the development of early DJD-related signs is stronger than detected by the model. 
Another limitation relates to the effect of hierarchical clustering on the multivariable model, since 
approximately a third of this study’s cats lived in a multi-cat household. Although this may have limited owner-
level variation and introduced bias, it was not possible to construct additional multivariable models within the 
study’s time frame. 
 
2.6 Conclusion 
The present study identified four risk factors that were associated with owner-reported early DJD-related 
signs at six years of age, supporting previous beliefs that obesity, outdoor access and a history of trauma 




3. STUDY TWO: ORTHOPAEDIC EXAMINATION, QUALITY OF 
LIFE ASSESSMENT AND ACTIVITY MONITORING OF CATS 
WITH OWNER-REPORTED SIGNS OF DEGENERATIVE JOINT 
DISEASE OVER SIX YEARS OF AGE 
This study was approved by University of Bristol’s Health Sciences Faculty Research Ethics Committee (69041; 
04/07/2018) and the Animal Welfare and Ethical Review Body (VIN/18/026; 09/08/2018). 
 
3.1 Aims and Objectives 
 The specific aims of this study were to:  
• Evaluate two owner assessment questionnaires designed to assess chronic pain in cats with 
musculoskeletal disease (FMPI) and the QoL of cats (VetMetrica) by comparing cats with and 
without early DJD-related changes in owner-reported mobility. 
• Using orthopaedic examination data, compare the joint health of cats with and without early 
DJD-related changes in owner-reported mobility. 
• Using accelerometry, compare the activity data of cats with and without early DJD-related 
changes in owner-reported mobility. 
 
3.2 Hypotheses 
We hypothesised that owners would be able to recognise early DJD-related pain in their cats, and that DJD-
related pain has a significant impact on the QoL of affected cats. We also hypothesised that joint health as 
evaluated by orthopaedic examination would reflect early DJD-related changes in owner-reported mobility, 
and that accelerometry would be able to identify these owner-reported mobility changes. 
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3.3 Materials and Methods 
3.3.1 Study Design 
A nested case-control study was designed in two groups of individuals, Cases and Controls, to: 
1. Identify differences in the activity profiles of cats with early DJD-related changes in owner-
reported mobility when compared to cats without owner-reported mobility changes. 
2. Establish whether joint health as evaluated by orthopaedic examination reflected early DJD-
related changes in owner-reported mobility. 
3. Investigate changes in the QoL of cats with early DJD-related changes in owner-reported mobility.  
4. Determine whether accelerometry was able to detect early DJD-related changes in owner-
reported mobility. 
 
3.3.2 Study Size 
It was not possible to estimate the anticipated incidence of early DJD-related changes in owner-reported 
mobility based on relevant literature to date, as this mainly concerns the radiographical presence of well-
established DJD (Clarke and Bennett, 2006, Godfrey, 2005, Lascelles et al., 2010b, Slingerland et al., 2011). 
Sample size calculation was therefore based on practical considerations with regards to the maximum number 
of cats that could be visited during the allocated time frame; the aim was to recruit 60 cats, 30 in each group. 
 
3.3.3 Setting 
The initial intention was to only include cats from the BC study, and therefore participants of the BC study were 
approached first. Unfortunately, there were not enough eligible BC study participants within a practical driving 
distance that could be visited within the allocated time frame and budget, and recruitment was expanded to 
also include non-BC (nBC) study cats. Recruitment began in July 2018 and January 2019 for BC and nBC study 
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participants, respectively, and ended in October 2019. Data collection began in December 2018 and March 
2019 for BC and nBC study participants, respectively, and ended in November 2019. Eligible participants of the 
BC study were contacted directly via phone, post, or e-mail (Appendix F). To recruit nBC participants, study 
advertisements were placed on relevant notice boards throughout the University of Bristol campus, posted to 
local veterinary practices and e-mailed to students and staff using relevant mailing lists (Appendix F). In 
addition, a social media page was created (https://www.facebook.com/feline.activity.study), and the study 
was advertised on a press release (Bristol, 2019), radio (BBC Radio Bristol, 22/05/2019), and television (BBC 
Points West, 22/05/2019).   
 
3.3.4 Participants  
Cats were excluded from the study where performing a clinical examination was not ethical, wearing an activity 
monitor was not possible, a diagnosis which was likely to influence mobility had been made, or medication 
which was likely to influence mobility was being administered. Inclusion and exclusion criteria are listed in 
Table 3.1.  
 
Table 3.1: Inclusion and Exclusion Criteria for Study Recruitment 
Inclusion Criteria Exclusion Criteria 
≥ 6 years of age Being fearful of strangers 
Cats with owners willing to habituate them to wearing a 
breakaway (safety) collar if they were not wearing one already 
Unable to acclimatise to wearing a collar or unduly 
stressed by the process 
Cats with owners willing to allow the placement of an activity 
monitor on their collar for a period of two weeks 
Diagnosed with any condition that could influence 
mobility 
Indoor only or with restricted outdoor access Receiving dietary supplements if initiated < 30 days 
before the visit and/or not continued during the study 
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Inclusion Criteria Exclusion Criteria 
Live within a 100-mile radius from Bristol Veterinary School (BS40 
5DU) 
Receiving anti-inflammatory or analgesic medications 
 Inadequate number of questions answered to calculate 
MS or a MS of 1 
Mobility Score (MS). 
 
If the cat was not already wearing a collar, owners were required to be willing to habituate their cat to wearing 
one for the study period. In these cases, a breakaway (safety) collar along with habituation instructions were 
provided at least two weeks before the visit took place (Appendix G). Cats that were unable to acclimatise to 
wearing a collar or were unduly stressed by the process were excluded from the study. Cats were also excluded 
from the study if they were fearful of strangers and therefore performing an orthopaedic examination would 
not be ethical. Cats that were receiving anti-inflammatory or analgesic medications for any reason were 
excluded as their administration could affect their mobility. Due to the cost of the accelerometry devices and 
the risk of losing them, cats that could leave the owners’ garden were excluded from the study. Included cats 
were required to be indoor only or have restricted outdoor access which included being walked on lead or 
being allowed in an enclosed area for limited periods of time, with or without owner supervision.  
Finally, cats were allocated to the Case or Control group according to their MS. Control cats were required to 
have no owner-assessed mobility impairment (MS = 0). Cats with owner-assessed mobility impairment (MS > 
1) were assigned to the Case group, whilst cats with a MS = 1 were excluded. As in the first study, the score of 
two and above was chosen to reflect early mobility impairment, whilst the score of one was excluded to avoid 
false positives.  
For BC study cats, the most recently completed BC questionnaire (Appendix C) was used to evaluate their 
eligibility and calculate MS; this was Q8-Q10 for 6-8-year old cats, respectively. For nBC study cats, an online 
inclusion questionnaire (Online Surveys) containing the same questions relating to mobility was used to 
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evaluate their eligibility and calculate MS (Appendix H). The same questions and same method of calculating 
the MS were used here as in the first study. 
Of the 1795 BC study cats that were alive at the start of the recruitment period and of the 282 nBC enquires, 
1727 and 177 cats, respectively, did not fulfil the eligibility criteria and were thus excluded from this study 
(Table 3.2).  
 
Table 3.2: Number of Cats and Associated Reasons for Study Exclusion 




Cat was < 6 years of age 38 10 
Cat lived outside the 100-mile study radius 774 14 
Cat had unrestricted outdoor access 237 95 
Cat reported to be fearful of strangers 46 21 
Cat reported likely to be stressed by collar habituation and/or 
accelerometer wearing process 
149 5 
Cat diagnosed with a condition that could influence mobility 33 9 
Cat receiving anti-inflammatory and/or analgesic medications 65 10 
Inadequate number of questions answered to calculate MS 69 1 
Cat had a MS = 1 316 12 
Total Number of Excluded Cats  1727 177 
Mobility Score (MS). 
 
It was not possible to contact 30 BC and 22 nBC owners, and 16 BC owners declined to participate in the study. 
A total of 22 BC and 63 nBC owners agreed to participate in this study, and a unique identification number was 
assigned to each of the 85 recruited cats. A total of 28 cats were removed from the study before (n = 22) or 

















Figure 3.1: Recruitment and Enrolment Flowchart 
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3.3.5 Data Collection 
3.3.5.1 Bias 
The researcher was blinded to each cat’s MS and other questionnaire results. 
 
3.3.5.2 Pre-visit Measures 
The study information sheet and consent form were sent to all eligible owners at least two weeks before the 
visit took place, and each owner signed an informed consent form prior to participating in the study 
(Appendices I and J). 
Owners of cats meeting the eligibility criteria were additionally asked to complete the FMPI and VetMetrica 
questionnaires online (Online Surveys) prior to the visit. The FMPI questionnaire (Appendix K) asked owners to 
rate their cat’s ability to perform 17 activities compared to a normal cat on an integer scale from 0 to 4, with 0 
= “not at all” and 4 = “normal”. The total FMPI score was the sum of scores for each question with a range 0-
68. In order to maintain the scale when questions were unanswered or non-applicable, calculation of percent 
was used for analysis using the following formula: 
FMPI% = (sum of answered questions) / (number of questions answered x 4) 
To obtain owner responses without passing on their personal information to a third party (VetMetrica), the 
QoL questionnaire was simulated exactly as it appears on their website on an online survey, not permitting 
owners to go back and change their answers or skip any questions (Appendix L). The VetMetrica questionnaire 
(NewMetrica, Glasgow, UK) asked owners to rate how 20 different words described their cat on an integer 
scale from 0 to 6, with 0 = “not at all” and 6 = “couldn’t be more”. One final question asked owners to rate the 
cat’s QoL on an integer scale from 0 to 3, with 0 = “very poor” and 3 = “very good”. The researcher registered 
the participating cats on the VetMetrica website using their unique identification number, and owner 
responses were inputted to the VetMetrica website manually with an appropriate check for accuracy via a 
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second person. Using the responses to the 20 initial questions, a proprietary algorithm automatically generated 
scores for the Vitality, Comfort and EWB QoL domains. The final question was not utilised in the algorithm. 
A clinical and orthopaedic examination protocol (Appendix M) was developed and piloted by the researcher 
with advice from an orthopaedic veterinary surgeon. 
 
3.3.5.3 Visit Protocol 
Participating cats were visited in their own homes. The duration of each visit was 30 to 60 minutes, and the 
first 15 to 30 minutes were dedicated to discussing the visit protocol with the owners, allowing the cat to 
acclimatise to the researcher’s presence before any handling took place. A physical and orthopaedic 
examination was then performed on the cat by the researcher, a veterinary surgeon. This lasted approximately 
two minutes in most cases. If at any point the cat showed behavioural signs of anxiety or fear, the researcher 
would pause the examination to allow the cat further time to habituate to their presence before trying again, 
depending on the individual circumstances and owner consent. If the cat avoided the researcher or showed 
signs of anxiety at the second attempt, the clinical examination was abandoned. 
The BCS was recorded, then each joint comprising the appendicular and axial skeleton was evaluated. The 
orthopaedic examination would follow the same order for all cats (right foreleg, right hindleg, left foreleg, left 
hindleg, axial skeleton). Pain responses for each joint were graded using a previously published integer scale 
(Lascelles et al., 2010b), where 0 = no resentment; 1 = mild withdrawal, mild resistance to manipulation; 2 = 
moderate withdrawal, body tenses, may orient to site, may vocalise/increase vocalisation; 3 = orients to site, 
forcible withdrawal from manipulation, may vocalise or hiss or bite; 4 = tries to escape or prevent manipulation, 
bites or hisses, marked guarding of area. Each appendicular joint was additionally evaluated for the presence 
of crepitus, thickening and effusion on an integer scale, where 0 = none; 1 = slight – moderate; 2 = severe. 
Finally, a score was assigned to each cat based on their temperament during the orthopaedic examination, 
with 0 = neutral attitude, purring, kneading; 1 = resistance to restraint; 2 = resistance to restraint, growling and 
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hissing; 3 = resistance with biting and scratching, hissing, spitting, and vocalising; and 4 = resistance with biting, 
scratching, vocalising, spitting, hissing urinating, or defecating (Jaeger et al., 2007). Following this, an activity 
monitor which was to be worn for a total period of fourteen days was placed upright on the ventral aspect of 
each cat’s collar (Figure 3.2).  
 
 
Figure 3.2: Study Participant Wearing the Collar-mounted Activity Monitor 
 
The activity monitor used was Actical® Z (Philips Respironics, Bend, Oregon USA), an omni-directional activity 
monitor with a titanium frame that measures 29mm x 37mm x 11mm, weighs 16g, and has a piezoelectric 
sensor mounted to an internal circuit board (Respironics, 2018). The sensor can measure analog voltage 
changes that are generated proportionally to the intensity and duration of change in acceleration (John and 
Freedson, 2012). The measurement range of this sensor is between 0.05 and 2G, whilst the measurement 
bandwidth is between 0.035 to 3.5Hz. The readings are converted into counts of 100 for the chosen 
measurement period (epoch) when the accelerometer reading goes above 0.02 G (at 1G peak). Actical® Z has 
a 32Hz sampling rate and can collect data in epoch lengths ranging from one second to one minute, or in raw 
collection mode. Depending on the set epoch, battery life allows recording from 12 to 301 days. There were 
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four devices available, all newly purchased and calibrated by the manufacturer at the same time. Epoch length 
in this study was set to one second, with each daily activity profile composed of 86400 second-by-second 
measurements. Recording was set to start the following morning (8:00 AM local time) to avoid the confounding 
effects of the visit and acclimation to wearing the activity monitor. The activity monitor was worn throughout 
the two-week study period, following which the researcher would visit the cat again to remove the device. 
Activity data were downloaded using a designated serial port reader (Actireader®) and software (Actical® 3.10); 
this created a graph containing activity counts per day (Figure 3.3) and imported raw data into an Excel 
spreadsheet to be used for statistical analysis. Finally, the owners were asked to keep a diary, recording the 
times when the device and/or the collar fell off and were replaced (Appendix N). Neither the examination 
findings nor the accelerometer outputs were shared with the owners in any oral or written form. 
 
 
Figure 3.3: Representative graph Illustrating Activity Counts as Generated by the Activity Monitor 




3.3.5.4 Outcome Measures 
Outcome measures included orthopaedic examination findings as well as subjective owner assessments of 
impaired mobility and QoL using the FMPI and VetMetrica questionnaires, respectively. Obtaining and 
analysing accelerometry data served as the first part and, thus, a proof of concept for a major study using 
exclusively BC study cats. 
 
3.3.6 Variables 
The 17 variables that were collected and subsequently considered for analysis are listed in Table 3.3. The cat’s 
status reflected the absence (Control = 0) or presence (Case = 1) of owner-reported early DJD-related signs. 
 
Table 3.3: Variables Used for Analysis of Orthopaedic Examination, Quality of Life Assessment and Activity 












< 7 years Prime 
≥ 7 – 11 years Mature 
≥ 11 – 15 years Senior 






DSH, DLH and their crossbreeds 
DLH 
Remaining specific breeds Purebred 
Neuter Status Categorical 
No Entire 
Yes Neutered 
FMPI Continuous 0 – 1 0 – 1 











VetMetrica Comfort Domain Continuous 0 – 70 0 – 70 




Very poor Very poor 
Poor Poor 
Good Good 
Very good Very good 






















Total Pain Score Continuous 0 – 80 0 – 80 
Total Crepitus Score Continuous 0 – 32 0 – 32 
Total Effusion Score Continuous 0 – 24 0 – 24 






Number of Joints 
with Bilateral Pain 
Continuous 0 – 8 0 – 8 
Body condition score (BCS); Domestic long hair (DLH); Domestic short hair (DSH); Emotional wellbeing (EWB); Feline 
Musculoskeletal Pain Index (FMPI); Quality of life (QoL). 
 
Age was regrouped into biologically relevant life stages which have clinical relevance in terms of the physical 
and behavioural changes that occur at different time points in cats’ lives, thereby informing veterinary care 
99 
 
(Hoyumpa Vogt et al., 2010). These were: < 7 years = “Prime”, ≥ 7 – 11 years = “Mature”, ≥ 11 – 15 years = 
“Senior”, and ≥ 15 years = “Geriatric”. 
As data were sparse for some of the lower BCS using the 9-point system (Bjornvad et al., 2011), cats were 
grouped for further analysis as “overweight/obese” for BCS 6–9, which included both overweight (6–7) and 
obese (8–9) cats, or “not overweight” for BCS 1–5, which included underweight (1–3) cats and cats of ideal 
weight (4–5). 
Data were also sparse for the temperament assessment scores, therefore these were collapsed for analysis 
with 0–2 = “friendly”, or 3–4 = “unfriendly” (Jaeger et al., 2007).  
Total appendicular and axial scores were generated for each cat by summing the pain score for each individual 
appendicular or axial joint with a possible range of 0–64 and 0–16, respectively, then a total pain score was 
created for each cat by summing the total appendicular and axial scores with a possible range of 0-80. Total 
crepitus, thickening and effusion (manipulation scores) were also generated for each cat by summing the score 
for each individual appendicular joint with a possible range of 0–32, 0–28 and 0–24, respectively. 
Individual pain and manipulation scores were additionally grouped into “no pain” and “no abnormal signs” if 
0, or “pain present” and “abnormal signs present” if ≥ 1, respectively. These scores were used in descriptive 
statistics to describe a) the number of joints with pain, crepitus, thickening, and effusion detected during 
orthopaedic examination, b) the most frequently affected appendicular and axial joints, and c) the frequency 
of bilateral pain. They were also used to compare the presence of bilateral pain as well as the number of joints 





3.3.7 Statistical Analysis 
Analyses were performed using SPSS (version 24.0.0.2, IBM Corporation, USA). Unless stated otherwise, an 
alpha value of ≤ 0.05 was set for statistical significance in all analyses, and an exact significance (2-tailed) is 
reported. Out of the 17 variables analysed, eight were continuous and nine were categorical. Continuous data 
were examined for normality using histograms and the Kolmogorov-Smirnov test; p-values ≥ 0.05 were 
required for data to be considered normally distributed. All continuous variables apart from Total Pain and 
VetMetrica Vitality Domain scores were non-normally distributed and, despite applying different 
transformations (logarithmic, square root and reciprocal), it was not possible to normalise them (Appendix O). 
Consequently, non-parametric statistical tests were used.  
Group comparisons were performed using a Mann-Whitney or chi-square test if the variables were continuous 
or categorical, respectively. Fisher’s exact test (FET) was used instead of the chi-square test when > 20% of cells 
had expected frequencies of < 5. A posthoc comparison using the Holm-Bonferroni correction (Holm, 1979) 
was performed to correct for the familywise error rate associated with multiple hypothesis testing. A corrected 
significance cut-off was calculated for each hypothesis as α/n – rank number of pair (by degree of significance) 
+1, where n = number of tests (Appendix P). The null hypothesis (there is no difference between the two groups 
of cats for the selected variable) was rejected when the p-value associated with each hypothesis was lower 
than the corrected p-value calculated using the Holm-Bonferroni correction. The measure of effect size (r) for 
the Mann-Whitney tests was calculated by dividing the z value from the test by the total number of 
observations; effect sizes between 0.1 – < 0.3, 0.3 – < 0.5 and ≥ 0.5 were considered small, medium, and large, 
respectively. Odds ratio (OR) and Cramér’s V were used as measures of effect size on the results of chi-square 
and FET tests depending on the degrees of freedom (df), with effect sizes classified as small, medium, and large 
for Cramér’s V, (Cohen, 1988). 
Before machine learning of the accelerometer data could be carried out, the researcher imported the raw 
accelerometer data into an Excel spreadsheet for each cat. Information obtained from owner diaries was then 
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used to ascertain the duration that the collar and/or the device was not worn by each cat, this establishing 
missing accelerometer datapoints. Finally, the researcher prepared two spreadsheet containing each cat’s 
metadata (unique identification number, Case or Control status, and age) as well as each cat’s missing 
accelerometer datapoints. The remainder of the analysis including machine learning of the accelerometer data 
was undertaken by Axel Montout, PhD student of Professor Andrew Dowsey, Bristol Veterinary School, using 
the Python programming language and scikit-learn 0.22.1. A pre-processing pipeline was used to read each 
spreadsheet containing accelerometer data and link it to the metadata spreadsheet via the cat identification 
number, then extract the date, time, and activity counts (Figure 3.4). Missing datapoints were replaced with 
the value of -1 which is not generated by the accelerometer, allowing 14 full days of data per cat for analysis. 
Accelerometer data were binned into 10-minute intervals for analysis. It was unfortunately not possible to 
perform analysis using a higher resolution than this due to lack of computational power. Accelerometer data 
were Anscombe transformed to remove heteroscedasticity due to Poisson counting statistics, then log 
transformed to remove residual heteroscedasticity. This was followed by a Continuous Wavelet Transform 
which has been shown to decorrelate the period of activity from its intensity so that the artificial intelligence 
can discriminate on activity durations as well as intensities (McCamley et al., 2012). Linear Discriminant Analysis 
was used for dimensionality reduction, reducing the original number of dimensions to two whilst maintaining 
the most important features in the input array and maximising class separation (McLachlan, 2004). The dataset 
was then randomly divided into training (60%) and testing (40%) datasets, and logistic regression was used to 
predict each cat’s class (status) with their age included as an additional variable at this stage. Each output was 
associated with a classification accuracy as well as two parameters for each class: accuracy and precision. 
Accuracy is the ratio of the number of correct predictions to the total number of predictions made, whereas 
precision is the ratio of the number of true positives divided by the sum of true and false positives. Recall for 

















Figure 3.4: Diagram Illustrating the Pre-processing Pipeline and the Steps Followed for Machine Learning 
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Demographic and eligibility data were obtained from the most recently completed BC study and inclusion 
questionnaires for BC and nBC participants, respectively. These were completed fully by all participating 
owners, resulting in no missing data in any of the demographic variables.  
All 57 participating cats were neutered, 29 (50.9%) were male, and most (n = 30, 52.6%) belonged in the Mature 
life stage age group (Table 3.4). The majority of cats were of mixed breed (n = 43, 75.4%), with the remaining 
14 purebred cats consisting of two (3.5%) of each for Bengal, British short hair and Burmese and one of each 
(1.7%) for Devon Rex, Exotic short hair, Malayan, Oriental short hair, Persian, Ragamuffin, Ragdoll and 
Snowshoe. Moreover, 51 (89.5%) cats lived in a single-cat household, and the remaining 6 (10.5%) lived in a 
household with a total of two cats. At the time of recruitment, most cats (n = 40, 70.2%) were not wearing a 
collar and were habituated to wearing one in due course. 
 
Table 3.4: Demographic Data for n = 57 Cats 
Variables N (%) of Cats 
Age  
in Life Stages 
Prime 5 (8.8%) 
Mature 30 (52.6%) 
Senior 13 (22.8%) 
Geriatric 9 (15.8%) 
Sex 
Male 29 (50.9%) 
Female 28 (49.1%) 
Neuter Status 
Entire 0 (0.0%) 
Neutered 57 (100.0%) 
Breed Category 
DSH, DLH and their crossbreeds 43 (75.4%) 
Purebred 14 (24.6%) 




3.4.2 Pre-visit Measures 
The FMPI and VetMetrica questionnaires were completed fully by 50 cat owners before the visit took place. 
Four and three owners, respectively, completed the FMPI and VetMetrica questionnaires approximately two 
weeks after the visit had taken place. Results for the continuous pre-visit measures are listed in Table 3.5. Most 
owners perceived their cat’s QoL as “very good” (n = 40, 70.2%) or “good” (n = 17, 29.8%), whereas no owners 
perceived their cat’s QoL as “poor” or “very poor”. 
 
Table 3.5: Pre-Visit Measures for n = 57 Cats 
Variable Range Median IQR 
Feline Musculoskeletal Pain Index 0.64 – 1.00 1.00 0.97 – 1.00 
VetMetrica Vitality Domain 26.5 – 64.0 49.8  44.6 – 55.1 
VetMetrica Comfort Domain 30.1 – 59.6 44.2  39.2 – 57.2 
VetMetrica Emotional Wellbeing Domain 34.4 – 58.8 51.9  45.6 – 56.3 
Interquartile range (IQR). 
 
3.4.3 Visit Measures 
3.4.3.1 Temperament Assessment 
There were no missing data for temperament assessment scores. These ranged from 0 to 4, with a median of 
1 and an IQR of 0 – 2 (Table 3.6). Most cats scored 0 (n = 22, 38.6%) or 1 (n = 20, 35.1%). Seven cats (12.3%) 
were quite vocal when initially approached and even after they were given more time to acclimatise to the 
researcher’s presence; however, they were happy to be handled and some were also kneading or purring. 
Consequently, the orthopaedic examination was performed without any stress to these cats and they were 
assigned a score of 3 to account for their more vocal nature. The score of 4 was assigned to a cat that was 
revealed to be extremely fearful of strangers when the researcher entered the house and therefore was not 
examined at all. Most cats (n = 49, 86%) were considered to have a friendly temperament towards the 
researcher (scores 0-2 inclusive). 
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Table 3.6: Temperament Assessment for n = 57 Cats 
Variable Range N (%) of Cats 
0: Neutral attitude, purring, kneading 22 (38.6%) 
1: Resistance to restraint 20 (35.1%) 
2: Resistance to restraint, growling and hissing 7 (12.3%) 
3: Resistance with biting and scratching, hissing, spitting, and vocalising 7 (12.3%) 
4: Resistance with biting, scratching, vocalising, spitting, hissing, urinating, or defecating 1 (1.7%) 
 
3.4.3.2 Body Condition Score (Assessed by Veterinary Surgeon) 
There were no missing data for BCS. These ranged from 3 to 7 with a median of 5 and an IQR of 4.5 – 6. Most 
cats (n = 18, 31.6%) had a BCS of 5 (Table 3.7, Figure 3.5). When grouped according to their score, 32 cats 
(56.1%) were not considered overweight and 25 cats (43.9%) were considered overweight/obese. 
 
Table 3.7: Body Condition Score (Assessed by Veterinary Surgeon) for n = 57 Cats 
Variable N (%) of Cats 
Body Condition Score 
(Assessed by Veterinary Surgeon) 
3 1 (1.8%) 
4 13 (22.8%) 
5 18 (31.6%) 
6 15 (26.3%) 
7 10 (17.5%) 
 




















Figure 3.5:  Body Condition Score (Assessed by Veterinary Surgeon) for n = 57 Cats 
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3.4.3.3 Orthopaedic Examination 
There were only 30/1140 (2.63%), 26/912 (2.85%), 12/684 (1.75%), and 14/798 (1.75%) missing pain, crepitus, 
effusion, and thickening scores, respectively, as a result of the generally friendly cat temperament. These 
included missing scores for both hip joints in five cats, and missing scores for all 20 joints (16 appendicular and 
four axial joints) in one cat due to its temperament. Consequently, only data from 56 cats were included in the 
analysis of orthopaedic examination data. The number of joints and spinal segments with or without clinically 
detected abnormalities on orthopaedic examination are summarised in Table 3.8.  
 
Table 3.8: Prevalence of Abnormalities Detected During Orthopaedic Examination of the Appendicular and Axial 
Skeleton in n = 56 Cats 
 
N (%) of 
Joints with 
Pain 
N (%) of 
Joints with 
Crepitus 
N (%) of 
Joints with 
Effusion 









Right Manus 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 56 56 
Right Carpus 3 (5.4%) 1 (1.8%) 0 (0.0%) 0 (0.0%) 52 56 
Right Elbow 40 (71.4%) 6 (10.7%) 0 (0.0%) 14 (25.0%) 15 56 
Right Shoulder 8 (14.3%) 0 (0.0%)  0 (0.0%) 48 56 
Right Pes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 56 56 
Right Tarsus 39 (69.6%) 3 (5.4%) 0 (0.0%) 1 (1.8%) 17 56 
Right Stifle 44 (78.6%) 7 (12.5%) 0 (0.0%) 28 (50.0%) 11 56 
Right Hip 40 (78.4%) 5 (9.8%)   11 51 
Left Manus 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 56 56 
Left Carpus 4 (7.1%) 4 (7.1%) 0 (0.0%) 0 (0.0%) 50 56 
Left Elbow 36 (64.3%) 4 (7.1%) 0 (0.0%) 4 (7.1%) 19 56 
Left Shoulder 6 (10.7%) 0 (0.0%)  0 (0.0%) 50 56 
Left Pes 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 56 56 
Left Tarsus 21 (37.5%) 1 (1.8%) 0 (0.0%) 0 (0.0%) 35 56 
Left Stifle 41 (73.2%) 2 (3.6%) 0 (0.0%) 4 (7.1%) 15 56 
Left Hip 37 (72.5%) 1 (2.0%)   14 51 
Cervical Spine 0 (0.0%)    56 56 
Thoracic Spine 46 (82.1%)    10 56 
Lumbar Spine 28 (50.0%)    28 56 




Figure 3.6 summarises the orthopaedic examination findings for the appendicular skeleton. No manus or pes 
joint was found to be painful on manipulation. Pain was detected in the hip, stifle, elbow, and tarsus in 
descending frequency. Crepitus was most frequently detected in the elbow and stifle joint, whereas thickening 
was most frequently identified in the stifle joint. Effusion was not detected in any joint. The thoracic and lumbar 



































Figure 3.6: Summary of Abnormalities Detected During Orthopaedic Examination of the Appendicular Skeleton 
































3.4.3.3.1 Pain and Manipulation Scores 
Total pain score ranged from 0 to 27 with a median of 15 and an IQR of 8.5 – 19. Total crepitus score ranged 
from 0 to 4 with a median of 0 and an IQR of 0 – 1, whereas total thickening score ranged from 0 to 4 with a 
median of 1 and an IQR of 0 – 2.  
 
3.4.3.3.2 Bilateral Pain 
Bilateral pain was most frequently detected in the stifle and hip joint, followed by the elbow and tarsus joint 
(Table 3.9).  
 
Table 3.9: Prevalence of Bilateral Pain in Each Joint Type in n = 56 Cats 
 Carpus N (%) of Joints 
Elbow 
N (%) of Joints 
Shoulder 
N (%) of Joints 
Tarsus 
N (%) of Joints 
Stifle 
N (%) of Joints 
Hip 
N (%) of Joints 
Yes 0 (0%) 29 (51.8%) 1 (1.8%) 17 (30.4%) 36 (64.3%) 35 (62.5%) 
No 56 (100%) 27 (48.2%) 55 (98.2%) 39 (69.6%) 20 (35.7%) 21 (37.5%) 
 
 
The number of joints affected with bilateral pain ranged from 0 to 5 with a median of 2 and an IQR of 1 – 3. 
Only 10 (17.9%) of cats did not have bilaterally detected pain in any joint, whereas the remaining 46 cats had 
one (n = 9, 16.1%), two (n = 12, 21.4%), three (n = 16, 28.6%), four (n = 8, 14.3%), and five (n = 1, 1.8%) bilaterally 
affected joints (Figure 3.8). 
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Figure 3.8: Total Number of Joints Affected with Bilateral Pain in n = 56 Cats 
 
3.4.4 Group Comparisons 
3.4.4.1 Participants 
Mobility score ranged from 0 to 13 (Figure 3.9) with a median of 3 (IQR = 0 – 4). All 27 Control cats had a MS 
of 0 and the 30 Case cats had a median MS of 4 (IQR = 3.75 – 6). 





















Figure 3.9: Owner-reported Mobility Score for n = 30 Case Cats 
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Neuter status was not analysed statistically as all cats were neutered. No significant difference was found 
between the two groups in terms of their demographic variables (Table 3.10). These were age in life stages (p 
= 0.079), sex (p = 0.11), and breed category (p = 0.765).  
 
Table 3.10: Group Comparisons for Demographic Data in n = 57 Cats 
 All Cats 
N (%) of Cats 
Cases 
N (%) of Cats 
Controls 




Prime 5 (8.8%) 3 (10.0%) 2 (7.4%) 
FET = 6.74, p = 0.079 
Cramér’s V (4) = 0.348 
Mature 30 (52.6%) 11 (36.7%) 19 (70.4%) 
Senior 13 (22.8%) 9 (30.0%) 4 (14.8%) 
Geriatric 9 (15.8%) 7 (23.3%) 2 (7.4%) 
Sex 
Male 29 (50.9%) 12 (40.0%) 17 (63.0%) χ2 (1) = 2.99, p = 0.11 
OR = 2.55 Female 28 (49.1%) 18 (60.0%) 10 (37.0%) 
Breed  
Category 
DSH, DLH and their 
b d  
43 (75.4%) 22 (73.3%) 21 (77.8%) χ2 (1) = 0.151, p = 0.765 
OR = 0.78 Purebred 14 (24.6%) 8 (26.7%) 6 (22.2%) 
Domestic long hair (DLH); Domestic short hair (DSH); Fisher’s exact test (FET); Odds Ratio (OR). Corrected significance cut-off 
values associated with each hypothesis testing are: Age in Life Stages = 0.01, Sex = 0.0125, Breed Category = 0.05. 
 
3.4.4.2 Pre-visit Measures 
There was a significant difference and a moderate effect size when comparing FMPI scores (p = 0.003); Case 
cats scored lower than Control cats, signifying a higher degree of impaired mobility. There was also a significant 
difference and a moderate effect size for Comfort (p = 0.002) domain scores, with Case cats scoring lower than 
Control cats; no statistical difference was detected for Vitality and EWB domain scores (Table 3.11, Figure 3.10).  
 
Table 3.11: Group Comparisons for Pre-Visit Measures in n = 57 Cats 




Median (IQR) Between Groups Analysis 
FMPI 1.00 (0.97-1.00) 0.98 (0.93-1.00) 1.00 (0.99-1.00) U = 236.50, z = -2.917, p = 0.003*, r = -0.39 
VetMetrica 
Vitality Domain 49.8 (44.6-55.1) 46.9 (40.2-53.2) 51.7 (48.60-58.8) U = 242.00, z = -2.605, p = 0.009, r = -0.35 
VetMetrica 
Comfort Domain 44.2 (39.2-57.2) 41.3 (36.0-46.0) 52.0 (40.4-59.6) U = 212.50, z = -3.099, p = 0.002*, r = -0.41 
VetMetrica 
EWB Domain 51.9 (45.6-56.3) 51.1 (43.6-55.3) 55.8 (49.2-57.0) U = 258.50, z = -2.349, p = 0.018, r = -0.31 
Emotional wellbeing (EWB); Interquartile range (IQR).  
Corrected significance cut-off values associated with each hypothesis testing are: FMPI = 0.005, Vitality = 0.0071, Comfort = 



























Figure 3.10: Group Comparisons for VetMetrica Domain Scores in n = 57 Cats 
 
Owner perception of QoL was not statistically analysed as two out of the four categories (“very poor” and 
“poor”) had no data. 
 
3.4.4.3 Visit Measures 
3.4.4.3.1 Temperament Assessment 
There was no significant difference between the two groups (p = 0.258) for the number of cats defined as 
friendly or unfriendly by the researcher (Table 3.12, Figure 3.11). 
 
Table 3.12: Group Comparisons for Temperament Assessment in n = 57 Cats 
 All Cats N (%) of Cats 
Cases 
N (%) of Cats 
Controls 
N (%) of Cats Between Groups Analysis 
Friendly Temperament 49 (86%) 24 (80%) 25 (92.6%) 
FET = 1.87, p = 0.258, OR = 3.125 
Unfriendly Temperament 8 (14%) 6 (20%) 2 (7.4%) 
Fisher’s exact test (FET); Odds Ratio (OR).  
























Figure 3.11: Group comparisons for Temperament Assessment in n = 57 Cats 
 
3.4.4.3.2 Body Condition Score (Assessed by Veterinary Surgeon) 
There was no significant difference between the two groups (p = 0.425) for the number of cats defined as 
overweight/obese or not overweight (Table 3.13, Figure 3.12). 
 
Table 3.13: Group Comparisons for Body Condition Score (Assessed by Veterinary Surgeon) in n = 57 Cats 
 
All Cats 
N (%) of 
Cats 
Cases 
N (%) of 
Cats 
Controls 
N (%) of Cats Between Groups Analysis 
BCS (Assessed by  
Veterinary Surgeon) 
Not Overweight 32 (56.1%) 14 (46.7%) 17 (63.0%) χ2 (1) = 0.97, p = 0.425,  
OR = 1.7 Overweight/Obese 25 (43.9%) 15 (50.0%) 10 (37.0%) 
Body Condition Score (BCS); Odds Ratio (OR).  





























Figure 3.12: Body Condition Score (Assessed by Veterinary Surgeon) in n = 57 Cats 
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3.4.4.3.3 Orthopaedic Examination 
3.4.4.3.3.1 Pain and Manipulation Scores 
There was a significant difference when comparing total pain (p < 0.0001), crepitus (p = 0.002), and thickening 
(p = 0.003) scores, with Case cats scoring higher than Control cats (Table 3.14, Figure 3.13). The observed effect 
size was large for total pain score and moderate for total crepitus and thickening scores.  
 
Table 3.14: Group Comparisons for Total Pain and Manipulation Scores in n = 56 Cats 




Median (IQR) Between Groups Analysis 
Total  
Pain Score 15 (8.50–19) 18 (15.5–20) 11 (4–15) U = 127.50, z = -4.338, p < 0.0001*, r = -0.58 
Total  
Crepitus Score 0 (0–1) 1 (0–1) 0 (0–0) U = 223.00, z = -3.095, p = 0.002*, r = -0.41 
Total  
Thickening Score 1 (0–2) 1 (0–2) 0 (0–1) U = 224.50, z = -2.902, p = 0.003*, r = -0.39 
Interquartile range (IQR).  
Corrected significance cut-off values associated with each hypothesis testing are: Total Pain = 0.0036, Total Crepitus = 0.0045) 




















3.4.4.3.3.2 Bilateral Pain 
The presence of bilateral pain was significantly different between the two groups (p = 0.005), with Case cats 
being 14 times more likely to have bilateral pain compared to Control cats (Table 3.15, Figure 3.14). 
 
Table 3.15: Group Comparisons for the Prevalence of Bilateral Pain in n = 56 Cats 
 All Cats N (%) of Cats 
Cases 
N (%) of Cats 
Controls 
N (%) of Cats Between Groups Analysis 
Bilateral Pain 
Yes 46 (82.1%) 28 (96.6%) 18 (66.7%) 
FET = 8.51, p = 0.005*, OR = 14 
No 10 (17.9%) 1 (3.4%) 9 (33.3%) 
Fisher’s exact test (FET); Odds Ratio (OR).  



















Figure 3.14: Group Comparisons for the Prevalence of Bilateral Pain in n = 56 Cats 
 





Table 3.16: Prevalence of Bilateral Pain in Different Joints for n = 30 Case and n = 27 Control Cats 
 
All Cats 
N (%) of Joints 
Cases 
N (%) of Joints 
Controls 
N (%) of Joints 
Carpus 
Yes 0 (0%) 0 (0%) 0 (0%) 
No 56 (100%) 29 (100%) 27 (100%) 
Elbow 
Yes 29 (51.8%) 20 (69%) 9 (33.3%) 
No 27 (48.2%) 9 (31%) 18 (66.7%) 
Shoulder 
Yes 1 (1.8%) 1 (3.4%) 0 (0%) 
No 55 (98.2%) 28 (96.6%) 27 (100%) 
Tarsus 
Yes 17 (30.4%) 11 (37.9%) 6 (22.2%) 
No 39 (69.6%) 18 (62.1%) 21 (77.8%) 
Stifle 
Yes 36 (64.3%) 25 (86.2%) 11 (40.7%) 
No 20 (35.4%) 4 (13.8%) 16 (59.3%) 
Hip 
Yes 35 (68.6%) 22 (81.5%) 13 (54.2%) 
No 16 (28.1%) 5 (18.5%) 11 (45.8%) 
 
There was a significant difference (p = 0.001) and a moderate effect size when comparing the number of joints 
affected with bilateral pain between the two groups, with Case cats having more affected joints than Control 
cats (Table 3.17, Figure 3.15). 
 
Table 3.17: Group Comparisons for the Number of Joints Affected with Bilateral Pain in n = 56 Cats 
Number of Joints 
All Cats 
N (%) of Cats 
Cases 
N (%) of Cats 
Controls 
N (%) of Cats 
Between Groups Analysis 
0 10 (17.9%) 1 (3.4%) 9 (33.3%) 
 
1 9 (16.1%) 3 (10.3%) 6 (22.2%) 
2 12 (21.4%) 7 (24.1%) 5 (18.5%) 
3 16 (28.6%) 11 (37.9%) 5 (18.5%) 
4 8 (14.3%) 6 (20.7%) 2 (7.4%) 
5 1 (1.8%) 1 (3.4%) 0 (0.0%) 
Median (IQR) 2 (1–3) 3 (2–3.5) 1 (0–3) U = 189.5, z = -3.391, p = 0.001*, r = -0.45 
Interquartile Range (IQR).  




















Figure 3.15: Group Comparisons for the Number of Joints Affected with Bilateral Pain in n = 56 Cats 
 
3.4.4.4 Accelerometry 
It was not possible to download the data from the accelerometers in two occasions, and therefore activity data 
from only 55 cats were included in the analysis. The accelerometer and/or collar fell off or were removed in 12 
cats (21.4%) for variable durations resulting in missing data points (Appendix Q).  
For the analysis, the log transform was enabled or disabled, then age was included or excluded, resulting in 
four different combinations: “log_enabled”, “log_disabled”, “log_enabled+age”, and “log_disabled+age”. The 
outputs (Figure 3.16) show that the accuracy was high for all combinations (86.4% to 90.9%), however enabling 
the log transform resulted in accuracy improving from 86.4% to 90.9%. Accuracy was not improved by the 
addition of age as a covariate. Precision was 91% for the Control group and 90% for the Case group in the 





Figure 3.16: Accelerometer Outputs 
(top-left) “log_disabled”; (top-right) “log_enabled”; (bottom-left) “log_disabled+age”; (bottom-right) “log_enabled+age” 
Controls (0) are represented with blue squares and Cases (1) are represented with orange triangles. There were 10 Controls and 
12 Cases in the training dataset, and 16 Controls and 17 Cases in the testing dataset (circled). Precision (p) is the ratio of the 
number of true positives divided by the sum of true and false positives; this is represented by the ratio of blue squares against 
the blue background for Controls (p0) and the ratio of orange triangles against the orange background (p1) for Cases (p1). 
Accuracy (acc) is the ratio of the number of correct predictions to the total number of predictions made. Recall for Controls (r0) 





This study confirmed the initial hypothesis that early DJD-related pain has a significant impact on the QoL of 
affected cats. It additionally demonstrated that changes in joint health as detected by orthopaedic examination 
reflected owner-reported mobility changes, and that accelerometers were almost as sensitive as owners in 
detecting early signs of DJD-related pain in cats. Although multiple studies have compared the activity profiles 
of healthy cats to those with DJD using both subjective and objective tools, the cats in these studies had well-
established DJD which was also confirmed using different imaging modalities (Gruen et al., 2015, Guillot et al., 
2012, Lascelles et al., 2007c). On the contrary, this is the first study where the activity profiles of healthy cats 
and cats with owner-reported early DJD-related signs were assessed using prospectively collected data from 
subjective owner assessment questionnaires, orthopaedic examination, and accelerometers. 
The FMPI has been established as a CMI with the ability to confidently differentiate between healthy cats and 
cats with both clinically and radiographically confirmed DJD (Benito et al., 2013a). Nevertheless, this is the first 
time that the FMPI was used to and was successful in detecting subtle differences between healthy cats and 
cats with early signs of DJD as evidenced by the significantly lower FMPI scores of Case cats compared to 
Control cats. This further validates FMPI as a useful tool that can be used in the clinical setting to assist with 
the earlier diagnosis of DJD.  
VetMetrica scores were also significantly lower in Case cats compared to Control cats in the Comfort domain, 
, suggesting that even the lower degree of DJD-related pain experienced by cats with early DJD has a significant 
impact on the physical aspect of their quality of life. One possible explanation for the lack of a statistically 
detected difference between groups for the Vitality and EWB domain scores could be that owners have 
difficulty in distinguishing early DJD-related changes affecting the mental and emotional aspects of their cat’s 
quality of life. This is the first time that this HRQoL instrument has been used in a population with early signs 
of DJD-related pain and no comorbidities, however this study’s findings suggest that further refinement of the 
scoring algorithm may be indicated, especially in relation to items loading to more than one domain. 
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The temperament of cats as assessed by the researcher was not significantly different between Case and 
Control cats, contrary to previous studies where cats with higher pain scores were shown to have an unfriendly 
temperament (Lascelles et al., 2012, Stadig et al., 2019). This could be explained by the fact that the cats in 
those studies had well-established DJD rather than early signs of DJD-related pain, as was the case with the 
cats of the present study. Another point to note would be the fact that, similarly to QoL, temperament is a 
multidimensional concept (Ha and Ha, 2017), and therefore a single question may not be able to measure it 
reliably.  
All pain and manipulation scores obtained during the orthopaedic examination were significantly higher in Case 
cats compared to Control cats. In addition, bilateral pain was detected in at least one joint in almost all Case 
cats, and Case cats were 14 times more likely to suffer from bilateral pain compared to Control cats. The 
number of joints where pain was detected bilaterally was also significantly higher in Case cats. These findings 
illustrate that, when performed in a consistent and systematic manner, orthopaedic examination is a valuable 
tool in the early diagnosis of DJD. Moreover, the results relating to bilateral pain further reinforce the previous 
belief that bilateral disease is a core component of feline DJD. Nevertheless, the higher prevalence of bilateral 
disease reported in this study should be interpreted with caution as it was a direct reflection of bilateral pain 
detected exclusively during orthopaedic examination. This is contrary to previous studies where the prevalence 
of bilateral DJD was estimated based on radiographic studies with/without orthopaedic examination findings 
(Clarke and Bennett, 2006, Godfrey and Vaughan, 2018, Godfrey, 2005, Kimura et al., 2020, Lascelles et al., 
2010b, Slingerland et al., 2011).  
Machine learning of the accelerometer data classified accurately 90.9% of all cats with a precision of 91% for 
the Control group and 90% for the Case group. Interestingly, adding age as a covariate did not improve accuracy 
for either group, illustrating that the accelerometry data already intrinsically contain the information that age 
provides. Nevertheless, owners in this study were highly motivated and may have been able to detect changes 
in their cats’ mobility more accurately than most cat owners. In any case, accelerometry appears to provide a 
good reflection of owner-reported mobility changes and is a useful alternative, particularly with less observant 
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owners. This finding supports the use of accelerometry for the earlier detection of DJD in the clinical setting. 
Additional research investigating the use of accelerometry in cats with early signs of DJD-related pain is in 
progress and will be published soon by the researcher. 
One of the limitations of this study’s design was the fact that, like the first study, it depended on owner-
reported data which could have introduced bias. Recruitment of cats outside the BC study cohort was only 
possible after the owners contacted the researcher themselves, possibly introducing response bias. Moreover, 
questionnaire data were used to classify cats as Cases or Controls as well as to assess impaired mobility (FMPI) 
and QoL (VetMetrica), possibly introducing reporting bias. Reporting bias could have been partially mitigated 
if the veterinary records had been checked for exclusion criteria that had not been reported by owners, such 
as the diagnosis of any condition that could influence mobility or the administration of any anti-inflammatory 
or analgesic medications. Unfortunately, this was not possible within the study’s time frame. In addition to 
reporting bias, questionnaire completion could have been affected by measurement bias, with owners not 
wanting to admit that their cats were showing signs of impaired mobility or QoL. Notwithstanding the fact that 
the researcher did not share any information regarding the cats’ orthopaedic examination or activity 
monitoring at any point during the study, subconscious clues may have been picked up by the owners; this 
could have biased their responses to the seven pre-visit questionnaires which were completed after the visit 
took place. Every effort was made to minimise interviewer bias by blinding the researcher to each cat’s 
classification as Case or Control and demographic data until data analysis began. This bias could be mitigated 
in future studies by having different veterinary surgeons perform the orthopaedic examination whilst following 
a standardised protocol to minimise inter-observer variability. Even though owners were advised to keep their 
cat’s routine unchanged, they may have introduced e.g. more play sessions with their cat, thereby skewing the 
accelerometer results to reflect a more active lifestyle than normal. Accelerometer removal was reported in 
one fifth of the study’s cats but, unless noted immediately, owners may have been inaccurate in recording the 
time when the device or the collar fell off and were replaced, thus introducing recall bias. Owners could have 
additionally omitted time periods when the device fell off for fear of being excluded from the study. Selection 
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bias can also not be excluded even though every attempt was made to randomly select cats to participate in 
this study. Another limitation relates to the fact that approximately 10% of the recruited cats belonged to the 
same households, therefore not all study cats were independent. This study’s population was generally similar 
to the UK cat population attending primary-care veterinary practices apart from the proportion of purebred 
cats which was higher (~25%) than the reported 11% (O'Neill et al., 2015). Owners in this study were possibly 
more motivated than owners attending primary-care veterinary practices since they were willing to complete 
several questionnaires, allow the researcher to visit and examine their cat as well as agree to the placement of 
an activity monitor on their cat for two weeks. Owners of pedigree cats may also be considered more motivated 
than the general cat-owning population as they have been shown to focus more on the companionship and 
health of their cats (Plitman et al., 2019) than owners of non-pedigree cats, which could in turn have made 
them more likely to wish to participate in this study. The Case and Control groups did not differ significantly in 
terms of their demographic characteristics (age in life stages, sex, neuter status, breed category). Although the 
initial consideration was to use each cat’s age as a continuous variable, most owners were only able to provide 
an estimate rather than an accurate age. Grouping the participants’ age according to life stages had a holistic 
clinical basis (Hoyumpa Vogt et al., 2010) and made it possible to recruit enough cats whilst making allowances 
for age estimates. With regards to omission bias, the decision to exclude cats less than six years of age from 
this study and with it approximately half the UK cat population (Sanchez-Vizcaino et al., 2017) was made based 
on the mean age of the reported prevalence of radiographic DJD (Tables 1 and 2). Cats with unrestricted 
outdoor access were excluded to avoid the risk of losing the activity monitor. Although 90.9% of UK cats are 
reported to have outdoor access (Murray and Gruffydd-Jones, 2012), there is no distinction between cats with 
unrestricted outdoor access and cats that go outside on a lead or an enclosed garden; the latter were not 
excluded from this study. Cats were also excluded if they lived further than 100 miles from Bristol Veterinary 
School as it was not possible to visit outside that radius based on the study’s allocated time frame and budget 
and, similarly to humans, there may be differences in the geographical prevalence of DJD between populations 
as a result of environmental or genetic factors (Zhang and Jordan, 2010). Despite not achieving the optimum 
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recruitment number of 30 cats per group, the study was able to detect significant differences between the two 
groups, suggesting that 27 cats per group may be sufficient for future case-control studies in cats with early 
signs of DJD-related pain. 
 
3.6 Conclusion 
The significant impact of even early DJD-related pain on the QoL of affected cats further supports the need to 
diagnose DJD earlier. Being able to recognise signs of mobility impairment sooner would allow interventions 
aimed at slowing DJD progression, thereby improving feline health and welfare. This study demonstrated that 
orthopaedic examination findings agree with information obtained from owners, and both can be used to 
confidently differentiate cats with early signs of DJD-related pain from healthy cats in the consult room. 
Accelerometry was also able to discriminate between the two groups with great precision, illustrating that this 





4. CONCLUSIONS AND FUTURE WORK 
The risk factor analysis study for owner-reported signs of early DJD at six years of age not only evaluated early 
life risk factors for the first time, but also utilised prospective data from a longitudinal cohort study, further 
expanding research on feline DJD by identifying novel risk factors for its development. Cats that were entire at 
six months of age, cats that were obese at six years of age, cats with outdoor access and cats with a history of 
trauma were more likely to have early DJD-related changes in owner-reported mobility at six years of age. 
Further research is needed to determine if other aspects of a cat’s husbandry, diet, lifestyle, and clinical history 
are implicated in the development of DJD. Additional research on the link between chronic inflammatory 
processes such as DJD, CKD and dental disease is also warranted. Future risk factor analysis on older BC study 
cats could corroborate the findings of the present study and identify additional risk factors for the development 
of DJD, as well as compare owner-reported signs of early DJD to well-established DJD. 
The need to diagnose DJD earlier is further supported by the significant impact of even early DJD-related pain 
on the comfort aspect of the QoL of affected cats. This study’s findings reinforced the belief that owners can 
recognise DJD-related changes in the activity profile of their cats, and that orthopaedic examination findings 
accurately reflect early DJD-related changes in owner-reported mobility. Moreover, the use of accelerometry 
identified these owner-reported changes with great precision, and further analysis already underway by the 
researcher aims to identify the aspects of a cat’s activity that discriminated between cats with and without 
owner-reported signs of early DJD. Future studies using the same cats and/or a larger sample of cats with 
radiographically confirmed joint changes would further substantiate this study’s findings with regards to owner 
report and orthopaedic examination, as well as validate the ability of accelerometry data to predict the 
presence of DJD. Further research may also include an intervention study to examine whether preventative 
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APPENDIX B SUMMARY OF ACTIVITY MONITORS AND RELEVANT 
LITERATURE 








Measure of activity 
and distance moved 
in healthy cats and in 
cats with DJD 
(Lascelles et al., 




between healthy cats 
and cats with DJD 
(Guillot et al., 2012) 
Activity levels 
• Physical activity of overweight cats (de Godoy and Shoveller, 2017) 
• Physical activity using a running wheel (Detweiler et al., 2017) 
• Physical activity of cats with DJD (Gruen et al., 2017a) 
Validation of CMIs 
• FMPI and CSOM (Gruen et al., 2015) 
• MiCAT(C) (Klinck et al., 2018a) 
Effect of therapeutic interventions on activity levels 
• Meloxicam (Gruen et al., 2014, Guillot et al., 2013) 
• Robenacoxib (Adrian et al., 2019) 
• Gabapentin (Guedes et al., 2018b) 
• Tramadol (Guedes et al., 2018a) 
• antiNGF (Gruen et al., 2016) 
• Therapeutic DJD diet (Lascelles et al., 2010a) 
• 17β-estradiol (Wara et al., 2015) 
Food intake 
• Effect of photoperiod on (Kappen et al., 2014) 
Diet and activity levels 
• Effect of feeding method (Naik et al., 2018), frequency (de Godoy et al., 2015, 
Deng et al., 2011, Deng et al., 2014) and dietary content (Gooding et al., 





No validation studies 
published. 
Activity levels 
• Effect of housing conditions and human presence (Piccione et al., 2014, 
Piccione et al., 2013) 
Therapeutic interventions 
• Meloxicam (Monteiro et al., 2016) 
• Tramadol (Monteiro et al., 2017) 
Validation of CMIs 
• MiCAT(V) (Klinck et al., 2018b) 
Clinical Metrology Instrument (CMI); Client-specific Outcome Measures (CSOM); Degenerative Joint Disease (DJD); Feline 
Musculoskeletal Pain Index (FMPI) 
 








Activity levels and 
distance moved 
(Hansen et al., 2007) 
• Association of activity levels with signalment (Michel and Brown, 2014) 
• Influence of device attachment on activity levels (Martin et al., 2017) 
Interventions 
• Cartrophen (Brown et al., 2010) 
• Meloxicam (Muller et al., 2018) 





correlation with activity 




• Assessing activity levels during weight loss (Morrison et al., 2018, Morrison 
et al., 2014) 
• Assess stress levels in shelter dogs (Jones et al., 2014) 
• Evaluation of open source method for calculating physical activity 
(Westgarth and Ladha, 2017) 
• Assess activity levels during chemotherapy (Helm et al., 2016) 
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No validation studies 
published. 





Actical (Mejia et al., 
2019) 
Effect of environmental noise and music on dexmedetomidine-induced sedation 
(Albright et al., 2017) 
PetDialog 
Recognition of eight 
behavioural states (den 





Actical (Belda et al., 
2018) 





(Griffies et al., 2018) 
Evaluation of changes in pruritic behaviours (Wernimont et al., 2018) 
VetSens 
No validation studies 
published. 
• Predicting rest (Ladha and Hoffman, 2018) 
• Evaluation of open source method for calculating physical activity 
(Westgarth and Ladha, 2017) 




Actical (Yashari et al., 
2015) 
• Activity recognition (Kiyohara et al., 2015) 
Degenerative Joint Disease (DJD) 
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APPENDIX D TRAUMA-RELATED KEYWORDS FOR FREE TEXT 
MINING 
RTA Vehicle Break Fell 
Hit by Ran Broke Fall 
Road Trauma Fracture Attack  
Car Injur* Dislocat* Bit* 





APPENDIX E STUDY ONE: BREED INFORMATION 
Breed N (%) of cats 
DSH and their crossbreeds 537 (67.7%) 
DLH and their crossbreeds 100 (12.6%) 
British short hair 44 (5.5%) 
Maine Coon 25 (3.2%) 
Siamese 13 (1.6%) 
Ragdoll 10 (1.3%) 
Burmese 8 (1%) 
Birman 7 (0.9%) 
Korat 7 (0.9%) 
Siberian 6 (0.8%) 
Norwegian forest 5 (0.6%) 
Oriental shorthair 4 (0.5%) 
Devon Rex 3 (0.4%) 
Persian 3 (0.4%) 
Selkirk Rex 3 (0.4%) 
Tonkinese 3 (0.4%) 
Bengal 2 (0.3%) 
Burmilla 2 (0.3%) 
Havana 2 (0.3%) 
Ragamuffin 2 (0.3%) 
Exotic Shorthair 2 (0.3%) 
Scottish Fold 1 (0.1%) 
Singapura 1 (0.1%) 
Malayan 1 (0.1%) 
Russian Blue 1 (0.1%) 







APPENDIX F RECRUITMENT E-MAILS AND ADVERTISEMENTS  
RECRUITMENT E-MAIL FOR BC STUDY PARTICIPANTS 
Hello from the Bristol Cats Study & the Feline Activity Study! 
I’m very excited to inform you that your cat, already a proud participant of the Bristol Cat study, is also eligible 
to participate in the in the Feline Activity Study which investigates the activity levels of our feline friends using 
cat "FitBits”! 
As your cat’s welfare is our top priority, included cats should also: 
• Be happy to meet and be stroked by strangers. 
• Be happy to wear a breakaway (safety) collar – do not worry if your cat is not wearing one already, 
this can be provided along with step by step instructions of how to slowly introduce your cat to it 
written by feline specialists. 
What is required from you – and your cat? 
• Completion of two short questionnaires (~15 minutes total). 
• A 30-60-minute home visit to meet both of you and conduct a gentle examination of your cat’s joints. 
• Your cat wearing a light activity monitor on their collar for 2 weeks. 
Please do not hesitate to contact me if you have any questions, I am looking forward to your response and I 
hope you will consider participating in this fantastic study! 






RECRUITMENT LETTER FOR BC STUDY PARTICIPANTS 
Dear <owner name>, 
A huge thank you for your continued participation in the Bristol Cats study!  
As part of the Bristol Cats study, we sometimes undertake more in-depth studies and, in order to really explore 
specific issues, we ask some of our Bristol Cat Owners to have greater involvement, such as chatting to us in 
more detail about your cats, or even allowing us to meet them in person!  
We contacted you earlier this month to invite you to participate with <cat's name> in one such study, looking 
at activity levels in cats. Helping us with this study would involve Evelyn Maniaki, our feline scholar, visiting you 
at home to find out a bit more about what [cat name] likes to get up to, gently examine <his/her> joints and 
place a cat “FitBit” on <him/her>. If <insert cat’s name here> does not normally wear a collar that is fine; you 
can still enrol. 
If you and <insert cat’s name> might be interested in helping us, please simply reply to this email with ‘yes 
please I’d like to find out more about what would be involved’ and we will get in touch with more details! If for 
any reason you do not feel that this study is for you, that is absolutely fine. 
Once again, thank you for your years of participation, as we are hugely grateful for each cat and each owner’s 










APPENDIX G COLLAR HABITUATION INSTRUCTIONS 
                 COLLAR INTRODUCTION GUIDELINES 
 
Many thanks for agreeing to help us with our study where your cat will wear a collar with the attached 
accelerometer for approximately 2 weeks, allowing us to assess their activity. Your cat’s welfare is our top 
priority and, as your cat does not normally wear a collar, we have written these guidelines to help you introduce 
it gradually.  
• The collar you have been provided with is a breakaway (safety) collar. This means that it will release if 
your cat gets caught on anything within the house. 
• By giving your cat opportunities to do things they enjoy whilst wearing the collar, positive associations 
will be built up which will ensure your cat feels relaxed and happy whilst wearing it. This can be 
achieved, for example, by giving your cat tasty treats or playing with their favourite toy whilst the 
collar is being worn.  
• The speed that you progress through the steps will depend on your cat and, as every cat is different, 
this process may take anything from a couple of days to a week. Once you are confident that your cat 
is relaxed, you can progress to the next step. However, if your cat shows any signs of being worried 
(see later), you should go back to the step in which your cat showed signs of relaxation. If at any point 
during the collar introduction you have any concerns, please do not hesitate to contact us. 
• Cats tend to choose the “flight” rather than the “fight” approach when confronted with something 
they are worried about, so if your cat freezes or moves away when you approach with the collar, that 
is your cat’s way of telling you that they are worried.  
• Carrying out the collar introduction process in an area that allows your cat to walk off or hide if they 
want will help them feel safer and more comfortable.  
 
Feel free to replace feeding in the following steps with any other activity your cat enjoys and can therefore be 
used to build up positive associations: 
1. Whilst holding the cat collar in obvious view or resting it on your lap if your cat is very timid, encourage 
your cat to approach you. If your cat approaches in a relaxed way, wait until they are close to you then 
give them a small amount of food. If your cat is slightly hesitant, do not wait until your cat has come 
all the way to you but, instead, gently throw some food towards them when they move in your 
direction. Do not move on to the next stage unless you are confident that your cat is approaching you 
in a relaxed way. Continue to feed when your cat is close to you and whilst holding the collar. 
2. Hold the collar out to allow your cat to sniff it, giving them some food for showing interest in it. Repeat 
this several times, so that you can be 100% certain that your cat is relaxed in the presence of the collar. 
3. Hold the collar a little bit away from your cat and fasten it whilst giving them some food, noting how 
they react to the ‘click’ noise it makes when it fastens. If your cat is worried by the ‘click’, repeat 
starting further away, far enough that your cat is not worried. Continue by gradually decreasing the 
distance between the collar and your cat until you can fasten and unfasten it very close without your 
cat showing any signs of worry. 
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4. Whilst feeding your cat, gently place the collar around their neck but do not fasten it, simply rest it 
around their neck for a couple of seconds. Repeat until your cat is relaxed with you placing the collar 
around their neck. 
5. Repeat the previous step, but this time fasten and then immediately unfasten the collar. Repeat until 
your cat is relaxed having the collar fastened and unfastened. 
Gradually increase the amount of time your cat wears the collar for. If your cat appears relaxed once 
the collar is on, you will be able to increase the amount of time your cat wears the collar for relatively 
quickly, whilst ensuring your cat continues building positive associations with it. Occasional scratching 
at the collar is OK, but if your cat looks worried or irritated you may need to build up the time your cat 
spends wearing the collar more gradually. 
 
Monitoring your cat’s response to the collar 
It is important that you monitor your cat as you introduce them to the collar and that you only progress on to 
the next step of training when you are 100% certain your cat is happy with the previous step. Cats use their 
body language to tell us how they feel and if you notice any of the key signs outlined below, you should move 
a step back and take it from there. 
• Avoidance: Your cat may walk (or run!) away or hide, either when you approach or when you attempt 
to put the collar on. 
• Eating: Your cat may stop eating or refuse to take the food offered, despite them not being full and 
the food being something that they would normally eat immediately. 
• Changes in body posture and/or facial expression: A relaxed cat will have a ‘soft’ body posture, 
possibly with paws tucked underneath if sat down or with a raised tail when approaching you. Signs of 
worry could be:  
o a cat that is tensing up, with or without an arched back, moving away from you or freezing in 
place 
o a cat with its hairs on end, most commonly on the base of the tail 
o a cat with a ‘tucked’ tail wrapped closely around their body which may or may not be swishing 
o a cat with ears in a fixed, backwards position or completely flattened 



























APPENDIX I STUDY PARTICIPANT INFORMATION SHEET 
      PARTICIPANT INFORMATION SHEET 
Study title: The impact of feline degenerative joint disease on mobility and quality of life in 
cats 
Research investigator: Dr Evelyn Maniaki 
Supervisors: Dr Emily Blackwell; Dr Jo Murrell; Professor Sorrel Langley-Hobbs 
 
We would like to invite you and your cat to take part in our research study. Before you decide, we 
would like you to understand why the research is being done and what it would involve for both of you. 
Talk to others about the study if you wish. Please do not hesitate to ask us if there is anything that is 
not clear. 
 
What is the purpose of the study?  
Feline degenerative joint disease (DJD) is a common, but challenging condition in cats, with 
prevalence estimates ranging between 61% and 99% in cats and increasing with age. Whilst it is clear 
that DJD can lead to reduced mobility and pain, with significant potential impacts on the cat’s quality 
of life (QoL), little is known about risk factors for this condition. Diagnosis of DJD is far from 
straightforward because it primarily depends upon owners detecting changes in the activity (e.g. 
reluctance to jump, reduced activity, sleeping more, stiff gait) or behaviour (e.g. sleeping more, playing 
less, grooming less, aggression towards owner or other cats) of their cat, then seeking veterinary 
advice. As cats are “masters of disguise”, it is likely that a significant number of cats go undetected. 
Differences in activity between cats with DJD and normal cats have been detected using 
accelerometry (imagine a FitBit – but for cats!) and this new technology could also be useful in picking 
up early signs of DJD. Ultimately, early detection of DJD would allow a multimodal approach (e.g. 
environmental modification, physiotherapy) to delaying/halting progression of the disease by 
educating veterinary personnel and owners, thereby improving the cat’s QoL. 
Approximately 9% of UK pet cats are thought to live indoors. There are some obvious benefits to 
keeping cats indoors, primarily the avoidance of road traffic accidents, predation and reduced 
exposure to infectious disease, however concerns have been raised about an indoor cat’s inability to 
display “normal” behaviours such as hunting, possibly resulting in an increased risk of problematic 
behaviours. This study will also investigate the complexity of the home environment and husbandry of 
indoor cats, comparing this information to owner-reported behaviours. 
 
Why have I (and my cat!) been invited?  
We are looking for cats over 6 years of age, of any breed, some of whom have early signs of DJD and 
others who do not. The cats should be otherwise healthy and not be on any medication, excluding 
flea/worm treatment and joint or other supplements. The cats should also not have outdoor access, 




Do I have to take part?  
We would love you to help us, but it is entirely up to you to decide if you and your cat would like to join 
the study. We will describe the study and go through the process in this information sheet, but feel 
free to contact us if you have any questions. If you decide to help us, but then change your mind, you 
would be free to withdraw at any time, without giving a reason. 
 
What will happen to me (and my cat!) if I take part and what will I (and my cat!) have to do?  
This study will be conducted in your home. To participate in this study, your cat must not be fearful of 
meeting and being stroked by strangers. You also need to be happy for your cat to wear a breakaway 
(safety) cat collar with the attached accelerometer for a short period of time. If your cat has never worn 
a collar or not wearing a breakaway collar, one will be provided. Collar introduction will be a step by 
step process; we will provide you with instructions on how to do so and your cat will be given a 
minimum of seven days to acclimatise to wearing it. Visits will be scheduled for a mutually convenient 
date and time, with a start time between 8am and 7pm. Most visits will be scheduled on weekdays, 
but weekend dates will also be possible. Each participating owner will need a total of two visits. The 
initial visit will take 30-60 minutes, whilst the visit to remove the collar and accelerometer will be 
approximately 15 minutes.  
 
Questionnaire completion  
Before we pay you a visit, we will ask you to complete two short (~15 minutes total) questionnaires 
that will include questions about your cat’s current health, mobility, behaviour, and quality of life. 
 
What is required from my cat? 
To prevent your cat being worried before, during and after the visits, Evelyn will allow your cat to 
acclimatise to her presence for at least 15 minutes before any handling and adhere to the principles 
of feline-friendly practice. This encompasses a long list of cat friendly rules, but for example Evelyn 
will allow the cat to approach her rather than the other way around, she will speak with a soft and calm 
voice and she will allow the cat to sniff her before attempting to touch them. Following this, your cat 
will undergo a gentle orthopaedic examination by Evelyn to detect the presence of joint pain. Evelyn 
may be accompanied by a student. Your cat will then wear an accelerometer, weighing 17g, on the 
breakaway collar for a total period of fourteen days, to measure their activity profile and sleep/rest 
patterns. 
 
Who will hold my cat during the examination? 
Our team are experienced with cats and will be able to complete the examination without assistance 
from you. However, if you would prefer to hold your cat, then this will be fine. We will take things 
carefully at your cat’s pace, although holding your cat will be at your own risk. 
 
What happens if my cat gets worried with any of the procedures? 
If at any point you or Evelyn feel that your cat is becoming worried by the procedures (wearing a collar, 
home visit, orthopaedic examination, wearing an accelerometer), then the procedure will stop 
immediately. In the case of the orthopaedic examination, and only if you consent, Evelyn may wait for 
a few minutes to allow your cat further time to habituate to their presence and try again, depending on 
the individual circumstances. 
 
What can I do to help? 
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It is helpful if other cats and dogs are kept out of the room when the visit takes place as they tend to 
want to ‘join in’. 
 
Hygiene 
As part of our general hygiene practices, members of the study team will wear a clean veterinary top 
at each visit. 
 
What are the possible disadvantages and risks of taking part? 
One possible adverse effect is your cat becoming worried during or after the visits. To prevent this 
from happening, cats whose owners report that they are fearful of strangers will be excluded from the 
study. Evelyn will also allow your cat to acclimatise to their presence for at least 15 minutes before 
any handling and adhere to the principles of feline-friendly practice as detailed above.  
Another possible risk would be strangulation as a result of wearing a collar. To prevent this from 
happening, a breakaway (safety) cat collar will be provided if your cat is not already wearing one, with 
collar introduction being a step by step process; we will provide you with instructions on how to do so 
and your cat will be given a minimum of seven days to acclimatise to wearing it.  
As stated above, if at any point you or Evelyn feel that your cat is becoming worried by the procedures 
then the procedure will stop immediately. In the case of the orthopaedic examination, and only if you 
consent, Evelyn may wait for a few minutes to allow your cat further time to habituate to their presence 
and try again, depending on the individual circumstances. 
  
What are the possible benefits of taking part?  
Although there is no personal gain for you, the information gained from this study will help advance 
the knowledge of feline DJD and the environmental needs of indoor cats, both of which will improve 
their QoL. 
 
What will happen if I do not want to carry on with the study?  
You can withdraw from the study at any time without giving a reason. Any data we have collected from 
you and your cat during the course of the study will be destroyed. 
 
Will my taking part in this study be kept confidential?  
• Your participation in the study will be completely confidential to all except the researchers 
involved. 
• All data collected from this study will be anonymised after collection, and no participants will 
be identifiable in resulting reports or publications. 
• Data will be collected by accessing your cat’s Bristol Cats and medical records, as well as 
during visiting your house. 
• The data will be stored both in hard copy and electronic format and securely held at School of 
Veterinary Science, University of Bristol in accordance with the Data Protection Act 2018.  
• The data will be retained for 10 years, following which it will be disposed of securely. 
 
What will happen to the results of the research study? 
You will be informed about the outcome of the study via social media and/or e-mail following study 
completion, depending on your preference. The study findings will be published in a peer review 
veterinary journal and/or presented at veterinary conferences, as well as in the Bristol Cats website, 




Who is organising and funding the research?  
The research is organised by Evelyn Maniaki at Bristol Veterinary School as part of her MSc, with her 
supervisory team listed at the header of the first page. The research has been funded by Zoetis UK 
Ltd. 
 
Who has reviewed the study?  
The study has been reviewed by University of Bristol’s Health Sciences Faculty Research Ethics 
Committee (FREC) and the Animal Welfare and Ethical Review Body (AWERB). 
 
Further information and contact details  
Researcher contact details: Dr Evelyn Maniaki (evelyn.maniaki@bristol.ac.uk) 
Supervisor contact details: Dr Emily Blackwell (emily.blackwell@bristol.ac.uk) 











APPENDIX J STUDY PARTICIPANT CONSENT FORM 
 
CONSENT FORM 
Research project title: The impact of feline degenerative joint disease on mobility and quality of life in 
cats 
Research investigator: Dr Evelyn Maniaki 
Supervisors: Dr Emily Blackwell; Dr Jo Murrell; Professor Sorrel Langley-Hobbs 
 
I agree that (please check off and initial each section to which you agree): 
    INITIALS 
    I have read and understood the information sheet dated 13/06/2018 for the above 
study and have had the opportunity to consider the information, ask questions and 
have had these answered satisfactorily. 
    I can ask any questions during the visit and may contact the researcher with any future 
questions. 
    I am voluntarily taking part in this project and I am free to withdraw at any time without 
giving any reason. 
    I do not expect to receive any benefit or payment from participation. 
  I consent to the researcher contacting my vet and obtaining my cat’s medical notes. 
 My Vet’s details: 
________________________________________________________________ 
    I understand that relevant sections of my cat’s medical notes and data collected during 
the study may be looked at by individuals from the research project team, where it is 
relevant to my taking part in this research. I give permission for these individuals to 
have access to my cat’s records. 
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    I consent for pictures of my cat being taken for use in reports and publications resulting 
from this study. 
    I understand that anonymised data may be published under the conditions stated 
above. 
    If I have any concerns about this research or the way it is being conducted, or if I wish 
to make a complaint, I may contact the Faculty of Health Sciences Ethical Committee.  
     I agree to take part in the above study. 




______________________ ___________________________ ______________________ 
Printed name of participant  Date     Signature 
 
 
______________________ ___________________________ ______________________ 
Printed name of researcher  Date     Signature 
If you would like a copy of the publication of the results, please supply your email address: 













Researcher contact details: 
Dr Evelyn Maniaki: evelyn.maniaki@bristol.ac.uk 
Supervisor contact details: 
Dr Emily Blackwell: emily.blackwell@bristol.ac.uk 






























APPENDIX L ONLINE VETMETRICA QUESTIONNAIRE 
Feline Activity Study Questionnaire – 
Quality of Life assessment 
 
 
Page 1: Feline Activity Study 
Thank you for taking the time to participate in our study. 
Completing the questionnaire should be straightforward and take less 
than 10 minutes. 
Please let us know if you have any questions before or during 
completing this questionnaire. 
 
Information about you and your cat 
E-mail address Required 
 











Page 2: Your cat's quality of life 
 
 
Please think about how your cat is behaving today and use the scale to tell us how 


























Page 3: Your cat's quality of life - continued 
 
 
Please think about how your cat is behaving today and use the scale to tell us how 


























Page 4: Your cat's quality of life - continued 
 
 
Please think about how your cat is behaving today and use the scale to tell us how 


























Page 5: Your cat's quality of life - continued 
 
 
Please think about how your cat is behaving today and use the scale to tell us how 




























Page 6: Your cat's quality of life - continued 
 
 
Please think about how your cat is behaving today and use the scale to tell us how 




























Page 7: Your cat's quality of life - continued 
 
 
Please think about how your cat is behaving today and use the scale to tell us how 




























Page 8: Your cat's quality of life - continued 
 
 
Please think about how your cat is behaving today and use the scale to tell us how 




























Page 9: Your cat's quality of life - continued 
 
 
Please think about how your cat is behaving today and use the scale to tell us how 




























Page 10: Your cat's quality of life - continued 
 
 
Please think about how your cat is behaving today and use the scale to tell us how 




























Page 11: Your cat's quality of life - continued 
 
 
Please think about how your cat is behaving today and use the scale to tell us how 




























Page 12: Your cat's quality of life - continued 
 
 
Please think about how your cat is behaving today and use the scale to tell us how 




























Page 13: Your cat's quality of life - continued 
 
 
Please think about how your cat is behaving today and use the scale to tell us how 




























Page 14: Your cat's quality of life - continued 
 
 
Please think about how your cat is behaving today and use the scale to tell us how 





Enjoying the things, he / she usually does (Engaging in usual behaviour and 
activity fully, deriving pleasure from usual activities) 
 
 



















Page 15: Your cat's quality of life - continued 
 
 
Please think about how your cat is behaving today and use the scale to tell us how 





Jumping or climbing up / down as usual (Jumping or climbing up/down to 
the things/heights and in the ways that are usual for your cat) 
 
 



















Page 16: Your cat's quality of life - continued 
 
 
Please think about how your cat is behaving today and use the scale to tell us how 




























Page 17: Your cat's quality of life - continued 
 
 
Please think about how your cat is behaving today and use the scale to tell us how 




























Page 18: Your cat's quality of life - continued 
 
 
Please think about how your cat is behaving today and use the scale to tell us how 




























Page 19: Your cat's quality of life - continued 
 
 
Please think about how your cat is behaving today and use the scale to tell us how 




























Page 20: Your cat's quality of life - continued 
 
 
Please think about how your cat is behaving today and use the scale to tell us how 




























Page 21: Your cat's quality of life - continued 
 
 
Please think about how your cat is behaving today and use the scale to tell us how 




























Page 22: Your cat's quality of life - continued 
 
 

































Page 23: Thank you very much for your help! 
 
 
Thank you very much for completing this questionnaire! 
 
We really appreciate the time that you have taken to complete this questionnaire to tell 
us about your cat. The information you give us about your cat will help us to help cats in 
the future. 
 




phone: 07827 981412 
 
post: Bristol cats (FREEPOST RSHR-AGRJ-UABZ) Dr Emily Blackwell, University 










APPENDIX M ORTHOPAEDIC EXAMINATION SHEET 
DJD ID: OWNER NAME: CAT NAME: 
  
RIGHT LIMB LEFT LIMB SPINE 
MAN CAR ELB SHO PES TAR STIF HIP MAN CAR ELB SHO PES TAR STIF HIP CER THOR LUM LS 
PAIN                                         
CREPITUS                                         
EFFUSION                                         
THICKENING                                         
BODY CONDITION SCORE:                
TEMPERAMENT SCORE:                
PAIN SCORE (APPENDICULAR & AXIAL SKELETON) 
0 No resentment 
1 Mild withdrawal; mildly resists 
2 Moderate withdrawal; body tenses; may orient to site; may vocalize/increase in vocalization 
3  Orients to site; forcible withdrawal from manipulation; may vocalize or hiss or bite 
4  Tries to escape/prevent manipulation; bite/hiss; marked guarding of area 
CREPITUS, THICKENING AND EFFUSION SCORE (APPENDICULAR SKELETON ONLY) 
0  None       
1  Slight – moderate       
2  Severe           
TEMPERAMENT SCORE           
0  Neutral attitude, purring, kneading           
1  Resistance to restraint       
2  Resistance to restraint, growling and hissing       
3  Resistance with biting and scratching, hissing, spitting, and vocalising       










APPENDIX O TESTS OF NORMALITY AND TRANSFORMATIONS 







































































APPENDIX P HOLM-BONFERRONI METHOD CALCULATIONS 
Holm-Bonferroni formula for each p-value: α / (n – rank + 1) 
Hypothesis-associated Variable p-value Rank Corrected p-value Reject Null Hypothesis? 
Total Pain score 0.0001 1 0.0036 Yes 
Number of joints affected with 
bilateral disease 
0.001 2 0.0038 Yes 
VetMetrica Comfort Domain score 0.002 3 0.0042 Yes 
Total Crepitus score 0.002 4 0.0045 Yes 
Feline Musculoskeletal Pain Index 0.003 5 0.0050 Yes 
Total Thickening score 0.003 6 0.0056 Yes 
Prevalence of Bilateral Pain 0.005 7 0.0063 Yes 
VetMetrica Vitality Domain score 0.009 8 0.0071 No 
VetMetrica Emotional Wellbeing 
Domain score 
0.018 9 0.0083 No 
Age in Life Stages 0.079 10 0.0100 No 
Sex 0.11 11 0.0125 No 
Temperament 0.258 12 0.0167 No 
Body Condition Score (assessed by 
veterinary surgeon) 
0.425 13 0.0250 No 
















(Date and Time) 
End of  
Recording 
(Date and Time) 
Total  
Recording Duration  
(Start to End) 
Duration of  
Device Not on Cat 
(minutes)  
Proportion that Device 






























































































































































































































































































13 days 4 hrs 0 mins  20 99.89% 
 
